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General introduction 
Diagnosing chronic fatigue syndrome
From 1990, the Nijmegen Fatigue Research Group of the University Medical Centre 
Nijmegen studied chronic fatigue syndrome (CFS). In the beginning, studies of CFS 
were imited by lack of proper diagnostics and different working case definitions1,2. 
The first objective of our interdisciplinary study group was to develop 
multidimensional assessment methods3. Nine dimensions were identified, measuring 
emotional, behavioural, cognitive and social functioning and each providing a unique 
contribution to the assessment of CFS. In this study the use of different methods in 
the multidimensional assessment was advised.
In 1994 the Nijmegen Fatigue Research Group contributed to the development of 
international guidelines for the clinical evaluation and study of fatigued persons4. In 
the revised and until now latest case definition, CFS is characterised by persistent or 
relapsing unexplained chronic fatigue, lasting for at least six months, of new or 
definite onset, not the result of an organic disease or ongoing exertion, not alleviated 
by rest, and resulting in substantial reduction in previous levels of occupational, 
educational, social and personal activities. Several additional criteria were specified. 
Our outpatient clinic has seen large numbers of patients suffering from chronic 
fatigue, both in the context of outpatient care and within the framework of scientific 
research. In both settings guidelines and measuring instruments had been developed 
to help improve CFS diagnostics. In our scientific studies patients filled out 
questionnaires to establish whether they meet the operational and CDC (Centers for 
Disease Control) criteria for CFS. At our outpatient clinic, a chronic fatigue protocol 
was applied5,6. Nevertheless, clinicians still voiced difficulty in diagnosing CFS, 
because there is no known organic substrate and there is debate as to which medical 
examinations are needed to exclude physical causes for the fatigue symptoms. Also, 
the criteria on the basis of which the physician could establish the severity of the 
fatigue and functional impairment were a matter of discussion.
Chronic fatigue syndrome: initiating and perpetuating factors
Several somatological and psychosocial hypotheses concerning the aetiology of CFS 
were explored7,8. In clinical, microbiological and immunological studies, causes for 
CFS were not found9-15. Up to now, the nature of the initial pathology is still poorly 
understood16. Longitudinal research pointed out that most patients do not 
recover17,18. Since causal factors were absent and the prognosis of CFS turned out to 
be poor, the attention of our studies for perpetuating factors was further elaborated. 
The discrimination between precipitating and perpetuating factors opened up 
hypotheses with regard to somatic and psychological factors. The possibility exists 
that a somatic event may have triggered the symptoms. Psychological processes 
appeared to be involved in the perpetuation of complaints in CFS patients19. These 
processes involved ideas of patients concerning complaints (cognitions) and
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behavioural factors such as persistent avoidance of activities associated with an 
increase in symptoms. A strong focus on bodily symptoms, low levels of physical 
activity and a poor sense of control contributed to an increase in the severity of the 
fatigue and functional impairment. Strong somatic attributions indirectly influenced 
fatigue, via lower levels of physical activity. Most factors in the model of perpetuating 
factors in CFS were found in other studies as well20,21. However, the model also had 
its limitations. The focus was on complaint-related cognitions and behaviours. 
Cognitions and behaviours concerning the patient’s surroundings were not included, 
although perceived social support and the relationship with doctors may also be of 
importance in the perpetuation of CFS.
Cognitive behaviour therapy for chronic fatigue syndrome
Obscurity about the cause of CFS is not necessarily an obstruction for an effective 
treatment. In 1994 our first case study of a CFS patient treated with cognitive 
behaviour therapy was published22. Since the results in clinical practice were 
promising, a preliminary treatment protocol for cognitive and behavioural 
interventions was developed23. In the meantime no pharmacological treatments had 
proven to be effective24,25 and the model of perpetuating factors in CFS had shown 
causal relations between perpetuating factors and complaints19. These findings were 
a good starting point for further elaboration of evidence-based cognitive behavioural 
treatment. Cognitive behaviour therapy (CBT) is a general form of psychotherapy 
directed at changing condition-related cognitions and behaviours. In controlled 
studies CBT appeared to be effective in conditions such as panic disorder, 
depression, obsessive-compulsive disorder (OCD) and irritable bowel syndrome 
(IBS)26-30. CBT is directed at cognitions and behaviours relevant for each specific 
disorder, which implies that CBT for depression is not the same as CBT for IBS or 
CBT for OCD. CBT for depression appeared to be not effective for CFS patients31. In 
our opinion, this finding was not surprising, since clear differences between 
depressed CFS patients and patients with a major depression were found32. In an 
uncontrolled study effect of CBT for CFS was found in 22 of 27 patients33. CBT was 
directed at increasing self-efficacy and performing activities that were avoided for a 
long time. In 80% of the treated CFS patients this effect was sustained over four 
years34. In the first randomised controlled trial (RCT), both CBT and medical 
treatment were combined with immunotherapy or placebo35. Results were 
disappointing. None of the groups treated had a larger effect than those receiving the 
standard medical treatment. In our view, CBT was too short, not stand-alone 
treatment and due to the combination with immunotherapy or placebo the somatic 
attributions were aggravated rather than reduced.
In 1995 we applied a grant proposal for a multicentre randomised controlled trial of 
CBT for patients with CFS. Shortly after the start of the trial in 1996 another RCT was 
published showing the effectiveness of CBT compared to medical care36. CBT 
consisted of 16 weekly sessions within four months. Therapy was directed at
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changing cognitions and a gradual increase in activity. The controls received 
standard medical care, mainly consisting of reassurance that no organic disease had 
been diagnosed. Twelve months later, at follow-up, 73 percent of the CFS patients 
treated with CBT showed significant improvement in daily functioning as measured 
by the Karnofsky scale, a global rating of the performance status. Improvement 
mostly occurred during the follow-up period, which can be best explained from the 
relatively short treatment duration. A period of four months seems rather short to 
extend the building up of activity to work rehabilitation. The rating of the Karnofsky 
scale is largely determined by being active in work. However, since the control group 
did not receive any treatment, it remained unclear whether the treatment effect was 
to be attributed to elements of the CBT or to non-specific factors such as attention by 
the therapist.
One year later three other RCT’s were published, in which CBT was compared to 
other treatments37-39. A controlled study of Deale and colleagues has ascertained that 
effects of CBT may not be attributed to non-specific treatment factors solely37. CBT 
and relaxation therapy, both consisting of an average of 13 sessions spread over six 
months, were compared. The CBT was educational in nature with an emphasis on 
behavioural changes. Not until the patient had made certain advances in his or her 
activity levels was cognitive restructuring started. The relaxation therapy entailed 
progressive muscle relaxation, visualisation and exercises inducing rapid relaxation. 
Sixty CFS patients were randomly assigned to CBT or relaxation therapy. Patients 
treated with CBT improved more on functional impairment and fatigue than patients 
treated with relaxation therapy. Improvements were sustained over six months of 
follow-up. After conclusion of the CBT the somatic attributions were unchanged and 
they were not found to predict a poorer outcome. Attitudes towards the avoidance of 
activity had changed in the CBT group, but not in the control group. This change 
coincided with a positive treatment outcome40. The condition of the immune system 
did not change during the treatment, nor was it predictive of improvement following 
CBT41. A major methodological limitation of this study was that one therapist 
performed all therapies of both kinds.
In a randomised controlled study Fulcher and White compared graded exercise 
therapy (GET) with a combined therapy of flexibility exercises and relaxation therapy, 
both consisting of weekly sessions in a period of twelve weeks38. Whereas the 
rationale for most types of CBT for CFS is fear and avoidance of activity, the 
experimental treatment was based on a physiological model of deconditioning. 
Patients weekly worked on their physical condition. Patients treated with GET 
reported significantly more improvement than the patients treated with relaxation and 
flexibility exercises. It was not possible to establish the effects of therapy at follow-up, 
because more than half of the patients crossed over from flexibility exercises to GET. 
Striking in this study was a selection-bias of the patients. Forty-one percent was 
treated preceding the study as a result of psychiatric co-morbidity. Wearden et al.39 
studied the effects of the anti-depressive drug fluoxetine or a placebo both with and
14 Chapter 1
without GET. No placebo was offered for GET. Merely one-third of the patients 
completed the 6-months treatment program. More dropouts were present among 
those who had been prescribed GET. Nevertheless, GET showed significant 
improvement with regard to fatigue and functional impairments, whereas the effect of 
fluoxetine was not significant.
In 2000 in a review, CBT and GET were found to be the only effective treatments for 
CFS patients16. However, it was questioned whether the results could be generalised 
outside specialist centres where only a few highly skilled therapists, or even a single 
therapist37, administered CBT.
Outline of the thesis
The studies presented in this thesis are primarily concerned with the effectiveness of 
cognitive behaviour therapy for CFS patients and factors influencing the outcome in 
CFS patients with and without treatment.
For these studies, between October 1996 and January 1998 all patients with a major 
complaint of fatigue referred to the outpatient clinic of general internal medicine of the 
University Medical Centre Nijmegen were clinically evaluated by physicians using a 
standardised protocol and also screened for CFS criteria by computerised 
assessment (MID TestOrganizer). Considering the above-mentioned problems of 
clinicians in diagnosing CFS, we asked the question whether the CFS diagnoses 
resulting from both methods were consistent. We were especially interested in the 
extent to which there is agreement on the diagnosis of CFS between physicians 
using the chronic fatigue protocol and researchers evaluating the computerised 
questionnaires. This study is presented in Chapter 2 .
Studying CBT for CFS, we first asked the question whether the treatment protocol for 
CFS patients was successful in systematic evaluation of several case studies. 
Multidimensional assessments of outcome measures and process variables at 
baseline, after treatment and during follow-up were made to compare the results to 
the data of healthy controls and to shed light on the criteria for clinical significant 
improvement. In one of these case studies the treatment protocol developed by our 
research group, which has many in commons with the treatments by Sharpe36 and 
Deale37 is extensively described. This study is presented in Chapter 3 .
Our next investigations dealt with the effectiveness of CBT for CFS in a randomised- 
controlled trial. In a multicentre study, we questioned the effectiveness of CBT, 
administered by 13 behaviour therapists of three different disciplines in three different 
settings, compared to guided support groups and natural course. None of the 
therapists was familiar with CBT for CFS at the start of the trial. The treatment 
protocol was further refined and consisted of 16 sessions. In the initial sessions 
impeding cognitions are dealt with. Subsequently, recognising and respecting limits is 
practised, and finally, increasing the activity levels becomes the central component. 
Main goal of the treatment was full recovery, supplementary objective being return to 
the workplace. The multicentre randomised controlled trial is described in Chapter 4 .
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In the RCT the role of perpetuating factors in treatment outcome was also studied. 
We addressed the question if the perpetuating factor physical activity could be 
defined by means of intra-individual physical activity patterns. In clinical practice we 
observed that part of the CFS patients was characterised by profound physical 
inactivity. Other patients were far more active but nevertheless judged themselves as 
rather inactive. We tested whether patients’ self-reported long-term inactivity after 
exertion as well as large day-to-day fluctuations in activity and pervasive inactivity 
could be substantiated by a behavioural measure of activity. This study is presented 
in Chapter 5 .
We addressed the questions which other factors of interest for the persistence of 
CFS complaints in patients with and without treatment could be identified. CFS 
frequently has been associated with psychiatric disorders. Obstacles in clarifying the 
role of psychiatric disorders in CFS arise from overlap between symptoms of CFS 
and psychiatric disorders like depression. Over- or underdiagnosis of psychiatric 
disorders may be the result. As predictors of outcome in the prognosis of CFS 
patients psychiatric disorders have shown conflicting results. These issues raise 
questions about the impact of psychiatric disorders on the effectiveness of CBT for 
CFS. The prevalence of lifetime or current psychiatric disorders among CFS patients 
and the role of psychiatric co-morbidity in treatment outcome are described in a study 
presented in Chapter 6 .
Another factor possibly influencing treatment outcome was financial benefit. In the 
Deale et al. RCT37 poor outcome was associated with making a new claim for 
disability-related benefit during CBT. In clinical practice we noticed that progress 
during CBT was slow and recovery often absent in patients engaged in legal 
procedures for financial benefits. Consequently, the treatment outcome of CFS 
patients with claims for disease-related financial benefits was studied. These results 
are presented in Chapter 7.
In former studies of the Nijmegen Fatigue Research Group, the social environment of 
CFS patients received little attention. Although we pay attention to environmental 
reactions in the treatment protocol of CBT for CFS, we are not familiar with the role of 
social support in the persistence of CFS. The research questions were the 
comparison of social support in CFS patients with other patient groups, the course of 
social support in patients with and without treatment and the role of social support as 
a predictor of CFS complaints. This study is presented in Chapter 8 
The general practitioner is part of the social environment too. The role of the general 
practitioner seems especially important, because often the general practitioner is the 
first professional confronted with the complaints of chronic fatigue. How this first 
consultation passes off may determine the future course of the CFS patient 
considerably. We were interested in the use of the diagnosis CFS by general 
practitioners, their reactions to self-diagnosis and their opinion about the 
communication with CFS patients, as well as the patients’ opinions about general 
practitioners. This study is presented in Chapter 9 .
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If the effectiveness of CBT for CFS patients is proven, transfer of the treatment from 
CFS research clinics to mental health institutes is essential to increase accessibility 
of CBT for more CFS patients in the future. One of the questions was if the treatment 
protocol of CBT for CFS could be transferred to therapists outside university medical 
settings. This was studied by checking if therapists had stuck to the standardised 
treatment and by questionnaires to reveal the therapists’ opinion of the treatment. 
This study is presented in Chapter 10.
Implementation of CBT for CFS not only depends on transferability of the treatment 
to other therapists, but also on the economic evaluation of the intervention. Before 
CBT for CFS can be implemented in day to day health care practice, information 
about cost-effectiveness is desirable. A cost-effectiveness analysis was an integral 
part of the effectiveness study. This study is presented in Chapter 11.
The results of the presented studies, practical implications and directions for future 
research will be discussed in Chapter 12.
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Diagnosing chronic fatigue syndrome: comparison of a protocol 
and computerised questionnaires
Abstract
Background In the context of outpatient care and within the framework of scientific 
research, guidelines and measuring instruments have been developed to help 
improve CFS diagnostics. The purpose of this study was to measure the agreement 
between the evaluations of chronically fatigued patients by physicians using a CFS 
protocol and by researchers using computerised questionnaires.
Methods The sample consisted of 516 patients referred to an internal medicine 
outpatient clinic with complaints of chronic fatigue. Retrospectively the medical 
records and the computerised questionnaires were checked separately and 
compared to see whether the criteria for diagnosis of CFS had been met. In addition, 
the reasons for not diagnosing CFS were evaluated.
Results Agreement between the physicians’ and the researchers’ evaluations was 
84%. Disagreement mostly concerned severity of fatigue and functional impairment, 
or premorbid exclusion criteria. A physical cause for the chronic fatigue was only 
found in 3% of the cases.
Conclusions For physicians questionnaire assessment may be complementary to the 
CFS protocol in optimising the process of diagnosing CFS.
Introduction
In recent years we have seen a rise in the diagnosis of chronic fatigue syndrome 
(CFS). A comparison of studies investigating the prevalence of CFS has revealed 
that general practitioners diagnose CFS more often than a decade ago. h 1993 27% 
of GPs never diagnosed CFS1. In a similar study in 1999 this percentage had 
dropped to 13%. However, despite this increase in diagnosing CFS, many clinicians 
still have difficulty in making this diagnosis, among other reasons because there is no 
known organic substrate. The international criteria that have facilitated scientific 
research2 have not been validated for individual patients and are thus less 
appropriate for use in clinical practice. There is a debate among medical 
professionals, for instance, as to which medical investigations are needed to exclude 
physical causes of the symptoms of fatigue. Also, the criteria on the basis of which 
the physician can establish the severity of the fatigue and functional impairment are a 
matter of discussion.
During the last decade our outpatient clinic has seen large numbers of patients 
suffering from chronic fatigue, both in the context of outpatient care and within the 
framework of scientific research. In both settings guidelines and measuring 
instruments have been developed to help improve CFS diagnostics3,4. At our 
outpatient clinic a chronic fatigue protocol is applied5. In our scientific studies patients 
fill in several computerised questionnaires to establish whether they meet the 
operational and Centers for Disease Control (CDC) criteria for CFS6.
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In this paper we report a retrospective study aimed at establishing the extent to which 
there is agreement on the diagnosis of CFS between physicians using the chronic 
fatigue protocol and researchers evaluating the computerised questionnaires.
Methods
Patients and procedure
The sample consisted of all patients referred to the general internal medicine 
outpatient clinic of the University Medical Centre St Radboud in Nijmegen with 
complaints of chronic fatigue between October 1996 and January 1998. These 
patients were screened according to the CFS protocol. The protocol included an 
extensive anamnesis administered by the attending physician, frequently a resident 
in internal medicine, followed by a medical examination and a restricted number of 
laboratory tests. This consultation lasted approximately one hour. Subsequently, after 
a trained nurse had instructed the patient on how to operate the computer, the 
patient was requested to fill in the questionnaires on a computer in a separate 
consulting room, which took about 30 minutes. The nurse remained available 
throughout the procedure for any questions. After four weeks the patient was called 
in for a second consultation during which the physician explained the findings of the 
clinical examination. The diagnosis of CFS was based solely on the physician’s 
judgment of these clinical findings. The outcome of the questionnaire assessment 
was used later to select CFS patients eligible for a randomised controlled trial6 and 
was not taken into account in the clinical judgment.
CFS protocol
To streamline and facilitate CFS diagnostics in patients referred with complaints of 
chronic fatigue, a CFS protocol for outpatients was developed containing guidelines 
for both the anamnesis and physical examinations as well as supplementary 
diagnostics.
CFS is defined as a self-reported fatigue that has lasted more than six months, is 
irrespective of physical exertion, leads to severe functional impairment, and where 
there is no medical explanation for the symptoms. For a diagnosis of CFS to be 
made, the physician needs to answer the following questions: Can a somatic 
explanation for the symptoms be excluded? Is this a case of severe fatigue 
associated with serious limitations in the patient’s professional, social and/or 
personal functioning? Have the symptoms and impairments been present for at least 
six months? Do any of the exclusion criteria as formulated by the CDC concerning 
depression, psychosis, eating disorders or alcohol abuse apply?
Anamnesis
The first step in the symptom-specific anamnesis is to try and gain insight into the 
patient’s expectations and objectives with respect to this consultation and this 
doctor? Frequently, CFS patients attribute their symptoms to a variety of factors, 
which cause them to have high expectations for the diagnostics. Also, there may be a 
hidden agenda involving insurance issues and invalidity benefit claims. It is essential
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to identify these issues and expectations at an early stage to make communication 
more transparent and to prevent both sides from digging in7. When it has been 
established what the patient may or may not expect from his or her visit to the clinic, 
the severity and extent of the functional impairment is investigated. A suitable 
technique is to have the patient describe what a normal, average day looks like, for 
instance the day before. Important details that should be discussed are: At what time 
does the patient get up? Does he or she take a shower, have breakfast, get dressed? 
Also issues such as who does the shopping, or the cooking, whether he/she goes to 
work, plays sports, etc. should be addressed. It is recommended to literally go 
through the patient’s day, hour by hour8. Subsequently, the duration and the course 
of the symptoms are discussed. It is essential to try and establish whether the patient 
has been fatigued his/her entire life or whether the onset of the complaints can be 
more or less clearly defined. This is assessed both from the physician’s and the 
patient’s perspective.
Next, any concomitant complaints are investigated, which are often abundant. It is 
important to determine whether fatigue is indeed the principal complaint. In principle, 
the interview continues with a full internal anamnesis, use of medication (including 
alternative medication) and stimulants, and the patient’s case history, specifically with 
respect to psychiatric complaints and eating disorders. Finally, any previous 
diagnoses and treatment(s) are discussed.
Physical examination
The patient is given a full physical examination during which specific attention is paid 
to the detection of so-called stigmata indicating possible endocrine causes for the 
fatigue symptoms, such as orthostatic hypotension, pigmentations, pattern of body 
hair, etc.
Supplementary diagnostics
Laboratory tests are restricted to erythrocyte sedimentation rate (ESR), 
haematological parameters, minerals, liver and renal functions, protein spectrum, 
thyroid stimulating hormone (TSH), ferritin and creatine phosphokinase (CPK). In 
rare cases this range of tests may be extended on the basis of the findings of the 
anamnesis and/or physical examination.
Computerised questionnaires
A total of four questionnaires was administered to verify whether patients fulfilled the 
international criteria for CFS as used in scientific research2. The fundamental 
criterion, i.e. exclusion of physical causes, could not be included in this part of the 
study since a medical practitioner can only evaluate this aspect. The remaining 
criteria were all assessed by means of the various questionnaires, which were 
administered on a personal computer. Patients completed the following five 
questionnaires: 1) a general questionnaire on the patient’s personal data, and the 
nature, duration and onset of the complaints, 2) the validated fatigue inventory 
Checklist Individual Strength (CIS)3,9, 3) a functional impairment questionnaire 
consisting of eight subscales of the Sickness Impact Profile (SIP-8): sleep/rest,
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housekeeping, mobility, social interaction, walking, alertness/intellectual functioning, 
work, recreational and leisure activities10, 4) a questionnaire scoring premorbid 
functioning and finally 5) a questionnaire assessing additional CFS-related physical 
complaints. For the diagnosis of CFS as commonly applied in research the following, 
criteria needed to be met:
- Fatigue is the principal complaint
- The fatigue symptoms have been present for at least six months, excluding 
lifelong incidence
- A score of 35 or higher on the CIS subscale fatigue severity
- A score of 800 or higher on the eight subscales of the SIP
- Absence of premorbid eating disorders, alcohol-related problems in the two years 
prior to the assessment, premorbid depressive disorders or psychotic episodes.
The concomitant physical complaints were not included in the diagnosis since it has 
already been established that these are not contributing factors4.
Analysis
A researcher from the department of general internal medicine (HK) retrospectively 
evaluated the medical files of all the patients examined in the above-mentioned 
period. A researcher from the department of medical psychology (JP) evaluated the 
computerised questionnaire data. Both evaluations were aimed at establishing 
whether a diagnosis of CFS had been made. In the absence of a CFS diagnosis, the 
rationale behind the judgment was determined. Next, the two datasets were linked 
and compared to determine statistically the agreement with respect to the CFS 
diagnosis for each patient. Concordance between the physician’s diagnosis and the 
researcher’s evaluation of the computerised questionnaires was evaluated by 
Cohen’s kappa, which is a measure of concordance between two dichotomous 
variables corrected for chance. A value of Cohen’s kappa of 0.40 or lower is 
considered moderate, between 0.40 and 0.70 satisfactory, and above 0.70 good.
Results
Patient characteristics
In the period investigated, 567 patients were referred to our outpatient clinic because 
of complaints of chronic fatigue. Fifty patients were not included in the study. Their 
symptoms could be explained on the basis of existing data and a consultation was 
not expected to reveal any additional information. Of the remaining 517 patients, 212 
were referred by their GPs, 46 by a medical specialist and 259 patients had 
contacted the clinic of their own accord. Nearly 75% of the patients attended the 
outpatient clinic in the expectation that they would be diagnosed with CFS, 16% 
mentioned participating in scientific research as their main reason for requesting the 
consultation, and 10% reported both these motives. In one patient a full assessment 
proved to be impossible. Thus, the data of 516 patients could be analysed and 
compared. Of the patients included in the analyses 78% were female, 22% male, and 
their mean age was 36 years and 9 months (range 14-69 years).
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CFS protocol
Figure 1 shows the results of the physical assessment of all 516 patients. Based on 
the protocol, the clinicians diagnosed 409 patients (79%) as suffering from CFS. In 
the remaining 107 patients CFS was not diagnosed on various grounds. In half of 
these patients (n=54) the fatigue-related symptoms or functional impairment were not 
judged sufficiently severe to justify a diagnosis of CFS. In 40 patients comorbidity, 
possibly explaining the fatigue, was diagnosed. The comorbidity included somatic 
illnesses (n=17), psychosocial problems (n=9), alcohol-related problems or eating 
disorders (n=4), and other principal complaints (n=10). Thirteen patients met the 
exclusion criteria for CFS relating to the premorbid condition, viz. eating disorders, 
depression or lifelong fatigue.
Figure 1. Number of patients referred for fatigue-related symptoms and the results of the protocol-based 
physicians’ and questionnaire-based computerised assessments
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Computerised questionnaires
The results of the questionnaire-based assessment of all 516 patients referred are 
also listed in figure 1. According to the outcome of the questionnaires, 369 patients 
(71%) met the CFS criteria investigated. The reasons why the remaining 147 patients 
were not diagnosed as suffering from CFS included insufficient scores on the CIS 
and/or SIP-8 (n=59), fatigue proved not to be the principal complaint (n=29) and the 
presence of premorbid eating disorders or alcohol-related problems, depression, 
psychoses or lifelong fatigue (n=59).
Comparison o f the two assessments
Table 1 indicates that in 84% of the cases there was agreement between the 
clinicians’ assessments and the researchers’ evaluations of the questionnaires as 
regards the presence or absence of a CFS diagnosis. The degree of agreement was 
analysed using Cohen’s Kappa and was 0.58 (se 0.04), a correspondence that is 
common in scientific research in a clinical setting11 and is generally regarded as 
satisfactory12.
Of all 516 patients examined, 21 (4%) were diagnosed as suffering from CFS on the 
basis of the computerised questionnaires whereas the internist excluded CFS. In 
these 21 patients a different diagnosis was made in six of them: either somatic (n=3) 
or psychiatric (n=3). In the remaining 15 patients the physician found insufficient 
complaints and/or impairments for a diagnosis.
Table 1. Numbers and percentages of patients evaluated for the diagnosis of CFS by physician’s use of CFS 
protocol and researcher’s evaluation of computerised questionnaires
QUESTIONNAIRES
CFS no CFS
CFS 348 61 409
CFS (67%) (12%) (79%)
PROTOCOL no CFS 21 86 107
(4%) (17%) (21%)
369 147 516
(71%) (29%)
In 61 (12%) of the patients the inclusion criteria for CFS were not met according to 
the questionnaire-based assessment, whereas the specialist did diagnose CFS. The 
scores on the CIS or SIP were found to be too low in 40% of the patients concerned, 
while the physician judged the complaints and impairments as sufficiently severe. In 
the computer assessment 29% of the patients had not indicated fatigue as their main 
complaint and 31% had reported premorbid eating disorders or alcohol-related 
problems, depression or lifelong fatigue, aspects that had not come to light during the 
physician’s consultation.
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Shortened Fatigue Questionnaire (SFQ)
University Medical Center Nijmegen, The Netherlands 
Dept. of Medical Psychology
Name:....................................................................... Gender : male/female
Date of birth: ................................
Today's date:................................
On this page you will find four statements indicating how you have been feeling 
the past two weeks.
You can answer each question by placing a mark in one of the seven boxes. The 
position of the marking indicates to what extent you feel the statement applies to 
you.
For example: if you think the statement is completely true, you should place a 
cross in the left box, like this:
yes, 
that is true X
no, that 
is not true
If you think the answer is not ‘yes, that is true' but also not ‘no, that is not true', 
you should mark the box that best corresponds with your feeling, for example like 
this:
yes, 
that is true X
no, that 
is not true
Please answer all the statements and place only one cross for each statement.
1. I feel tired
2. I tire very quickly
3. I feel fit
4. Physically I feel exhausted
yes, 
that is true
yes, 
that is true
yes, 
that is true
yes, 
that is true
no, that 
is not true
no, that 
is not true
no, that 
is not true
no, that 
is not true
Figure 2 a. Shortened fatigue questionnaire (SFQ)
Discussion
It goes without saying that the diagnosis of CFS can and should never be solely 
based on an assessment using computerised questionnaires. First and foremost, any 
physical cause for the complaints should be excluded, a criterion that always requires 
the judgment of a physician. In this study, a physical cause for the fatigue symptoms 
could only be found in a few cases. Apparently, prior to their referral, the majority of 
patients had been screened in such a way that further diagnostics did not yield any 
additional information. We concluded that referral of CFS patients to our internal 
medicine outpatient clinic seldom lead to new medical insights. Therefore, referrals
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Score form SFQ
University Hospital Nijmegen
Department of Medical Psychology
Name: .............. .......................................................Gender : male/female
Date of birth: ....
Today's date:
Chief complaint: 
Date of origin: .
Diagnosis:.......
.(month).......................(year)
Groups
Average < = >
age low average average average high
Healthy groups: 
healthy adults
students normal circumstances 
students demanding circumst. 
servicemen at rest (normal) 
servicemen in field exercise
Patient groups: 
cancer
functional bowel disease 
multiple sclerosis 
chronic fatigue syndrome
37 4 4 5-8 9-14 >15
22 4 5-7 8-14 15-21 >22
21 <5 6-9 10-17 18-23 >24
21 4 5-6 7-14 15-22 >23
21 <5 6-11 12-18 19-24 >25
61 4 5-12 13-21 22-27 28
41 < 6 7-12 13-21 22-27 28
36 <12 13-19 20-26 27 28
38 <22 23-25 26-27 28 28
1. I feel tired
2. I tire very quickly
3. I feel fit
4. Physically I feel exhausted
yes, 
that is true
yes, 
that is true
yes, 
that is true
yes, 
that is true
7 6 5 4 3 2 1
7 6 5 4 3 2 1
1 2 3 4 5 6 7
7 6 5 4 3 2 1
no, that 
is not true
no, that 
is not true
no, that 
is not true
no, that 
is not true
Total score SFQ:
Figure 2 b. Score form Shortened fatigue questionnaire
could be limited to those patients for whom the expertise of a specialist is required to 
exclude any physical causes, for instance in case of suspected adverse effects of 
medication, slightly deviating laboratory test results or somatic comorbidity. 
According to a recent unpublished survey among general practitioners, currently 78% 
of fatigued patients are still being referred to a medical specialist. It is our view that 
administration of the presented protocol for chronic fatigue complaints by GPs not 
only would lead to substantial reductions in public spending, but would also prevent 
undue expectations in patients about new or additional medical diagnoses. 
Retrospectively comparing the diagnoses based on the CFS protocol with the
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diagnoses on the basis of the computerised questionnaires, agreement between both 
assessments was found in the majority of the cases. In 16% of the cases the 
clinicians’ and the researchers’ conclusions were contradictory. In quite a few 
instances, there was ambiguity about the severity of the fatigue and functional 
impairment. When a physician is having doubts about symptom severity, 
questionnaire assessment might be considered. Supplementary to the protocol the 
Shortened Version of the Fatigue Questionnaire13,14 could be administered to assess 
fatigue severity (figure 2) or the physical functioning subscale of the SF-36 
questionnaire (MOS-Short Form-36)15-17 to measure functional impairment (figure 3).
MOS-Short Form-36 questionnaire (SF-36) 
subscale physical functioning 
Ware J, Sherbourne C, 1992
The following items are about activities you might do during a typical day. Does 
your health now limit you in these activities? If so, how much?___________
Yes, 
limited a 
lot
Yes, 
limited a 
little
No, not 
limited 
at all
Vigorous activities, such as running, lifting heavy 
objects, participating in strenuous sports 1 2 3
Moderate activities, such as moving a table 
pushing a vacuum cleaner, bowling or playing golf 1 2 3
Lifting or carrying groceries 1 2 3
Climbing several flights of stairs 1 2 3
Climbing one flight of stairs 1 2 3
Bending, kneeling, or stooping 1 2 3
Walking more than a mile 1 2 3
Walking several blocks 1 2 3
Walking one block 1 2 3
Bathing or dressing your self 1 2 3
Score range 10-30
Score < 25 indicative of severe impairment in physical functioning
Figure 3. MOS-Short Form-36 questionnaire (SF-36), subscale physical functioning
Physicians using the CFS protocol more often diagnosed CFS than researchers 
evaluating the computerised questionnaires (79% and 71% respectively). Premorbid 
exclusion criteria for the diagnosis CFS, such as alcohol dependency, eating 
disorders or depressive disorders, were found more in the computerised 
questionnaires than in the physician’s consultation. Obviously, it is difficult to 
establish the patient’s case history or current situation with respect to psychological
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problems or psychiatric disorders. Questionnaire assessment might lead to additional 
information.
At our outpatient clinic, after consulting the internist patients with chronic fatigue 
routinely fill in computerised questionnaires to establish whether they meet the 
operational criteria for CFS. The physician is able to consider the questionnaire data 
concerning fatigue severity, functional impairment and actual and premorbid 
functioning before the second consultation. In this way the questionnaire assessment 
is complementary to the CFS protocol and the process of diagnosing CFS is 
optimised.
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Cognitive behaviour therapy for chronic fatigue syndrome: 
a case study
Abstract
The case of a 26-year old woman with Chronic Fatigue Syndrome (CFS) is 
presented. Multidimensional assessment showing severe debilitating fatigue and 
considerable psychological, social and occupational impairment confirmed the 
diagnosis. Cognitive behaviour therapy (CBT) was based on a tested causal model of 
CFS and individual behavioural analyses. Key elements in CBT were process 
variables from the CFS model, like sense of control, causal attributions, physical 
activity and focusing on bodily functions. Goals were recovery of fatigue, returning to 
work and relapse prevention. The course of therapy is described in detail to illustrate 
difficulties in treating CFS. Assessments were made five times, at baseline and at 8, 
14, 21 and 33 months. Comparison of the pre-test, post-test and follow-up scores of 
the outcome variables, fatigue and functional impairment and of the process 
variables showed clinically significant improvement from the range of CFS patients to 
the range of healthy controls.
Introduction
Chronic fatigue syndrome (CFS) is characterised by persistent or relapsing unexplai­
ned chronic fatigue of new or definite onset and lasting for at least six months. 
Fatigue is not the result of an organic disease or ongoing exertion, it is not alleviated 
by rest and it results in substantial reduction in previous levels of occupational, 
educational, social and personal activities1. In clinical, microbiological and 
immunological research, causes for CFS have not been found2. Longitudinal 
research pointed out that most patients do not recover3,4. No pharmacological 
treatments have proven to be effective5,6.
Cognitive behaviour therapy (CBT) seems to be the most promising treatment of 
CFS7. Obscurity about the cause of physical complaints is not necessarily an 
obstruction for an effective treatment. The effect of CBT was also proved in other 
somatic complaints without a known course, like irritable bowel syndrome8,9. 
However, several of the studies on CBT for CFS suffer from methodological 
shortcomings. One of the difficulties is the definition of the outcome variables. Most 
studies report effects of CBT on functional impairment, health status or self-reported 
improvement, but hardly on fatigue, the main complaint of patients with CFS. In an 
uncontrolled study Butler and colleagues10 showed effect of CBT in 22 of 27 CFS 
patients. CBT was directed at increasing self-efficacy and performing activities that 
were avoided for a long time. In 80% of the treated patients this effect was sustained 
over four years11. In a randomised controlled trial of Sharpe and colleagues12 CBT 
was compared to medical care. CBT consisted of 16 sessions within four months. 
Therapy was directed at changing cognitions and gradually building up activities. 
Twelve months later, at follow-up, 73% of the CFS patients treated with CBT showed
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significant improvement in daily functioning as measured by the Karnofsky scale, a 
global rating of the performance status. Perhaps the short duration of CBT may 
explain the absence of a post-test effect. A period of four months seems rather short 
to extend the building up of activity to work rehabilitation. The rating of the Karnofsky 
scale is largely determined by being active in work. A controlled study of Deale and 
colleagues13 has ascertained that effects of CBT may not be solely attributed to non­
specific treatment factors. CBT and relaxation therapy, both consisting of 13 sessions 
within six months, were compared. Patients treated with CBT improved more on 
functional impairment and fatigue than those treated with relaxation therapy. 
Improvements were sustained over six months of follow-up. A major methodological 
limitation of this study was that one therapist performed all therapies of both kinds. In 
a randomised controlled study Fulcher and White14 found a specific effect in the 
treatment of CFS patients. They compared graded exercise with flexibility exercises 
and relaxation therapy, both consisting of weekly sessions in a period of 12 weeks. 
Patients treated with graded exercise showed significantly more self-reported 
improvement than the patients treated otherwise. However, striking in this study was 
a selection-bias of the patients. Forty-one percent was treated preceding the study as 
a result of psychiatric co-morbidity. Further, it was not possible to establish the 
effects of therapy at follow-up, because more than half of the patients crossed over 
from flexibility exercises to graded exercise. CBT in a format of six sessions is less 
effective for CFS patients when it is combined with immunologic therapy or 
placebo15. CBT developed for depression is also not effective for CFS patients16. This 
latter finding is not surprising. Although it has been suggested that depression plays 
a pathogenic role in CFS and even that CFS is a form of depression17, Powell and 
colleagues18 have shown clear differences between depressed CFS patients and 
patients with a major depression. Furthermore, pharmacological anti-depressant 
therapy has proven not to be effective for depressed and non-depressed CFS 
patients6. From the above facts it has been made clear that CBT is indeed an 
effective treatment for CFS. However, only little is known about the processes 
contributing to improvement.
The Dutch Fatigue Research Group has developed CBT for CFS19 based on a model 
of maintaining factors in chronic fatigue syndrome20. The model is shown in Fig. 1.
In this model factors playing a role in perpetuating fatigue were tested with structural 
equation modelling. Attributing complaints to a somatic cause produced low levels of 
physical activity, which in turn had a causal effect on fatigue severity. Sense of 
control and focusing on bodily symptoms each had a direct causal effect on fatigue. 
Depression had to be deleted from the model. The model showed an excellent fit for 
CFS patients, but was rejected for fatigued patients with multiple sclerosis. The newly 
developed CBT is directed at the mechanisms underlying CFS. Sense of control and 
physical activity will be increased and somatic attributions and focusing on bodily 
symptoms will be reduced. Goals of the therapy are recovery from fatigue and 
functional impairment, work rehabilitation and relapse prevention.
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The primary goal of this case study was to evaluate the model-based form of CBT. 
Additional goals were to give insight in both the mechanisms underlying CFS and the 
cognitive and behavioural techniques used in therapy, and to illustrate pitfalls in 
cognitive behaviour therapy for patients with CFS.
Figure 1. Model of CFS, developed and tested with LISREL (Vercoulen et al. 1998)
Case description
Mrs.B, aged 26 years, was referred to the department of Medical Psychology at the 
University Hospital Nijmegen by the general practitioner because of chronic fatigue 
complaints and severe myalgia. First of all a consultation was requested with the 
internist, who did not detect any physical defects and who diagnosed CFS. Additional 
assessment at Medical Psychology involving an interview and measurements of the 
complaints, confirmed the diagnosis. During interviews Mrs.B told the clinical 
psychologist that she had come from East Germany, where she had met her present 
Dutch husband seven years ago when she was studying information science. Her 
intention of marrying him and moving to the Netherlands caused resistance with her 
parents, because they would hardly be able to keep in touch with her from the then 
GDR (German Democratic Republic). In spite of periods of doubt and active 
opposition from the ‘Staatssicherheitsdienst’, Mrs.B was able to leave the country two 
years later, a month before the Berlin wall came down and permission was not 
required anymore. Meanwhile, her education had been completed. Half a year after 
the marriage took place, Mrs.B’s father passed away. This message reached her 
three days late, because of an over-occupied telephone network in her native
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country. Feelings of guilt and presumed, but non-existent reproaches from her 
mother because she had been absent when her father had been ill, played tricks on 
her. At the same time, living in the Netherlands meant a big change for her. She 
mastered the Dutch language quickly, resulting in a full-time position as a systems 
analyst. Her spare time was filled up with obligatory courses, sports and various 
hobbies.
After the last exam, Mrs.B became extremely fatigued. A few weeks later the feeling 
of too much strain disappeared, but she remained tired and listless, had muscular 
pains, slept a lot and often felt as if she was coming down with something. The 
general practitioner did not find any defects after physical and laboratory 
examinations. Mrs.B herself supposed that she had taken on too much. Back at 
work, she often had headaches and she dreamt a lot about her last period in East 
Germany. The general practitioner suspected that there was a relation between her 
fatigue and her problems in dealing with her emigration and her father’s death. 
Therefore he referred her to a social worker. An important aim was coming to terms 
with the pain of losing her father. Interventions were among others conversations 
with her mother about her feelings of guilt and the supposed criticism on the way that 
she acted. The effect of the treatment was a decrease in stress, but the fatigue 
remained. Still, she went back to work part-time and at great cost managed to work 
half days for a period of almost six months. Eight months later when referred to our 
institute, Mrs.B underwent a provisional examination in connection with the 
Disablement Insurance Act and was been found completely unfit for work. At home, 
too, extreme exhaustion, muscular pains and problems in focusing, seriously 
weakened her. Even light household chores were often too much for her. Activities in 
the field of sports, spare time and social contacts hardly ever took place anymore.
Behavioral assessment
Holistic theory
In the past years Mrs.B was faced with great mental and physical efforts. Thanks to 
discipline and efficiency she succeeded in passing examinations and in receiving 
permission to leave the country. In the Netherlands new goals were adapting to the 
regimen of the Dutch community, learning to command the new language like a 
native speaker and getting a job. Because of her strong motivation and high 
intelligence her plans worked out. However, once her goals had been attained she 
became extremely fatigued. She realised that her fatigue was the result of being 
overloaded in the previous months and she reposed for several weeks. Despite her 
husband’s advice to take a longer period of rest after years of exertion, she 
insufficiently seized the opportunity to recover and took up the thread of daily life. 
However, she did not succeed in resuming her work like before and lost her balance. 
Periods of high activity caused by the pressure of work alternated periods of 
exhaustion while being at leisure. Regularity was absent in daily life. Mrs.B was 
disappointed and angry for not being capable of continuing her former lifestyle.
CBT for CFS: a case study 39
These feelings were mitigated by her final assumption that a physical abnormality 
must be causing the complaints and that she was not responsible for this situation 
herself.
Behavioural analyses
Two patterns of the perpetuation of fatigue were revealed. The first behavioural 
analysis starts with an increase of fatigue or myalgia. Despite of night’s rest and lack 
of exertion Mrs.B is suffering of extreme fatigue and muscular pains. Her first 
reaction is based on thoughts like ‘it is awful being fatigued again and not being 
capable of normal daily activities’. Consequently, she feels depressed. She avoids 
activities as much as possible. Short-term, avoidance is followed by diminished 
fatigue. However, this short-term decrease of fatigue is not beneficial and antecedent 
to the second behavioural analysis. Long-term avoidance leads to decline in physical 
fitness. The patient’s body is not used anymore to exertion and reacts with fatigue 
and pain. Thus, inconsiderable effort causes physical overburden.
The second behavioural analysis starts with a decrease of fatigue or myalgia. The 
most prominent thought of Mrs.B is to profit by her good form and to make up 
arrears. She feels restless and tense, and strives to get going quickly before fatigue 
or pain hit her again. Compared to other days she is rather active. Short-term, she 
feels relieved and satisfied with the tasks finished. However, later that day fatigue 
increases because she engaged in more activities than her body could cope with. 
Mrs.B has tried a lot to recover. She was bedridden for a while, at other times she 
forced herself to activity, but she did not find a way to cope with fatigue. On the 
contrary, complaints increased due to the described ways of reacting to fatigue and 
pain. Peaks of activity and inactivity interchange. The level of activity is mainly based 
on thoughts considering her present situation and is no longer in accordance with 
physical sensations. Both behavioural analyses result in an increase of fatigue. In the 
long run the second behavioural analysis occurs less frequently. Mrs.B seldom feels 
less fatigued and her level of activity has declined more and more.
According to these analyses an important goal of therapy must be increasing the 
level of activity. However, this goal cannot be reached until Mrs.B has learned to 
react to fatigue in a different way. Irrational cognitions considering fatigue prevent 
improvement of the level of activity. Therefore, at first therapy will be directed at 
changing these irrational cognitions.
Measures
Prior to the initiation of treatment (T1), Mrs.B was administered multidimensional 
assessment for patients with CFS21. These measures were administered again 
during treatment at 8 months (T2), post-treatment at 14 months (T3), and both at 21 
months (T4) and at 33 months as follow-up (T5). The outcome variables such as 
fatigue and functional impairment, the process variables sense of control, physical 
activity, somatic attributions and focusing on bodily functions, and the CFS related
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dimensions pain, concentration and attention, and psychological well-being were 
assessed. The following measures were used.
Checklist Individual Strength: A 20-item self-report instrument of fatigue referring to 
the previous two weeks. Each item is scored on a 7-point Likert scale. From factor 
analysis four factors emerged. In this case study the factors subjective experience of 
fatigue (CIS-fat) and concentration (CIS-con) are used. The checklist has good 
reliability (Cronbach's alpha's varying from 0.83 to 0.92) and discriminative validity21. 
Self-observation list daily functioning: During 12 days patients rate fatigue and pain 
on a prescheduled diary four times daily on a scale of 0 (not at all) to 4 (very much). 
The daily observed fatigue (DOF) score and the daily observed pain (DOP) score 
vary from 0 to 16. Daily registration of hours being at work is registered as well 
(WORK). The psychometric qualities are good22.
Sickness Impact Profile: Impairment in daily functioning is assessed using eight out 
of 12 subscales: home management, mobility, alertness behavior, sleep/rest, 
ambulation, social interactions, work, recreation and pastimes. A total score (SIP) is 
calculated23,24.
Causal Attribution List: This list presents 10 possible causes of the complaints 
patients have, and distinguishes physical and psychosocial causes. A mean score of 
causal somatic attributions (SOM-att) is calculated22.
Actometer: A matchbox sized motion-sensing device used to provide a measure of 
actual levels of physical activity. The actometer is attached to the ankle of the patient 
and worn for a period of two weeks, day and night. It provides activity scores every 5 
minutes. The data are read by a computer program which calculates the average 
activity over the two week period (ACTO) and produces a visual display of the 
activity25.
Modified Pain Cognition List: A subscale of the MPCL was used to assess 
catastrophic thoughts concerning fatigue (MPCL-ca)22,26.
Sense o f control scale: Consisting of one specific question and four selected items of 
the modified Pain Cognition List in which the word pain is replaced by fatigue. 
Responses are scored on a 5-point Likert scale and the total score is calculated by 
adding all items (SE). The reliability is reasonable (Cronbach's alpha coefficients of 
0.75)22.
Symptom Checklist (SCL-90): The Symptom Checklist is a 90-item indicator of 
psychopathology and screens for anxiety, agoraphobia, depression, somatization, 
cognitive difficulties, interpersonal sensitivity, hostility and sleep disturbances. Scores 
on each item range from 1 to 5. The total score ranges from 90 to 450 (SCL-tot). The 
subscale somatization (SCL-som) was used to assess the process variable focusing 
on bodily functions27.
Beck Depression Inventory: A standardised self-report questionnaire, consisting of 21 
items, to measure depression (BDI). Scores on each item range from 0 to 3. The 
maximum total score is 63. Four diagnostic categories are based on the total score: 
0-9 non-depressed, 10-15 mildly depressed, 16-23 moderately depressed, 24 or
CBT for CFS: a case study 41
more severely depressed. A score of 16 or more is indicative of a clinical 
depression28,29.
Complex Reaction Time Task: Composed of three succeeding tasks, each providing 
a reaction time (RT) and movement time (MT). RT reflects speed of information pro­
cessing and MT reflects motor speed30.
Treatment
CBT consisted of 22 sessions within 14 months. Three follow-up sessions followed in 
the next 7 months. Treatment goals were recovery of fatigue and accompanying 
symptoms, returning to work and relapse prevention. CBT was directed at the 
process variables in the model of CFS20: to increase sense of control and physical 
activity and to decrease somatic attributions and focusing on bodily symptoms. CBT 
consisted of four phases, partially overlapping in time. The course of Mrs.B’s therapy 
will be described in order to illustrate different treatment methods.
Phase 1: Cognitive restructuring session 1-8 
Conditions to treatment
First of all, the therapist checked with Mrs.B whether she found herself sufficiently 
tested for physical abnormalities. This seemed to be the case. Then the therapist 
explained in detail the difference between factors causing fatigue in the past and 
factors perpetuating the complaints in the present. In Mrs.B’s case no somatic 
defects were found that could explain the present complaints. The therapist clarified 
that it would not be advantageous and may even be devastating to further speculate 
about the cause of CFS. The central question should rather be: ‘How can I recover?’ 
Mrs.B agreed with this view. Next, two important conditions of CBT were discussed. 
Firstly, agreement upon no further examinations or treatments for CFS was asked 
for. Secondly, Mrs.B was asked to express her willingness to active participation 
during therapy. She agreed with both conditions.
Discussing behavioural analyses and goals
By means of the behavioural analyses it was explained to Mrs.B how her cognitive 
and behavioural reactions might aggravate her complaints. Different thoughts and 
behaviour could stop the complaints from worsening. Mrs.B’s goal ‘recovering 
quickly’ was redefined as ‘learning to cope with fatigue in order to recover and to 
resume important activities, like work’.
Changing impeding cognitions into cognitions reflecting acceptance of fatigue 
The next step in therapy was drawing up an inventory of cogniti ve reactions to 
fatigue. Impeding cognitions and accompanying feelings were shown to aggravate 
fatigue. To avoid this aggravating effect a different cognitive reaction should contain 
elements of acceptance of the complaints. Goal of this intervention was to make 
Mrs.B familiar with thoughts like ‘I will stop resisting to my complaints and looking 
back for possible causes. Instead I will find out what I can do about it’. Next, Mrs.B 
was asked to imagine a situation in which fatigue had aggravated. She learned how 
to evoke more accepting thoughts. She went on to apply this technique at home. She
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realized that she was able to prevent fatigue from quickly aggravating.
Recognizing and respecting limits
Registration of fatigue and daily activities taught Mrs.B to see that she goes on with 
activities for a long time, thus causing increased fatigue. She learned to detect early 
symptoms of fatigue, being a signal of reaching her current limit. If she was able to 
stop in time, she could notice that fatigue did not increase and after some time some 
reduction of fatigue occurred. She was instructed to stop with daily activities as soon 
as fatigue comes up or increases. This exercise was hard for Mrs.B, whose discipline 
and opinions about work prevented her from suddenly stopping activities. Impeding 
cognitions resulting from this attitude were changed in cognitions helping her to come 
to a stop when necessary. In her view stopping meant not completing. However, 
stopping may also mean interrupt temporarily or take rest in-between. In the first 
phase of treatment Mrs.B realised that she could exercise influence on her 
complaints, a sign of increased sense of control. Focusing on bodily symptoms was 
decreased because of the agreement upon no further examinations and because of 
altered cognitions about fatigue and accompanying symptoms. Somatic attributions 
were diminished because she had stopped speculating about the causes of her 
complaints. At the end of this phase Mrs.B was not continuously extremely fatigued 
anymore. Therefore, she could start with building up physical activity.
Phase 2: Building up activity, session 6 -1 5
Next, physical activity was built up gradually and systematically. Mrs.B was asked to 
select a physical activity that she could perform every day, that could easily be 
registered and that enabled her to build up gradually. Mrs.B chose cycling as a lot of 
other patients do. Some patients prefer walking. The level to start with building up 
activity is defined by the period that the patient is able to perform the selected 
activity, without getting fatigued. Mrs.B. had a secure start at 5 minutes each day. 
Every week this period was increased with 1 or 2 minutes. She cycled every day, in 
the beginning building up systematically, but later taking pains to fulfil the daily 
cycling. She reported being afraid of a relapse when building up further. Her fear was 
reinforced by a visit to a meeting of the ME-association, at that time frequented by 
mainly non-believers of CBT. Their reaction compelled her to visit a colour-therapist, 
who diagnosed a lot of viruses and advised his special treatment for her complaints. 
The act of visiting another therapist for her complaints was conflicting with the 
agreement at the beginning of therapy. The therapist confronted her to choose 
between CBT and colour-therapy. Because of the progress she had already made 
with CBT, she decided not to engage in the other treatment. This incident gave rise 
to a renewed start of building up activities. It was suggested to Mrs.B to cycle twice a 
day, thus accelerating the building up of activities. From that point on she actively 
engaged in the therapy again. In time mental and social activities were added too. 
Vigilance to respect her limits was harder during these latter activities, but she took 
more pleasure in those activities than in cycling. Gradually, Mrs.B performed more
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and more activities in daily life without getting fatigued. The return of regularity in 
daily activities was considered a good preparation of returning to work.
In the second phase of treatment Mrs.B achieved a huge improvement in the level of 
activity. She also felt less frequently fatigued and depressed. She was still suffering 
from myalgia, although she reported a different kind of myalgia. The therapist 
labelled this pain as a possible consequence of building up activities.
Phase 3: Returning to work, session 12-22
Before the building up of activities was fully achieved, it was suggested to Mrs.B to 
draw up a plan for returning to work. She reacted frightened, judging herself not 
sufficiently recovered to even consider returning to work at that time. However, it was 
possible to motivate her to evaluate the reactions of the company doctor and the 
general manager to a plan of reintegration. In case of Mrs.B the company doctor was 
positive about her plan to return to work for several hours a day as an extension of 
therapy. He advised her to discuss this plan herself with her employer. Together with 
the therapist Mrs.B drew up a specific plan, containing the date she liked to resume 
work, the number of hours she was able to work each day and a program of building 
up the hours being at work every three or four weeks. Despite the preparation, the 
first meeting with the employer was very disappointing. In his opinion she could not 
come back in her former capacity as systems analyst. This profession was 
considered too stressful for her. Furthermore, the employer was of the opinion that 
he was not legally obliged to co-operate with the reintegration plan of resuming work 
therapeutically. With the aid of an occupational expert of the office executing the 
Disablement Insurance Act Mrs.B eventually succeeded in convincing the employer 
of the advantages of her plan. The first month she worked two hours each day. The 
second month the number of hours being at work was built up to four hours daily.
In the third phase of treatment Mrs.B was able to maintain the achieved 
improvements, despite of the hard negotiations with her employer and the number of 
hours being at work each day.
Phase 4: Relapse prevention, session 19-22 
Discussing changed lifestyle
Mrs.B’s expectations of recovery were explored. She was no longer afraid of relapse. 
She hoped that she could function again like she did before she became ill. It was 
discussed that resuming the premorbid lifestyle might increase the risk of relapse. 
During therapy Mrs.B made herself familiar with a new lifestyle. The changed lifestyle 
will be of help in problematic situations. Mrs.B’s perfectionism is less prominent and 
she has learned to say no. She was able to stop if a situation was extremely fatiguing 
and she displayed several cognitive alternatives in her repertoire to support these 
behavioural changes.
Stop labelling oneself as a patient
The term ‘patient’ literally means someone being ill or suffering. Mrs.B no longer
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suffers from extreme fatigue. She considers herself cured. Continuing to name 
herself ‘CFS patient’ will influence her cognitions and behaviour and those of others. 
Undoubtedly, Mrs.B will enter situations in which she exceeds her limits and 
becomes very fatigued. This will be no problem, because she has learned what she 
can do about it.
In the last phase of therapy cognitive restructuring of the premorbid lifestyle 
consolidated improvement. The former lifestyle was no longer an ideal for Mrs.B.
Results
Based on the model of CFS, fatigue and functional impairment were chosen as 
variables to assess therapy outcome. Variables to assess the therapy process were 
sense of control, physical activity, somatic attributions and focusing on bodily 
functions. Based on the behavioural analyses the therapy effects on complaints of 
pain, psychological wellbeing and concentration were analysed as well. Individual 
scores on these variables were compared to scores of CFS patients and healthy 
controls 2230.
Table 1. Outcome variables fatigue (CIS-fat, DOF) and functional impairment (SIP, WORK-hours) at five times 
(T1, T2, T3, T4, T5) compared to mean scores of CFS patients and healthy controls
T1 T2 T3 T4 T5 CFS Healthy
m sd m sd
CIS-fat 56 39 33 36 21 48.2 7.9 17.3 10.1
DOF 10 5.8 3 2.8 3 8.6 2.6 1.7 1.6
SIP 1554 1307 623 523 130 1741 698 a -
WORK-hours 0 0 3.9 6.8 4.8 0.9 1.6 6.1 2.2
a Data not available; test not suitable for healthy controls.
Outcome variables: fatigue and functional impairment
Table 1 shows the scores of the outcome variables at five times. At baseline the 
scores on fatigue and functional impairment are within the range of the scores of 
CFS patients. During treatment (T1-T3) fatigue and functional impairment decrease 
and this change is further continued during follow-up (T4). At the final follow-up the 
scores are within the range of healthy controls.
Process variables: sense o f control, physical activity, somatic attributions and 
focusing on bodily functions
The results of the process variables are shown in Table 2. During treatment an 
increase of sense of control to almost maximal is found as well as an increase in 
physical activity to the level of healthy controls. This result is maintained during 
follow-up. Scores reflecting focusing on bodily functions and catastrophic thoughts 
decreased to the range of healthy controls and remained stable during follow-up. 
Causal somatic attributions did not change during treatment and follow-up.
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Other dimensions o f CFS: pain, psychological wellbeing, concentration and attention 
Table 3 shows that the CFS-related complaints reported by Mrs.B at baseline have 
changed too from the range of CFS patients to the range of healthy controls.
Table 2. Process variables sense of control (SE), catastrophic thoughts (MPCL-ca), somatic attributions 
(SOM-att), physical activity (ACTO) and focusing on bodily symptoms (SCL-som) at five times (T1,T2, T3, T4, T5) 
compared to mean scores of CFS patients and healthy controls
T1 T2 T3 T4 T5 CFS Healthy
m sd m sd
SE 16 22 22 21 23 14.8 3.2 a -
MPCL-ca 54 38 29 37 33 42.2 9.0 32.3 14.2
SOM-att 3.3 3.8 3.5 2.5 3.3 3.7 0.8 - a -
ACTO 53 69 90 93 86 65 28 88 25
SCL-som 32 23 19 18 17 30.1 8.0 14.5 3.5
a Data not available; test not suitable for healthy controls.
Table 3. Variables concerning pain (DOP), psychological well-being (BDI, SCL-tot) and concentration and 
reaction time (CIS-con, RT) at five times (T1, T2, T3, T4, T5) compared to mean scores of CFS patients and 
healthy controls
T1 T2 T3 T4 T5 CFS Healthy
m sd m sd
DOP 7.3 2.2 1.3 1.3 1 6.5 3.4 0.1 1.5
BDI 15 10 7 9 3 10.8 4.7 2.7 3.7
SCL-tot 162 129 113 108 100 156.1 28.1 108.6 21.4
CIS-con 29 21 10 11 8 26.2 7.2 9.5 5.0
RT 0.649 0.326 0.350 0.317 0.321 0.502 0.236 0.373 0.05
Discussion
In this case study cognitive behaviour therapy for chronic fatigue syndrome was 
highly successful. At baseline the diagnosis CFS was confirmed by multidimensional 
assessment. Compared to other CFS patients the symptoms of Mrs.B were severe. 
During treatment practically all process variables improved to the level of healthy 
controls. The outcome variables consequently improved too, reaching the level of 
healthy controls during follow-up. It is concluded that clinically significant change was 
realised, defined by Jacobson and Truax31 as the extent to which therapy moves 
someone outside the range of the dysfunctional population or within the range of the 
functional population.
Cognitive behaviour therapy was based on both an empirically developed model of 
CFS and individual behavioural analyses of Mrs.B’s complaints. Probably, the 
strength of this therapy lies in the combination of empirically derived and individual
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aspects. The model points out psychological factors crucial for recovery. Individual 
behavioural analyses reveal the relative importance of each of these factors in 
treatment.
Despite the successful results some side-notes should be discussed. In this case 
study experimental analyses of behaviour were absent. This leaves open the 
possibility that other factors, like repeated contacts with the therapist, may have 
contributed to the favourable changes. In our opinion therapist attention is ruled out 
as a contributing factor. Before the start of cognitive behaviour therapy, Mrs.B had a 
therapeutic relationship with a social worker, which she described as warm and 
empathic. However, the attention of this therapist was not sufficient in remedying the 
severe somatic complaints of Mrs.B. As to the contents of the therapy some critical 
remarks can be made too. Preparation of work rehabilitation was initiated too late in 
therapy and took a great deal of time. Mrs.B had lost sight of the important goal of 
work rehabilitation. Therefore, a gap was caused between building up of physical 
activity and returning to work. Further, the duration of therapy could have been 
diminished in case of more rapid building up of physical activity. Probably, more 
moments in the physical activity program each day should have speeded up therapy 
and should have avoided disappointment in the rate of improvement. In this phase of 
therapy the therapist was less active too and followed a wait-and-see policy. Looking 
back, it is not surprising that in this period two incidents came up. Mrs.B decided to 
visit a meeting of members of the ME-association again. No one of the patients she 
met was as optimistic as Mrs.B about cognitive behavior therapy, which caused a 
severe fear of relapse. In this period she chose to undergo color-therapy, thus not 
standing by the agreement made at the start of cognitive behavior therapy. These 
incidents urged on the therapist to breathe new life into therapy. The motivation of 
Mrs.B was restored and the therapy passed off smoothly.
Although part of the model of CFS, causal somatic attributions did not change during 
cognitive behavior therapy. This may be a result of therapy. At first Mrs.B was taught 
to make a distinction between initiating and perpetuating factors in CFS. After that, 
CBT was directed at the perpetuating factors, like gradually building up physical 
activity. The therapist has thus disconnected causal attributions and physical activity. 
Cognitive behavior therapy based on both the model of CFS and individual 
behavioral analyses seems a promising treatment. At the moment the Dutch Fatigue 
Research Group is conducting a multicenter randomized controlled trial to test the 
efficacy of an 8-month treatment protocol of this newly developed cognitive behavior 
therapy.
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Cognitive behaviour therapy for chronic fatigue syndrome: 
a multicentre randomised controlled trial
Abstract
Background Cognitive behaviour therapy (CBT) seems a promising treatment for 
chronic fatigue syndrome (CFS), but the applicability of this treatment outside 
specialised settings has been questioned. We compared CBT with guided support 
groups and the natural course in a randomised trial as three centres.
Methods Of 476 patients diagnosed with CFS, 278 were eligible and willing to take 
part. 93 were randomly assigned CBT (administered by 13 therapists recently trained 
in this technique for CFS), 94 were assigned the support-group approach, and 91 the 
control natural course. Multidimensional assessments were done at baseline, 8 
months, and 14 months. The primary outcome variables were fatigue severity (on the 
checklist individual strength) and functional impairment (on the sickness impact 
profile) at 8 and 14 months. Data were analysed by intention to treat.
Findings 241 patients had complete data (83 CBT, 80 support groups, 78 natural 
course) at 8 months. At 14 months CBT was significantly more effective than both 
control conditions for fatigue severity (CBT vs support groups 5.8 [2.2-9.4]; CBT vs 
natural course 5.6 [2.1-9.0]) and for functional impairment (CBT vs support groups 
263 [38-488]; CBT vs natural course 222 [3-441]. Support groups were not more 
affective for CFS patients than the natural course. Among the CBT group, clinically 
significant improvement was seen in fatigue severity for 20 of 58 (35%), in Karnofsky 
performance status for 28 of 57 (49%), and self-rated improvement for 29 of 58 
(50%). Prognostic factors for outcome after CBT were higher sense of control 
predicting more improvement, and a passive activity pattern and focusing on bodily 
symptoms predicting less improvement.
Interpretation CBT was more effective than guided support groups and the natural 
course in a multicentre trial with many therapists. Our study showed a lower 
proportion of patients with improvement than CBT trials with a few highly skilled 
therapists.
Introduction
Chronic fatigue syndrome (CFS) is characterised by persistent or relapsing 
unexplained fatigue, of new or definite onset and lasting for at least six months. 
Fatigue is not the result of an organic disease or ongoing exertion, rest does not 
alleviate it, and there is substantial limitation of occupational, educational, social and 
personal activities1. No cause of CFS has been found, and most patients do not 
recover. No somatic or pharmacological treatments have proven to be effective2. 
Cognitive behaviour therapy (CBT) seems to be a promising treatment of CFS3-5. 
Two randomised controlled trials reported positive results6,7. A recent review 
questioned whether these results can be generalised outside specialist centres were 
only a few highly skilled therapists, or even a single therapist administered CBT.
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Furthermore, in both studies the primary outcome variable was functional impairment 
and not fatigue, the main complaint of CFS patients. In our study, criticisms of both 
previous randomised trials were addressed.
The effectiveness of CBT was tested in a multicentre randomised trial. CBT was 
compared with a treatment condition, guided support groups, and a control condition, 
the natural course. CBT was administered in three different centres rather than one 
specialist centre. Experts taught the treatment protocol to many therapists with no 
previous experience in CBT for CFS. Guided support groups should control for the 
absence of specific cognitive-behavioural interventions and the presence of therapist 
attention and treatment expectations. We assumed that support groups, as in other 
chronic diseases8,9, might contribute to a feeling of mutual understanding, 
acceptance and support and thereby have a healing effect.
In this study, the outcome variables were fatigue severity and functional impairment, 
with the same instruments for inclusion and outcome. Moreover, CBT for CFS was 
based on a statistically tested model of perpetuating factors in CFS10,11 rather than 
on hypothesised factors n CFS or on treatments of other medically unexplained 
syndromes. The model of CFS is shown in figure 1. Focusing on bodily symptoms, 
low levels of physical activity and sense of control contribute to increasing severity of 
fatigue and functional impairment. CBT is directed at these perpetuating factors.
The main aim of our multicenter trial was to show the effectiveness of CBT for 
patients with CFS. Our hypothesis that fatigue severity and functional impairment 
should decrease significantly more in the group of patients assigned CBT than in 
patients in the control groups.
Figure 1. Model of CFS, developed and tested with LISREL (Vercoulen et al. 1998)
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Patients and methods
Patients
All patients with a major complaint of fatigue referred to the outpatient clinic of the 
departments of internal medicine of the University Medical Centre Nijmegen and the 
University Hospital Maastricht between October, 1996, and January, 1998, were 
assessed by means of detailed history, physical examination, and computer 
assessment of questionnaires. Patients were eligible for the study if they met the US 
Centers for Disease Control and Prevention criteria for CFS1, with the exception of 
the criterion requiring four of eight additional symptoms to be present. Severe fatigue 
and severe functional impairment were defined by cut-off scores- a score of 40 or 
more on the subscale fatigue severity of the Checklist Individual Strength and a score 
of 800 or more on the Sickness Impact Profile. Additional inclusion criteria for this 
study were age between 18 and 60 years, and residence within 1-5 h travelling time 
of one of the study centres. Additional exclusion criteria were previous or current 
participation in CFS research, pregnancy, and current treatment to achieve 
pregnancy.
A sample size of 80 patients per group was estimated assuming significance of 5%, 
power of 90%, a dropout rate of 20%, and a medium effect size on the actometer, the 
measure of our multidimensional approach in need of most individuals to show 
improvement. Multidimensional assessment has been recommended for studies 
assessing the effect of therapeutic interventions for CFS, to measure change in 
different dimensions of the patients’ functioning12. During the trial the dropout rate 
was higher than that estimated in the calculation of sample size. Therefore, the target 
sample size for inclusion was set at 90 patients per study group.
Design and procedures
The study was an open multicentre randomised controlled trial in which individual 
CBT was compared to participation in guided support groups and with the natural 
course, a control condition in which no treatment was offered. The ethics committees 
of the three participating centres gave approval for the study. Treatment effects were 
expected in the primary outcome variables fatigue severity and functional impairment 
and were explored in the secondary outcome variables: Karnofsky performance 
status, psychological well-being, quality of life, and work. The predictive role of 
perpetuating factors in the model of CFS was tested exploratively also.
Patients who met the trial criteria and were willing to take part in the trial had to give 
informed written consent. To ensure adequate generation and adequate concealment 
in the allocation process, patients were allocated sequentially to one of three 
conditions, by blockwise randomisation (block size six), separately for each centre. 
The allocation was concealed in series of envelopes for each centre and assigned by 
(assistant) researchers before baseline in the presence of the patient, in order of 
enrolment in the trial. CBT and support groups took place in three different settings, 
the Department of Medical Psychology of the University Medical Centre Nijmegen,
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the Department of Psychiatry of the Leiden University Medical Centre, and the 
Department of Psychotherapy of the Maastricht Mental Health Institute. CBT and 
support groups were administered by different therapists and on different days to 
prevent contamination. CBT consisted of 16 sessions of 1 h over 8 months. Patients 
in this group had to meet the requirements of no further medical examinations or 
other treatments for CFS during the trial. These conditions were essential in reducing 
focusing on bodily symptoms and somatic attributions. A preliminary version of CBT 
has been extensively described. An essential part of CBT is self-control: this means 
that the CFS patient is acquiring control over symptoms instead of dependence on 
physicians prescribing treatments or medications. In this study, CBT was outlined in 
a treatment protocol. First, the model of perpetuating factors was explained, and the 
therapist attempted to motivate the patient for CBT. Next, fatigue-related cognitions 
were challenged to diminish somatic attributions, to improve sense of control over 
symptoms, and to facilitate behaviour change. Patients were encouraged to attain 
and maintain a base level of physical activity needed to prevent bursts of activity and 
resultant extreme fatique. Subsequently, a structured activity programme was 
started. After a gradual increase of physical activity, a plan for work rehabilitation was 
outlined and carried out. For patients without a job, rehabilitation in other personal 
activities was achieved. The final sessions dealt with relapse prevention and further 
improvement of self-control.
Thirteen behaviour therapists of three different disciplines (psychologist, 
psychiatrists, and health scientists) took part. Therapists varied in previous CBT 
(non-CFS-related) experience, because the study was done with the therapists 
available within the three centres. However, none of the therapists was familiar with 
CBT for CFS at the start of the trial. Two experts in CBT for CFS (GB, EB) trained the 
therapists in using the treatment protocol in a workshop, consisting of two blocks of 2 
days each, separated by a month, in which the therapists started the treatment of two 
CFS patients in a pilot study. Therapists were supervised once every 2 weeks 
throughout the trial. Patients were allocated to therapists in a fixed sequence by the 
researcher in order of patients’ random allocation to CBT in each centre separately. 
An integrity check of a random sample of 5% of all audiotaped CBT sessions was 
done. An independent judge used a checklist to rate the degree and the amount of 
time spent on the basic elements of CBT (restructuring of fatigue-related cognitions, 
attaining a base level of daily activity, gradual increase of physical activity, and 
returning to work or personal activities) in each session. The analyses showed that 
91.5% of the time spent in therapy was relevant for CBT and that 87% of the 
sessions were adequate or good overall.
The guided support groups were similar to CBT in terms of time spent and treatment 
schedule. Each group, consisting of about eight patients, had 11 meetings of 1-5 h 
over 8 months. One social worker was available for all 11 groups in the three centres. 
The treatment orientation was non-directive and client-centred. The social worker 
was supervised once every 2 weeks by a psychotherapist, who had no links with
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CBT or CFS. The goal of the support groups was to offer mutual understanding and 
recognition by means of exchanging experiences with one central theme during each 
meeting. In this study group, patients were free to have other examinations or 
treatments. All support-group sessions were videotaped, and the tapes were 
randomly checked to make sure that the social worker was not using CBT-like 
strategies. In the control condition natural course, no interventions were offered, and 
no further requirements were made. Patients were free to have other examinations or 
treatments.
Assessment
Multidimensional assessments were made at baseline, at 8 months, and a follow-up 
(14 months). The baseline assessment included the screening assessment before 
randomisation (fatigue, functional impairment, criteria of the Centers for Disease 
Control and Prevention) and those made immediately after randomisation.
Fatigue severity was assessed by a subscale of the Checklist Individual Strength14. 
In this questionnaire, the patient is asked about fatigue in the two weeks preceding 
the assessment. The subscale consists of 8 items, each scored on a 7-point Likert 
scale (range 8-56). The questionnaire has good reliability (Cronbach’s alpha varying 
from 0.83 to 0.92) and discriminative validity12,14,15.
Functional impairment was measured by the Sickness Impact Profile16,17. This widely 
used measure has good reliability and content validity18. As in our previous studies, a 
total score was calculated by addition the weights of items (range 0-5799) in eight 
subscales: home management, mobility, alertness behaviour, sleep/rest, ambulation, 
social interactions, work, and recreation and pastimes. Comparison data for CFS 
patients were available12.
The Karnofsky performance status scale is a descriptive, ordinal scale. An 
independent clinical psychologist rated the patient’s functional status in 10-point 
intervals from 0 to 100. The validity and reliability of this scale have been shown in 
several populations19,20. Comparison data for CFS patients were available6.
The Symptom Check List 9021 measured psychological well-being. The scale 
consists of 90 items scored on a 5-point Likert scale. The total score ranges from 90 
to 450. A low total score reflects high psychological well-being. This scale is widely 
used and the reliability and discriminating validity are good.
The visual analogue scale of the EuroQol22 measured quality of life. The scale 
ranges from 0 (worst health status) to 100 (best health status). The EuroQol has 
been validated in normal populations, patients and in CFS patients23.
Hours working in a job were recorded on a 24 h timetable of the 12-day self­
observation list24.
Self-rated improvement was measured at 8 months and at follow-up by one specific 
question: patients indicated whether they had completely recovered, felt much better, 
had the same complaints or had become worse compared with the previous 
measurement. This measure has been validated in several of patients populations
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and was used in this study as one of the measures for clinically significant
improvement24-26.
The Self-Efficacy Scale, consisting of five questions, measured sense of control in 
relation to CFS complaints. Four items were scored on a 5-point Likert scale and one 
item on a 4-point Likert scale. The total score ranges from 5 to 24, a higher score 
reflecting more sense of control. Cronbach’s alpha reliability coefficients range from 
0.70 to 0.77 10,12,25.
Somatic attributions with respect to CFS were measured by the causal attribution list 
consisting of five questions scored on a 4-point Likert scale. The total score ranges 
from 5 to 20, a higher score indicating stronger somatic attributions. Cronbach’s 
alpha reliability coefficients range from 0.71 in previous studies12,25 to 0.74 in this 
study.
Physical activity was measured by the actometer, a motion-sensing device attached 
to the ankle and worn continuously for 12 days. Such devices are reliable and valid 
measures of physical activity27. The activity pattern of each patient was typified by 
comparison of daily activity scores with the reference score of CFS patients. Three 
categories were defined: pervasively passive (90% or more beneath the reference 
score); moderately active; pervasively active (90% or more above the reference 
score)28.
Focusing on bodily symptoms was measured by the subscale somatisation of the 
symptom checklist 9021, as in previous studies in which CFS patients were compared 
with healthy individuals and patients with multiple sclerosis10,29. The subscale 
consists of 12 items scored on a 5-point Likert scale. The score ranges from 0 to 60.
Analysis
A general linear model fo r repeated measurements (by the method of mixed linear 
models) was used to analyse the effects of CBT on the two primary variables (fatigue 
severity and functional impairment and the secondary variables Karnofsky 
performance status, symptom checklist 90, Euroqol, and hours working in a job. 
Differences at 8 months and 14 months from baseline were used as repeated 
measurements, with treatment (3 levels), centre (3), time (2 levels) and their first­
order interactions as fixed factors. The covariance matrix was specified as 
unstructured (implying a general structure), estimation method used was restricted 
maximum likelihood, and Satterthwaite’s method was used to estimate denominator 
degrees of freedom. First, we tested, for the primary variables, whether the centre 
terms could be regarded as redundant (likelihood ratio test comparing the 2 models). 
If this was the case for both variables, reduced models with treatment and time 
factors and their interaction were used in all subsequent analyses. All treatment 
effects, as well as differences between treatments were estimated within these 
models; 95% CI were computed from these estimates and their standard errors. We 
used the procedure MIXED from the SAS package (version 6.12). Although the 
methods of analysis for the primary and secondary variables are the same, results for
CBT for CFS: a multicentre randomised controlled trial 57
the latter should be regarded as exploratory.
To define clinically significant improvement in fatigue severity, we first calculated for 
each patient a reliable change index to decide whether statistically significant 
improvement had occurred (reliable change > 1.64, p<0.05). Second, a cut-off score 
of 36 or lower was calculated to decide whether a patient’s score had moved from 
the range of CFS patients to the range of healthy individuals30. A patient was 
classified as showing clinically significant improvement if both criteria were met. 
Improvement in the Karnofsky performance status was explored also, so that we 
could compare the results with those of Sharpe and colleaques6. Clinically significant 
improvement was defined as an improvement of 10 points or more and a score of 80 
or more.
Figure 2. Trial profile
Self-rated improvement was defined as a patient’s indication that he or she was 
completely recovered or felt much better. The categorical variables which were 
calculated by the procedures applied on the original variables checklist individual 
strength, Karnofsky performance status and Self-rated improvement, were compared 
between treatments by Fisher’s exact test at 8 months and 14 months.
Analyses of possible predictors were done with multiple linear regressions. The
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predictors were included and excluded with the stepwise method. Independent 
variables were treatment, baseline value of the dependent variable, age, sex, 
duration of complaints, education, and the baseline values of the perpetuating 
factors: sense of control, activity pattern, focusing on bodily symptoms, and somatic 
attributions, and all first-order interactions between treatment and other factors. The 
main interest was the relation between predictors and the direct treatment effect. 
Therefore, only the outcomes at 8 months were analysed. Results from these 
analyses should be regarded as exploratory.
Results
518 patients were referred to the University Medical Centre Nijmegen with a major 
complaint of fatigue; CFS was diagnosed in 410. Another 66 patients were diagnosed 
with CFS at the University Hospital Maastricht. Of these 476 patients, 99 did not 
meet the eligibility criteria and 99 refused to take part. The remaining 278 patients 
were randomly to the study groups at the centres of Nijmegen, Leiden and Maastricht 
(figure 2). In total, 93 patients entered the CBT group, 94 the support groups, and 91 
the control natural course group. Six patients were excluded: five developed other 
diseases during the trial and one was pregnant at baseline. After randomisation, two 
patients were found not to meet the criteria for CFS because they had premorbid 
anorexia nervosa. Thus, the trial consisted of 270 patients (92 CBT, 90 support 
groups, 88 control groups), of whom 203 (75%) completed 8 months and 186 (69%) 
14 months in the trial. 18 patients did not start treatment. 49 withdrew during the test 
phase and 17 withdrew during follow-up. Withdrawal was defined differently for the 
three groups. In the natural course group, only patients not attending the 
assessments were classified as withdrawing, whereas in the two intervention groups 
those who stopped treatment were also counted. Moreover, in contrast to CBT, 
frequent non-attendance in the guided support groups had no consequences for 
further treatment, unless a patient declared the intention to withdraw. This difference 
was reflected in the significant difference in mean hours of attending treatment 
between CBT group and the guided support group (15,6 vs 13.2; p< 0. 0001). Table 
1 shows the baseline characteristics of the three groups.
At 8 months, 241 patients (89%) had complete data (83 CBT, 80 support groups, 78 
natural course). At 14 months, 196 patients (73%) had complete data (58 CBT, 62 
support groups, 76 natural course). The data of these patients were included in the 
analyses. Only 9% of the patients had missing data at one or both posttreatment 
assessments.
For both primary outcome variables, a reduced model without any centre term could 
be used (p= 0.437 fcr checklist individual strength, fatigue; p=0.202 for sickness 
impact profile, likelihood ratio test with 8 df). Consequently, all subsequent analyses 
were done with such models.
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Table 1. Baseline characteristics of study participants
CBT 
(n= 92)
Guided support 
groups (n= 90)
Natural course 
(n= 88)
Demography
age (yrs) 36.2 9.4 37.1 10.6 36.7 10.3
duration of complaints (yrs) 4.9 4.8 6.6 6.4 5.3 5.4
education (1=low to 7=high) 3.9 1.6 4.3 1.4 4.4 1.6
M/F * 22/70 19/71 17/71
Dependent variables
CIS fatigue 52.2 3.9 52.3 4.0 51.9 4.1
SIP total 1755 613 1842 560 1859 671
Karnofsky 71.5 8.5 71.2 7.5 70.8 7.9
SCL-90 170 38.5 169 41.5 166 36.0
EuroQol 46 17 43 16 40 14
work (hours in 12 days) 16.3 21.1 12.8 19.1 13.5 18.6
Indepedent variables
sense of control 14.8 3.5 14.6 3.1 14.6 3.6
somatic attributions 13.9 2.8 14.1 2.5 13.5 2.4
focusing on bodily symptoms 30.7 6.9 30.0 7.6 29.8 7.2
Activity pattern#
generally passive* 21 (23%) 16 (19%) 24 (29%)
moderately active* 56 (62%) 53 (62%) 50 (59%)
generally active* 13 (15%) 16 (19%) 10 (12%)
Data are mean (sd) or *numbers of participants. # 11 cases had incomplete actometer data and are not included
Table 2. Estimated effect of CBT compared with support groups and natu ral course on fatigue severity (CIS) and 
functional impairment (SIP)
CBT vs support groups CBT vs natural course
Treatment effect p 
( 95%CI )
Treatment effect 
( 95%CI )
p
CIS 8 months 6.0 (3.1-9.0) 0.0001 6.0 (3.1-9.0) 0.0001
14 months 5.8 (2.2-9.4) 0.0015 5.6 (2.1-9.0) 0.0016
SIP 8 months 217 (26-408) 0.0261 213 (22-403) 0.0287
14 months 263 (38-488) 0.0223 222 ( 3-441) 0.0470
CBT= Cognitive Behaviour Therapy
In the primary outcome variables, significant differences between the treatment 
effects of CBT support groups, and natural course were found (figure 3). Estimated 
differences are shown in table 2.
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Months Months
Figure 3. Effect of three study conditions on the two primary outcome variables, fatigue severity (CIS) and 
functional impairment (SIP)
Table 3 gives the estimated differences between the study groups in secondary 
outcome variables. A t 8 months, improvement in Karnofsky performance status, 
psychological well-being and quality of life was statistically significantly greater in the 
CBT group than in either of the other groups. Differences in the time spent working in 
a job did not reach the 5% level of significance. Statistically significant treatment 
effects between CBT and support groups were found in all secondary outcome 
variables at 14 months. Treatment effects of CBT and natural course showed 
statistically significant differences for the Karnofsky performance status at both 8 and 
14 months and for psychological well-being at 8 months.
Table 3. Estimated effect of CBT compared with support groups and natural course on secondary endpoints
CBT vs support groups__________ CBT vs natural course
Treatment effect 
( 95% CI )
p Treatment effect 
( 95% CI )
p
Karnofsky 8 months - 5.7 (-8.4 to -3.1) 0.0001 - 5.2 (-7.8 to -2.6) 0.0001
14 months - 6.3 (-9.6 to -3.0) 0.0002 - 5.4 (-8.6 to -2.2) 0.0009
SCL-90 8 months 13.9 (4.3 to 23.5) 0.0048 13.4 (4.0 to 22.7) 0.0053
14 months 11.2 (1.1 to 21.3) 0.0304 6.7 (-3.0 to 16.5) 0.1767
EuroQol 8 months - 7.8 (-14.0 to -1.8) 0.0114 - 4.0 (-10.0 to 2.0) 0.1878
14 months - 9.2 (-15.6 to -2.8) 0.0049 - 2.3 (-8.4 to 3.8) 0.4619
Work 8 months - 5.6 (-11.7 to 0.4) 0.0681 - 2.9 (-8.8 to 3.0) 0.3362
14 months - 9.6 (-17.1 to -2.0) 0.0132 - 5.9 (-13.2 to 1.4) 0.1134
CBT= Cognitive Behaviour Therapy
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Table 4. Clinically significant improvement in the treatment groups for fatigue severity, Karnofsky performance 
status, and self-rated improvement
Number of patients with improvement / total P*
CBT Support Natural CBT CBT
Groups (SG) Course (NC) vs SG vs NC
8 months CIS fatigue 27/83 33% 10/80 13% 10/78 13% 0.003 0.005
Karnofsky 29/71 41% 11/69 16% 9/75 12% 0.001 <0.001
Self-rated 42/74 57% 12/71 17% 23/78 30% <0.001 0.001
improvement
14 months CIS fatigue 20/58 35% 8/62 13% 13/76 17% 0.009 0.026
Karnofsky 28/57 49% 12/62 19% 17/75 23% 0.001 0.001
Self-rated 29/58 50% 9/62 15% 24/76 32% <0.001 0.034
improvement
CBT= Cognitive Behaviour Therapy. CIS=checklist individual strength. * Fisher's exact test
Table 5. Parameter estimates, SE and partial R2 of all factors related to the outcome measure fatigue severity or
functional impairment (baseline minus 8 months) at p<0.05 in order of entrance to the models
Factor Coefficient SE Partial R2
Fatigue severity (CIS)
CBT x sense of control 0.5088 0.0883 0.0856
baseline CIS fatigue severity 0.7010 0.1469 0.0515
focusing on bodily symptoms -0.2611 0.0838 0.0368
CBT x activity pattern 1 -8.902 2.545 0.0208
activity pattern 2 -3.439 1.229 0.0229
sense of control 0.3535 0.1723 0.0147
sex (female) 2.761 1.386 0.0133
Functional impairment (SIP)
baseline SIP 0.4767 0.0604 0.1788
CBT 1005 281.9 0.0321
CBT x focusing on bodily symptoms -25.06 8.838 0.0266
CIS=checklist individual strength; SIP=sickness impact profile.
Table 4 shows the proportions of patients with clinically significant improvements in 
fatigue severity, Karnofsky performance status, and self-rated improvement. For 
these three variables, the proportion with clinically significant improvement was 
statistically significantly higher in CBT than in the control conditions.
All factors in the stepwise regression related to the outcome measures fatigue 
severity and functional impairment at p<0.05 are presented in order of entrance in the 
model in table 5. The improvement in fatigue severity at 8 months was predicted by 
interactions of CBT with sense of control and by a passive activity pattern, rather 
than by CBT alone. In the CBT study groups, patients with a greater sense of control 
at baseline had a larger decrease in fatigue severity at 8 months, immediately after
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CBT, than patients with lower sense of control. The reverse was true for patients with 
a passive activity pattern; they improved less than patients with other activity 
patterns.
Improvement in functional impairment at 8 months was predicted by CBT alone and 
by interaction of CBT and focusing on bodily symptoms. Patients assigned CBT 
improved more than patients in both control groups. However, patients in CBT with a 
high level of focusing on bodily symptoms were improved less than patients with 
lower scores on this factor
Discussion
In this study, CBT was more effective for CFS patients than guided support groups or 
the natural course. Intention-to-treat analyses showed clinically significant 
improvement in fatigue severity, Karnofsky performance status, and self-rated 
improvement in substantial proportions of patients treated with CBT.
An unexpected finding was that support groups were no more effective than the 
natural course (figure 3). This finding contrasts with other chronic diseases in which 
support groups are beneficial. However, 80% or more of the patients experienced 
mutual understanding in the support group, and rated the contact with the therapist 
and the atmosphere in the group as good. These findings suggest that clinical 
improvement and patients’ satisfaction are not correlated and may be independent. 
There was a large withdrawal rate in the trial, especially in the CBT and support 
groups. Many CFS patients eagerly expect a medical solution for their complaints 
and are quite sceptical about psychological treatments. Others expected more 
benefit from medical examinations or alternative treatments. These patients may 
have withdrawn prematurely. The physical burden of travelling to the centre for 
therapy was another reason for patients to withdraw. However, many patients who 
withdrew during treatment were willing to attend for assessment of the primary 
outcome variables. At 8 months, there was a withdrawal rate of 25%, but only 11% of 
the patients had missing data.
Results of the analyses depend among other assumptions on that of “missingness at 
random” which means that missingness is possibly related to the observed data, but, 
conditional on these data, not to the (unknown) value of the variable itself. Although 
we cannot prove the assumption, we can partially check in as follows31: comparison 
of characteristics of completers and non-completers (age, sex, duration of 
complaints, centre, and all baseline measures) showed no differences. Furthermore, 
the results of the intention-to-treat analyses and those of the analyses of the 
completers, were mostly qualitatively similar.
Supporting evidence of the effectiveness of CBT was found in the significant 
improvement in Karnofsky performance status rated by an independent clinical 
psychologist in the group of patients treated with CBT compared with the control 
groups. A significant treatment effect on quality of life, psychological wellbeing, and 
work rehabilitation was only found in the comparisons of CBT with support groups
CBT for CFS: a multicentre randomised controlled trial 63
and not between CBT and natural course. We were especially interested in work 
rehabilitation, a new element in the tested treatment protocol. The final goal of CBT 
for CFS included work rehabilitation for patients who used to be active in a job and 
resumption of other personal activities for patients without a job. We good not 
conclude the extent to which this goal was reached, because only hours working in a 
job were measured. However, in our sample of 270 patients only 33% had a job at 
baseline, whereas 76% had been employed before the onset of CFS. For the 
unemployed patients, securing employment within the limited period of treatment and 
follow-up would be difficult, although most of these patients did resume personal 
activities. The development of adequate measures of rehabilitation should have high 
priority in future research on CBT for CFS.
The proportions of patients with clinically significant improvement in this study were 
lower than in other CBT trials. We suggest several explanations for this discrepancy. 
First, therapists in this study had no clinical experience with CFS patients at the start 
of the trial. Afterwards, 82% of the therapists agreed with the statement that CFS 
patients are more difficult to treat than patients with psychiatric diagnoses, and 54% 
agreed that CFS patients are more difficult to treat than patients with other functional 
somatic syndromes. Second, criteria for statistical and clinical significance in this 
study were more stringent than in the previous trials. The cut-off score for clinically 
significant improvement was based on normative comparisons of CFS patients and 
healthy individuals and was perhaps overly stringent. In a recent evaluation of the 
concept of clinically significant improvement32, Kendall and colleagues questioned 
whether patients should be compared with a non-representative “supernormal” 
sample of healthy people, from which all individuals with any psychological or 
physical disorders are excluded. Third, the treatment protocol seemed not to be 
suitable for a group of CFS patients who showed passive activity patterns. Analyses 
of prognostic factors showed that patients with this activity pattern and patients with a 
strong tendency to focus on bodily symptoms improved less than did patients not 
characterised by one of these factors. In our clinical practice, the treatment protocol 
already has now been adjusted to both aspects. In the new treatment protocol, the 
emphasis is now on impeding cognitions and behaviour rather than on symptoms. 
Furthermore, a different treatment protocol has been developed for patients with a 
passive activity pattern. The early emphasis in CBT on a base level of daily activity, 
so important for moderately active CFS patients, seems to increase the fear of 
physical activity in passive CFS patients and impedes the subsequent gradual 
increase of physical activity. Therefore, CBT for patients with passive activity patterns 
starts with building up physical activity, whereas more active patients still start with 
attaining and maintaining a base level of daily activity.
The results of this trial suggest that CBT can be transferred from CFS research 
clinics to therapists with no previous experience in CBT. This transfer is essential to 
detach the treatment from medical research settings, in which only a limited number 
of CFS patients can be treated. To increase accessibility of this treatment for all CFS
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patients in future, CBT will have to be implemented outside university medical 
settings. This idea accords with Wessely and colleagues’ suggestion of transferring 
the diagnosis and treatment of functional somatic syndromes from medical 
subspecialists to more broadly based general physicians aided by psychiatrists or 
psychologists33. Ideally, general practitioners should diagnose CFS and refer patients 
to psychotherapists for CBT, without detours to medical specialists, as in other 
functional somatic syndromes33. Before this goal can be reached, expertise needs to 
be generalised from specialist centres to general practitioners and behaviour 
therapists in general (mental) health settings.
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Identifying physical activity patterns in chronic fatigue syndrome 
using actigraphic assessment
Abstract
Objective: Changes in physical activity are thought to play an important role in 
maintaining symptoms in chronic fatigue syndrome (CFS). The aim of this study was 
to describe intra-individual physical activity patterns in more detail and to identify 
pervasively passive patients.
Methods: With help of a movement-sensing device, physical activity levels were 
registered continuously over a 12-day period in 277 CFS patients. Within this 
registration period, the ten largest activity peaks were computed. The intensity and 
duration of these activity peaks and their subsequent rest periods were described 
and compared to those of 47 healthy controls. In addition, the patients’ 12 daily 
activity scores were used to identify patients who were characterised by low levels of 
physical activity throughout the registration period.
Results: The CFS sample had less intense and shorter activity peaks, while the 
average rest periods that followed these peaks lasted longer. Approximately one 
fourth of the CFS sample differed distinctly from the control group and was labelled 
as pervasively passive.
Conclusion: The measurements and classification of actual physical activity levels 
were found to reduce heterogeneity in the CFS population and therefore could 
provide the opportunity to optimise behavioural intervention protocols fo r  CFS.
Introduction
Patients with chronic fatigue syndrome (CFS) often describe themselves as being 
profoundly less physically active, and unable to reach similar physical activity levels 
as compared to before the onset of their illness. Many CFS patients report that even 
minor physical exertion results in a significant increase in fatigue and CFS related 
symptoms. There is evidence that many CFS patients cope with their illness by 
resting or avoiding physical activity1-3. In cognitive behaviour models of CFS it has 
been hypothesised that pervasive avoidance of physical activity decreases the 
tolerance for physical exertion, and as such can perpetuate the CFS-related 
symptoms4.
Clinical observations and especially patients’ self reports suggest, that the lifestyles 
of some other CFS patients are characterised by very active periods, followed by 
abnormally long periods of inactivity. Some authors have suggested that in CFS the 
periods of rest are interrupted by short periods of marked activity during which 
patients perform at “normal” levels5. These short periods of high physical activity may 
have detrimental effects and cause fatigue in patients with a low overall physical 
activity level. However, until now no empirical data are available to test this 
assumption.
Since changes in physical activity patterns are supposed to play an important role in
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maintaining symptoms and subsequently many therapeutic interventions have 
emphasised on activity regulation, it is crucial to identify abnormal activity patterns in 
a valid and reliable way. In earlier studies of our research group, actual motor-activity 
has been recorded with an ankle-worn motion sensing device (actometer) in 
conjunction with self-report measures of physical activity6,7. The data of these studies 
suggest that self-report measures of activity reflect the patients’ view about their 
physical activity and may have been biased by cognitions concerning illness and 
disability.
In clinical practice it has been observed that part of the CFS patients are 
characterised by profound physical inactivity, while other patients are far more active 
but nevertheless judge themselves as rather inactive. Both, research results and 
clinical impressions, indicate that it is important to test whether patients’ self-report 
concerning long term inactivity after exertion, large day-to-day fluctuations in activity, 
and pervasive inactivity, can be substantiated by a behavioural measure of activity.
In this study, physical activity was measured with an actometer over 12 consecutive 
days in both healthy controls and CFS patients. The general activity scores that were 
used in previous studies provided little information about intra-individual differences 
and might have obscured large fluctuations in daily activity scores. Therefore, 
parameters were developed to describe changes in physical activity in more detail. 
Specific attention was paid to periods of high activity and subsequent rest periods. 
Furthermore, it was tested whether the CFS sample was characterised by many 
large day-to-day fluctuations in physical activity. The actometer measurements were 
also used to subtype activity patterns in CFS in order to identify pervasively passive 
patients.
Previous studies found that part of the CFS patients had elevated depression scores. 
Since physical inactivity could be a symptom of depression, one might hypothesise 
that in particular pervasively passive patients would be characterised by increased 
levels of psychological distress. Therefore, it was tested whether levels of fatigue, 
psychological distress and functional impairment were elevated in pervasively 
passive CFS patients, as compared to more physically active CFS patients.
Method
Subjects
All patients with a major complaint of fatigue, referred to the outpatient clinics of 
internal medicine of the University Medical Centre Nijmegen and the University 
Hospital Maastricht between October 1996 and January 1998 were assessed by 
means of detailed history, physical examination and questionnaires. Patients had to 
fulfil the CDC criteria for CFS8. Additional criteria were age between 18 and 60 years, 
no previous or current engagement in CFS research, not pregnant or engaged in 
pregnancy-stimulating techniques and living within one-and-a-half hour travelling time 
of the participating centres. Ninety-nine of the 476 patients who fulfilled the criteria of 
CFS did not meet the additional operational criteria. The remaining patients were
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asked whether they wanted to participate in a randomised controlled study to assess 
the effects of cognitive behavioural therapy upon fatigue and functional disability. 
Ninety-nine patients refused participation and one patient was excluded because of 
pregnancy at pre-test. The baseline data of the remaining 277 CFS patients were 
analysed in this study.
Furthermore, actometer and self-report data of 47 healthy subjects were collected. 
Most of these subjects were asked by fatigued patients as neighbourhood controls in 
other chronic fatigue studies.
Instruments
The actometer (©Actilog V3.0) that was used is a motion sensing device that can 
register and quantify human physical activity6. The actometer is small (55*25*15mm) 
and light (26gr) and has to be worn at the ankle. The small size makes the actometer 
suitable for long term continuous registrations. The actometer has a piezo-electric 
sensor that is sensitive in three directions. Accelerations of the sensor larger than a 
pre-defined threshold are considered as activity and are stored into an internal 
memory. Each second the counter of the actometer is read and reset by the micro 
controller. The integration counter is set at five minutes providing every 5 minutes an 
activity score that is stored in the internal memory of the actometer. At the end of the 
registration period data are fed into an external computer.
In this study the actometer was worn day and night during at least a 14-day period. In 
order to retain twelve complete registration days, the first and last registration days 
were omitted for the analyses. Subjects were asked to remove the actometer only in 
certain situations (swimming, bathing) and to write in a daily complaint diary whether 
there were any other lengthy periods that they removed the actometer. When the 
actometer had failed more than two days, patients were asked to carry the actometer 
for an additional two weeks. In the final statistical analyses, maximally one invalid 
registration day was allowed. This missing value was replaced by the mean value of 
the remaining 11 registrations days.
Specialised software was used to calculate several parameters. This software also 
graphically visualised the levels of activity (figure 1). The software distinguished rest 
(night) and wake (day) periods, resulting in a day length score. All other parameters 
that were developed pertain to these daily active (wake) periods.
Definition of general physical activity
For the total registration period 12 daily physical activity scores were calculated. 
Subjects who were missing more than one valid registration day were omitted from 
further analyses. In case of one missing day, that day was substituted with the mean 
value of the remaining 11 registration days. A general physical activity score reflected 
the average physical activity level over the total 12-day time period and was 
expressed in the average number o f accelerations per five minute period.
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Figure 1. Twelve day actigraphs of a pervasively active and pervasively passive patient
Definition of parameters of high activity and subsequent rest periods 
In order to distinguish between relatively high (peak) and low (valley) activity periods 
the average general physical activity score of the control group (table 2, mean score 
=91) was designated as cut-off. The succeeding (5-minute) time periods above this 
cut-off were labelled as peaks and the succeeding 5-minute time periods below this 
cut-off as valleys. The program identified the ten largest activity peaks by calculating 
the total energy of each peak (duration peak * D number of accelerations in each 
succeeding 5 minute period). Subsequently, both the average peak duration and 
average peak amplitude of these ten largest peaks were calculated.
Specific attention was paid to what happened after each of these ten activity peaks. 
Rest periods were defined as the amount of time (after a large peak) that the 
actometer score stayed below the pre-set value of 91. The average duration of these 
ten rest periods was calculated for each subject (rest duration after peak).
Both, peak and rest duration were expressed in minutes by multiplying the number of 
succeeding registration intervals by 5. The number of accelerations occurring in a 5- 
minute interval expressed the intensity of activity (peak amplitude).
Furthermore, the average intensity of activity during the one-hour period following 
each peak was computed. Theoretically, another peak could occur during this time 
period. Subsequently, the average peak amplitude during the 10 largest peaks was 
compared with the average actometer amplitude during the one-hour periods 
following these peaks. This comparison made it possible to calculate the relative 
decrease in activity after peak performance, which could be expressed as a 
percentage of reduction in activity: %  activity reduction after peak.
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Definition of large day-to-day fluctuations
Both absolute and relative fluctuation scores were computed to detect fluctuations in 
activity over subsequent days. A major day-to-day fluctuation was counted as the 
individuals’ daily physical activity score showed a 22-point difference with the 
subsequent day. The absolute difference of 22 points that was used equals the 
standard deviation of the mean general physical activity score of the total CFS 
sample (table 1). The number of absolute large day-to-day fluctuations in a 12-day 
period could range from 0 to 11. Relative large fluctuations were defined as day-to- 
day differences of more than 33%; the total score was the number of relative large 
day-to-day fluctuations and could also range from 0-11 points.
Definition of pervasively passive CFS patients
The individuals’ activity patterns were based on the 12 individual daily physical 
activity scores. Since our purpose was to make a classification within the CFS 
sample, the mean general physical activity score of the total CFS sample served as 
reference value (mean=66). For each subject the 12 daily physical activity scores 
were compared to this reference value. When a daily physical activity score fell below 
this value, that day was labelled as relatively inactive. A daily physical activity score 
equal or above this value was labelled as relatively active.
Taking in account the possibility of unforeseen external circumstances affecting 
activity levels, it was decided that pervasively passive patients had to be less active 
compared to other CFS patients for at least 90% of the total observation period. 
Subsequently, pervasively passive patients were defined as those subjects whose 
average daily physical activity scores stayed below the reference score in at least 
eleven of the twelve assessment days. Patients scoring at least eleven days above 
the pre-set value were defined as pervasively active, while the remaining patients 
were labelled as moderately active. For comparison, activity profiles of healthy 
controls were calculated by using the same procedure and the same CFS reference 
value.
Self-reported fatigue, activity, depressive symptoms and functional disability 
Patients and controls were asked to rate their fatigue and activity levels four times a 
day on a five point (0-4) scale. These daily ratings were averaged into experienced 
daily fatigue and reported daily activity scores (range 0-16). Depressive symptoms 
were rated with the Beck Depression Inventory (BD-tot)9. Seven subscales of the 
Sickness Impact Profile (SIP) were used to assess functional disability in the 
following areas: home management, mobility, alertness behaviour, sleep/rest, 
ambulation, social interactions and recreation and pastimes10. These seven 
subscale-scores were added to provide a total score of general disability.
Statistical analyses
Testing differences between CFS and controls on nominal variables was done by the 
Chi2 test, and continuity correction was applied. T-tests or analyses of variance were
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used to make group comparisons between other variables. To control for the gender 
differences in both samples, gender was introduced as fixed factor in the analysis. 
We tested two-sided and the apha was set at 0.05.
For the behavioural measures a multivariate analysis of variance was carried out with 
general physical activity, peak duration, peak amplitude, rest duration after peak and 
% activity reduction after peak, as dependent variables and group and gender as 
factors. Similar multivariate analyses were carried out for the relative and absolute 
large day-to-day fluctuation scores, and for the experienced daily fatigue and 
reported daily activity score.
Four one-way Anova’s were used to assess whether pervasively passive, moderately 
active, and pervasively active CFS patients differed with respect to their experienced 
daily fatigue, reported daily activity, depressive symptoms and general disability 
scores. In case of an overall significance, the Bonferoni correction was applied to 
compare the three individual groups.
Results
The group characteristics of the CFS patients and healthy controls are displayed in 
table 1. The CFS sample had significantly more females but the groups were 
comparable concerning their average age. Tables 2 and 3 show that the general 
physical activity was significantly higher for the controls and that in both groups men 
had higher general activity scores compared to women.
Table 1. Group demographics
CFS total 
(n= 277)
Controls 
(n= 47)
Gender
F/M 218/59 23/24 Chi2 =14.2, p=0.00a
% females 79% 49%
Age
yrs 37.5 40.1 t=1.5, p=0.14b
range (18-60) (19-63)
a Chi2 test, b t-test
Peaks and subsequent rest periods
Tables 2 and 3 illustrate that the average peak amplitude of healthy controls was 
higher, and men (across groups) had higher peaks compared to women. The peak 
duration was also longer for healthy controls, while in both the control and CFS group 
men had longer peaks than females. The rest duration after peak was longer for CFS 
patients and no gender differences were found. The % activity reduction after a peak 
was larger for CFS patients, no gender differences were found.
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Table 2. Means, standard deviations and proportions of activity parameters and the types of activity patterns
&
(n=218)
CFS66
(n=59)
Total &
(n =23)
Control66
(n=24)
Total
1
General physical activity 65 ± 22 70 ± 22 66 ± 22 84 ± 16 97 ± 30 91 ± 25
1
Peak amplitude 177 ± 27 182 ± 30 178 ± 28 179 ± 20 198 ± 27 189 ± 25
Peak duration in minutes 102 ± 40 124 ± 55 107 ± 44 141 ± 40 157 ± 51 150 ± 46
Duration rest period 
after peak 92 ± 51 87 ± 43 91 ± 50 53 ± 22 70 ± 58 62 ± 45
% activity reduction 
after peak 59 ± 15 57 ± 15 59 ± 15 44 ± 16 47 ± 19 46 ± 17
Nr. of relative large 
day-to-day fluctuations 4.0 ± 2.2 3.6 ± 2.1 3.9 ± 2.2 3.3 ± 1.8 3.3 ± 1.9 3.3 ± 1.8
Nr. of absolute large 
day-to-day fluctuations 3.4 ± 2.0 3.7 ± 2.1 3.5 ± 2.0 3.8 ± 1.6 4.1 ± 2.0 3.9 ± 1.8
Experienced daily fatigue 8.1 ± 2.2 7.7 ± 2.0 8.0 ± 2.1 2.4 ± 1.8 1.0 ± 0.8 1.7 ± 1.6
Reported daily activity 4.7 ± 1.7 4.4 ± 1.5 4.6 ± 1.7 6.0 ± 2.5 6.2 ± 2.4 6.1 ± 2.4
% pervasively passive 26% 17% 24% 0% 0% 0%
% moderately active 58% 69% 60% 56% 58% 59%
% pervasively active 16% 14% 15% 44% 42% 41%
1
activity levels expressed in number of accelerations per 5 minute period2
peak and rest durations expressed in minutes
Large day-to-day fluctuations
There were no significant group, gender or interaction effects for the number of 
absolute large or relatively large day-to-day fluctuations (tables 2 and 3).
Pervasively passive CFS patients
In total 64 CFS patients (24%) were subtyped as pervasively passive. None of the 
healthy controls met this qualification. (0% controls vs. 24% CFS, Chi2 =14.2, 
p=0.000) In both the control and CFS group the majority of subjects was classified as 
moderately active (58% controls vs. 60% CFS, Chi2=0.07, p=0.870), while 
proportionally more controls got the qualification pervasively active (42% controls vs. 
15% CFS, Chi2 =18.1, p=0.000).
Experienced daily fatigue and reported daily activity
Multivariate analysis showed significant group and gender effects, but no interaction 
effect. CFS patients reported more experienced daily fatigue and less reported daily 
activity compared to controls. Overall, men reported less experienced daily fatigue 
compared to women (tables 2 and 3).
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Table 3. Results of the statistical analyses
Dependent measures F df P Dependent measures F df P
Number of relative large
General physical activity day-to-day fluctuations
group* 39.7 3,320 0.00 group 2.0 3,308 0.16
gender 6.1 3,320 0.01 gender 0.1 3,308 0.70
group x gender 0.9 3,320 0.35 group x gender 0.3 3,308 0.56
Number of absolute large
Peak Amplitude day-to-day fluctuations
group 3.9 3,320 0.05 group 1.3 1,308 0.25
gender 7.3 3,320 0.01 gender 0.7 1,308 0.39
group x gender 2.4 3,320 0.13 group x gender 0.1 1,308 0.94
Peak duration Experienced daily fatigue
group 25.8 3,320 0.00 group 346.1 1,311 0.00
gender 7.3 3,320 0.01 gender 6.8 1,311 0.01
group x gender 0.2 3,320 0.68 group x gender 2.6 1,311 0.11
Duration rest period after peak Reported daily activity
group 12.2 3,320 0.00 group 24.8 1,308 0.00
gender 0.7 3,320 0.42 gender 1.8 1,308 0.68
group x gender 2.0 3,320 0.16 group x gender 0.1 1,308 0.84
% Activity reduction after peak
group 25.3 3,320 0.00
gender 0.1 3,320 0.72
group x gender 1.0 3,320 0.32
*group: CFS/Controls
Activity patterns and the relation with experienced daily fatigue, reported daily 
activity, depressive symptoms, and general disability
One-way analyses of variance revealed a significant effect for reported daily activity 
(table 4). Post-hoc testing revealed that pervasively passive CFS patients reported 
less daily activity compared to moderately active and pervasively active CFS 
patients. Moderately active patients had significantly lower reported daily activity 
scores compared to the pervasively active patients.
Pervasively passive CFS patients had higher general disability scores compared to 
moderately active and pervasively active CFS patients. Levels of daily experienced 
fatigue and psychological distress were equal for the three types of activity patterns 
(table 4).
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Table 4. The relation between activity patterns and self-report measures
Pervasively
passive
Moderately
active
Pervasively
active
F-value p-value
Experienced daily Fatigue 8.3 ± 2.3 7.9 ± 2.1 7.8 ± 1.8 F(2,261)= 1.0 p=0.372
Reported daily Activity 4.0 ± 1.4 4.7 ± 1.6 5.6 ± 1.7 F(2,236)=11.3 p=0.00
Psychological Symptoms 
(BDI-tot)
13.4 ± 6.3 13.2 ± 6.4 12.9 ± 5.7 F(2,266)= 0.1 p=0.93
General Disability 
(SIP7-total)
1967 ± 630 1743 ± 580 1793 ± 690 F(2,266)= 3.2 p=0.04
One-way analyses of variance with type of activity patterns as independent factor
Discussion
Previous studies showed that CFS patients were as a group less physically active 
compared to healthy controls. Nevertheless, quite large variations in actometer 
scores suggested considerable individual differences. Earlier studies also indicated 
that self-report measures of physical activity and actual measurement of activity were 
not highly correlated. Furthermore, our clinical observations strengthened our belief 
that by merely comparing overall levels of physical activity important information 
about the individual’s physical activity patterns would be lost.
To our knowledge this study is the first attempt to distinguish and describe physical 
activity patterns in a large CFS sample by means of prolonged measurement of 
actual physical activity. The mean general physical activity score indicated that over 
a prolonged period of time, CFS patients not only reported to be less active but also 
were physically less active compared to healthy controls. Overall, men were more 
physically active compared to females. However, inspection of the average scores 
indicated that this was especially true for the control group. The relatively small 
control group could have reduced the statistical power to detect a significant 
interaction effect (group x gender).
The average peak amplitude of the ten largest peaks was lower for the CFS group 
and the average duration of these intense activity periods were significantly shorter 
for CFS patients. It is possible that the intensity of peaks reflects to a larger extent 
physical or motor capacity, while the length of the peaks reflects the endurance 
capacity for physical exertion and is as such more closely related to fatigue. In future 
research one could test this assumption by comparing physical condition data of 
endurance tests with the actometer parameters.
Since CFS patients often indicate that they need lengthy and excessive rest periods 
after physical exertion, the periods after peak activity were inspected. The results 
showed that CFS patients indeed had longer rest periods following their activity 
peaks and patients were characterised by a larger drop in activity during the hour 
after a peak. These overall (group) findings seem to fit the general statements 
patients give about changes in their activity. Compared to healthy controls, no
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indication was found that the CFS patients as a group were characterised by a high 
number of large day-to-day fluctuations in activity. However, this finding does not 
exclude that there are individuals who have such a pattern. The fluctuation measures 
used were limited to day-to-day changes and did not control whether some patients 
were active for some days, and then inactive for a prolonged period of time. The day- 
to-day fluctuation measures were based on somewhat arbitrary criteria (one standard 
deviation and 33% activity change). However, when we post-hoc tested alternative 
criteria (50 or 66% activity change) again no significant group differences between 
controls and CFS patients emerged. One could argue that large day-to-day 
differences are rare in a group of patients that is overall inactive. Additional testing 
revealed that when the pervasively passive patients were omitted from the analyses 
again no differences on day-to-day fluctuations occurred between the remaining 
more active CFS patients and controls. Previous research of our group has shown 
that self-report measures of activity and behavioural data often correlate poorly6. One 
reason for these low correlations could be that self-report of complaints and 
behaviour may be biased by illness and disability related cognitions.
In earlier studies we observed that CFS patients differed considerably in their 
physical activity levels, but that a subgroup of CFS patients seemed to be physically 
inactive all the time. However, with self-ratings of activity it was rather difficult to 
isolate this group, since the majority of CFS patients reported to be rather inactive. 
With a simple procedure we tried to identify these patients. The validity of this 
procedure was backed up by the fact that none of the healthy controls fell into the 
category of pervasively passive and by the fact that pervasively passive had 
significantly lower daily reported activity scores. In the current sample ambulant 
patients who volunteered and were able to participate in an intervention study were 
studied. Therefore, it is possible that the obtained results underestimate the 
prevalence of pervasively passive CFS patients in the total population of CFS 
patients.
The results of this study showed no relation between type of activity pattern and 
levels of depressive symptoms. As such, psychological distress or levels of 
experienced fatigue were unlikely to be the major determinants of differences in 
physical activity levels. One possible explanation could be that pervasively passive 
patients are more inclined to avoid physical exertion in order to prevent fatigue, or 
that those pervasively passive patients are characterised by more physical 
dysfunctioning. Higher incidence of physical dysfunctioning could be in line with the 
fact that pervasively passive patients reported more disability. In future studies it 
would be worthwhile to compare physiological and psychological parameters of 
patients according to their physical activity patterns.
Attempts have been made to associate levels of physical activity with other 
behavioural and psychological measures. A recent study reported a relation between 
neuropsychological impairment and functional disability in patients with CFS11. 
Patients who failed a higher number of neuropsychological tests reported significantly
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more days of general inactivity. The authors suggested that this association was not 
merely a result of psychiatric factors but perhaps indicated a failure in a common 
physiological mechanism. However, these findings could have been biased by the 
fact that physical activity, in contrast to neuropsychological functioning, was 
measured by self-report.
The obtained results confirmed that the CFS patients were as a group less active and 
took more rest after physical exertion, and that it was possible to identify pervasively 
passive patients. However, the results also showed that a proportion of CFS patients 
had activity patterns and parameters comparable to those of controls. One can 
hypothesise that pervasively passive CFS patients do need quite a different 
approach compared to relatively active CFS patients. Perhaps that passive patients 
benefit more from increasing physical activity, while activity regulation is more 
important for the more active CFS group. Preliminary findings of our research group 
indeed indicated that subtyping physical activity patterns at baseline could 
significantly improve the prediction of success of cognitive behaviour therapy. 
Although the current findings need further exploration, they offer several perspectives 
for individualising treatment protocols according to the type of activity pattern, and a 
further refining of CFS classification.
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Psychiatric disorders among patients with chronic fatigue 
syndrome in a randomised controlled trial for the effectiveness of 
cognitive behaviour therapy
Abstract
Background Lifetime and current psychiatric disorders have been associated with 
poor outcome in the prognosis of patients with chronic fatigue syndrome. The impact 
of psychiatric disorders on treatment withdrawal and outcome of cognitive behaviour 
therapy, an effective treatment for chronic fatigue syndrome patients, is not known. 
Subjects and methods Lifetime and current psychiatric diagnoses were assessed at 
baseline with a structured psychiatric interview in a multicentre randomised controlled 
trial of 270 patients allocated to cognitive behaviour therapy, support groups or 
natural course during 14 months. The proportions of psychiatric diagnoses in chronic 
fatigue syndrome patients were compared to data of a general population study. 
Proportions of patients with and without psychiatric diagnoses were compared 
concerning treatment withdrawal and clinical improvement. Outcomes of patients with 
and without current psychiatric diagnoses were examined in general linear models. 
Results Lifetime and current psychiatric disorders were found in 50% and 32% of the 
chronic fatigue syndrome patients. The proportions of mood disorders were higher 
than in the general population. No significant differences were found between 
patients with and without current or lifetime psychiatric diagnoses in treatment 
adherence or clinical improvement in each of the conditions. In cognitive behaviour 
therapy, support groups and natural course patients with a current psychiatric 
diagnosis had outcomes of fatigue severity and functional impairment identical to 
patients without a current psychiatric diagnosis.
Conclusions Chronic fatigue syndrome patients with psychiatric co-morbidity have 
not a higher withdrawal rate or worse outcome than patients without, when treated 
with cognitive behaviour therapy.
Introduction
Chronic fatigue syndrome is characterised by persistent or relapsing unexplained 
chronic fatigue, of new or definite onset and lasting for at least six months. Fatigue is 
not the result of an organic disease or ongoing exertion, rest does not alleviate it, and 
it results in substantial reduction in previous levels of occupational, educational, 
social and personal activities. Causes for CFS have not been found and most 
patients do not recover. In the past decade chronic fatigue syndrome (CFS) 
frequently has been associated with psychiatric disorders. Discussions about the 
prevalence of psychiatric disorders in CFS have been obscured by different criteria 
for CFS, different instruments for psychiatric disorders and different settings in which 
patients were seen. Another obstacle in clarifying the role of psychiatric disorders in 
CFS arises from the overlap between symptoms of CFS and psychiatric disorders 
like depression. Over- or underdiagnosis of psychiatric disorders may be the result.
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Despite these methodological and definition problems, Wessely and colleagues1 
compared a large number of studies and concluded that the evidence for some 
association between psychiatric disorders, most common depressive disorders, and 
CFS is convincing. Several explanations for the association found were considered, 
like misdiagnosis of CFS as a psychiatric disorder or the reverse, co-morbidity in the 
onset of both diagnoses or psychological symptoms as a normal reaction to physical 
illness. As predictors of outcome in the prognosis of patients with CFS psychiatric 
disorders have shown conflicting results. In two studies lifetime dysthymia has been 
associated with poorer outcome2,3, whereas in another study no association with 
premorbid psychiatric diagnoses was found4. In the latter study a worse outcome was 
found for patients with a primary psychiatric diagnosis assessed at follow-up4. The 
complex issue of psychiatric disorders in CFS raises questions about the impact of 
psychiatric co-morbidity on treatment of CFS. Cognitive behaviour therapy (CBT) and 
graded exercise therapy were found to be the only effective therapies for CFS 
patients5,6. In two randomised controlled trials of CBT for CFS psychiatric diagnoses 
were assessed, but effects on treatment outcome were not reported in one study7 
and no significant differences in the presence of psychiatric diagnoses at baseline 
were found between improved and unimproved patients in the other study8. However, 
the latter finding may have been due to small sample size. In an uncontrolled trial 
CFS patients with a poor outcome four years after CBT were likely to have had a 
previous psychiatric history9. Considering the limited results available, the impact of 
psychiatric disorders on treatment outcome in CBT remains unclear.
In our trial CBT was more effective for CFS patients than guided support groups or 
the natural course10. However, the proportions of patients with clinically significant 
improvement were lower than in previous CBT trials. Several factors were suggested 
to explain these results. Therapists in this study had no clinical experience with CFS 
and afterwards many of them agreed that CFS patients are more difficult to treat than 
patients with psychiatric diagnoses. Also, criteria for clinical significant improvement 
were very stringent. Further, the treatment protocol seemed not to be suitable for 
patients with a passive activity pattern and patients with a strong tendency to focus 
on bodily symptoms10, and patients who were engaged in a legal procedure 
concerning financial benefits had a worse outcome11. Besides lower improvement 
rates the trial suffered from a large withdrawal rate, especially in the treatment 
groups. Withdrawal was defined differently for the three groups in the trial. In the 
natural course group, only patients not attending the assessments were classified as 
withdrawing, whereas in the two intervention groups those who did not start or who 
stopped treatment were also counted. The explanations we suggested for the large 
withdrawal rate were scepticism about psychological treatments and the physical 
burden of travelling for treatment. Psychiatric co-morbidity might offer another 
explanation for the larger withdrawal rate and the smaller improvement rate in our 
multicentre randomised controlled trial of CBT for CFS.
In this article we will address the impact of psychiatric co-morbidity on the prognosis
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of CFS in our trial. First, the proportions of lifetime and current psychiatric diagnoses 
occurring in association with CFS will be studied. Next, lifetime and current mood and 
anxiety disorders will be compared to the published results of a prospective study in 
a large sample of the general population in the Netherlands with the same age range 
during the same period also using a structured clinical interview12. Finally, the role of 
psychiatric diagnoses in treatment outcome, treatment withdrawal and the natural 
course of CFS will be evaluated.
Subjects and methods
Study design and sample
Psychiatric disorders were studied in 270 CFS patients, who entered a multicentre 
randomised controlled trial of cognitive behaviour therapy between October 1996 and 
January 1998. For full details of this study see Prins et a l.10 All patients had a major 
complaint of fatigue and were referred to the outpatient clinic of the departments of 
internal medicine of two university medical centres in the Netherlands. Patients aged 
between 18 and 60 years were assessed by means of detailed history, physical 
examination and computer assessment of questionnaires and had to fulfil the CDC- 
1994 criteria for CFS or idiopathic chronic fatigue13. Severe fatigue was assessed 
with a score of 40 or more on the subscale fatigue severity of the Checklist Individual 
Strength14 and severe impairment with a score of 800 or more on the Sickness 
Impact Profile15-17.
Measures
Assessments of fatigue and functional impairment, being the primary outcome 
measures in the RCT, and of the secondary outcome variables depression and 
psychological distress were made at baseline, 8 months and 14 months. Psychiatric 
disorders were assessed at baseline.
The Dutch translation of the Structured Clinical Interview for DSM-III-R patient 
version (SCID-I/P)18 was used to assess anxiety disorders, mood disorders, 
somatoform disorders, and posttraumatic stress disorder. A psychologist (EKR) 
administered the SCID during one session of approximately one and a half-hours. 
The reliability and validity of the SCID were tested in many international studies.
A subscale of the Checklist Individual Strength (CIS)14 assessed fatigue severity. In 
this questionnaire, the patient is asked about fatigue in the two weeks preceding the 
assessment. The subscale consists of eight items, each scored on a 7-point Likert 
scale (range 8-56). The CIS has good reliability and validity10,14.
Functional impairment was measured by the Sickness Impact Profile (SIP)15-17. A 
total score was calculated by addition of the weight of items in eight subscales: home 
management, mobility, alertness behaviour, sleep/rest, ambulation, social 
interactions, work, and recreation and pastimes. This measure has good reliability 
and validity17.
The Symptom Checklist (SCL-90)19 consists of 90 items and screens for anxiety,
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agoraphobia, depression, somatisation, cognitive difficulties, interpersonal sensitivity, 
hostility and sleep disturbances. The total score can be considered as a general 
measure of psychological distress.
The Beck Depression Inventory (BDI)20,21 is a standardised self-report questionnaire 
used to measure depression.
Analyses
Proportions were calculated for each of the separate disorders in the SCID. Lifetime 
prevalence was the proportion of patients who reported having experienced a given 
disorder at some time in their lives and current prevalence refers to those that had 
the disorder at the time of the study. To control for overlap between symptoms of 
depression and CFS, mood disorders were calculated both with and without fatigue 
and/or poor concentration as criteria for the diagnosis. The proportions of psychiatric 
disorders in CFS patients were compared to the proportions in the general population 
by calculating z-scores.
Clinical improvement in fatigue severity was defined as a reliable change index >1.64 
and a score < 36 indicating that the patient had moved to the range of healthy 
individuals10. Treatment withdrawal was found in different stages of the trial and 
subdivided in patients who did not start treatment, patients who withdrew during the 
test phase, patients who withdrew during follow-up and patients who completed the 
trial. The proportion of patients with and without lifetime or current psychiatric 
disorders in treatment withdrawals and improved patients in each of the three groups 
were compared with Fischer’s exact test.
Main and interaction effects of psychiatric diagnoses on the primary outcome 
variables fatigue severity and functional impairment in each condition were analysed 
with a general linear model for repeated measurements. Outcome variables at 8 and 
14 months were used as repeated measurements, with condition (three levels), 
current psychiatric diagnosis (two levels) and their first-order interactions as 
independent variables. Treatment effects of the secondary outcome variables 
psychological distress and depression were analysed using the same model.
Results
The data of 264 patients (90 CBT, 87 support groups, 87 control group) were 
analysed, since the SCID data of 6 patients were missing.
The presence of at least one lifetime psychiatric disorder was found in 50% of the 
CFS patients. One lifetime psychiatric diagnosis was assessed in 28% of all CFS 
patients, two or more diagnoses in 22%. A current psychiatric disorder was reported 
by 32.2% of the CFS patients. One current psychiatric diagnosis was found in 21.2% 
of all CFS patients, two or more diagnoses in 11%. The proportions of lifetime and 
current mood and anxiety disorders are shown in table 1. Lifetime mood disorders 
were found in 98 patients (37.1%), 50 patients (18.9%) had a current mood disorder. 
Dysthymia and depression were assessed most, while cyclothymia and bipolar
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disorder hardly occurred. Lifetime anxiety disorders were found in 52 patients 
(19.7%); 35 patients (13.3%) had a current anxiety disorder. Each of the separate 
anxiety disorders was assessed in 3 to 10 patients (1.1 to 3.8%) with the exception of 
simple phobia, which was found more frequently. Of the 21 patients (8%) with simple 
phobia 13 patients also had another psychiatric diagnosis. Only 2 patients (0.9%) 
had a past post-traumatic stress disorder in remission and 13 patients (4.9%) a 
lifetime somatisation disorder. Current other somatoform disorders were assessed in 
22 patients (8.3%).
Table 1. Proportions of DSM-III-R diagnoses in a sample of CFS patients compared to the published data of a 
sample of the Dutch general population (de Bijl et al. , 1998)
CFS patients general population
n = 264 n = 7076
18-60 yr 18-64 yr
SCID CIDI
DSM-III-R Lifetime Current Lifetime 1-month
n % n % % %
Mood disorders 98 37.1 50 18.9 19.0 3.9
depression 74 28.0 16 6.1 15.4 2.7
dysthymic 30 11.3 6.3 1.6
bipolar 5 1.9 1 0.0 1.8 0.6
cyclothymic - 6 2.3
Anxiety disorders 52 19.7 35 13.3 19.3 9.7
panic disorder 29 11.0 10 3.8 3.8 1.5
agoraphobia 8 3.0 7 2.7 3.4 1.0
simple phobia - - 21 8.0 10.1 5.5
social phobia 4 1.5 4 1.5 7.8 3.7
generalised anxiety disorder - 6 2.3 2.3 0.8
obsessive compulsive disorder 4 1.5 3 1.1 0.9 0.3
When controlling for the CFS symptoms fatigue and poor concentration at least one 
lifetime psychiatric disorder was found in 113 patients (42.8%), one disorder in 23.5% 
and two or more in 19.3%, and at least one current disorder in 75 patients (28.4%), 
one disorder in 18.6% and two or more in 9.8%. With fatigue and poor concentration 
excluded 70 patients (26.5%) had a lifetime mood disorder and 37 patients (14%) 
had a current mood disorder.
As is shown in table 2, patients with lifetime or current psychiatric disorders were not 
significantly different from patients without these disorders in age, duration of 
complaints, education, fatigue and functional impairment. Significantly more female 
than male patients had a lifetime psychiatric diagnosis (53.9% vs. 36.2%, p<0.05). 
No gender differences were found in percentages of current psychiatric disorders 
(33% and 29%).
88 Chapter 6
Table 2. Patient characteristics of CFS patients with and without lifetime and current psychiatric disorders
Lifetime Current
yes no yes no
n=132 n=132 n=85 n=179
mean ( s.d.) mean ( s.d.) mean ( s.d.) mean ( s.d.)
Age (yr) 36.5 (10.2) 36.8 (10.1) 36.5 ( 9.9) 36.8 (10.2)
Duration of complaints (yr) 6.1 ( 6.4) 5.0 ( 4.8) 5.8 ( 5.7) 5.5 ( 5.6)
Education (1=low to 7=high) 4.3 ( 1.6) 4.2 ( 1.5) 4.1 ( 1.7) 4.3 ( 1.5)
CIS-fatigue 52.3 ( 3.8) 51.9 ( 4.2) 52.1 ( 4.1) 52.1 ( 4.0)
SIP8-functional impairment 1848 (591) 1797 (641) 1904 (647) 1784 ( 603)
Male / female (%) 36.2 (53.9) a 29.3 (33.0)
a p<0.05
Table 3. Number of withdrawals, completers and improved patients with and without lifetime and current 
psychiatric diagnoses in the conditions cognitive behaviour therapy, support groups and control group at 8 and 14 
months
Psychiatric diagnoses in 264 CFS patients
Lifetime Current
Randomisation total yes no P yes no P
Cognitive behaviour therapy 90 49 41 34 56
not start 8 5 3 n.s. 3 5 n.s.
withdrew 8 months 23 11 12 n.s. 10 13 n.s.
withdrew 14 months 4 2 2 n.s. 2 2 n.s.
completed trial 55 31 24 n.s. 19 36 n.s.
improved 8 months 27/82 14 13 n.s. 10 17 n.s.
improved 14 months 20/58 9 11 n.s. 7 13 n.s.
Guided support groups 87 40 47 23 64
not start 7 2 5 n.s. 0 7 n.s.
withdrew 8 months 16 9 7 n.s. 5 11 n.s.
withdrew 14 months 4 2 2 n.s. 2 2 n.s.
completed trial 60 27 33 n.s. 16 44 n.s.
improved 8 months 10/79 3 7 n.s. 1 9 n.s.
improved 14months 8/61 4 4 n.s. 1 7 n.s.
Control group 87 43 44 28 59
not start 0 0 0 n.s. 0 0 n.s.
withdrew 8 months 8 4 4 n.s. 4 4 n.s.
withdrew 14 months 9 5 4 n.s. 5 4 n.s.
completed trial 70 34 36 n.s. 19 51 n.s.
improved 8 months 10/77 6 4 n.s. 1 9 n.s.
improved 14 months 13/76 6 7 n.s. 3 10 n.s.
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The proportions of current and lifetime mood and anxiety disorders in our CFS 
sample were compared to the proportions in a sample of the Dutch general 
population in the NEMESIS study12 (table 1). The proportion lifetime mood disorders 
in CFS patients is significantly higher than the proportion in the general population 
(37,1% vs. 19,1%; z=7.2, p<0.0001). The same is true for current mood disorders 
(18,9% vs 3,9%; z=12.5, p<0.0001). No significant differences were found between 
the proportions lifetime anxiety disorders in both samples (19,7% vs. 19,3%; z=0.16, 
p=0.87). Also no significant difference between both samples in current anxiety 
disorders was found (13,3% vs. 9,7%; z=1.89, p=0.058).
In table 3 the number of patients who did not start treatment, who withdrew during 
the test phase or follow-up, who completed and who improved during the trial are 
shown in the categories with and without lifetime and current psychiatric diagnoses. 
Analysing separately the different withdrawal groups and the completers we did not 
find any significant differences between patients with and without lifetime or current 
psychiatric diagnoses, neither in the whole trial nor in each of the conditions. Also, no 
significant differences were found between patients with and without lifetime or 
current psychiatric diagnoses in the groups of improved and not improved patients in 
each of the conditions.
In the primary outcome variables fatigue severity and functional impairment general 
linear model testing showed neither main effects of current psychiatric diagnosis 
(F=0.333, df=1, p=0.564; F=1.58, df=1, p=0.209) nor interactions effects of condition 
and current psychiatric diagnosis (F=0.065, df=2, p=0.937; F=0.848, df=2, p=0.430). 
The treatment effects are shown in figure 1.
Figure 1. Effect of study conditions and current psychiatric diagnoses on the two primary outcome variables 
fatigue severity (CIS) and functional impairment (SIP)
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In the conditions cognitive behaviour therapy, support groups and natural course 
CFS patients with a current psychiatric diagnosis had outcomes almost identical to 
patients without a current psychiatric diagnosis. In the secondary outcome variables 
depression and psychological distress, main effects of current psychiatric diagnosis 
(F=25.4, df=1, p<0.001; F=20.2, df=1, p<0.001) were found and no interaction effects 
of condition and psychiatric diagnosis (F=0.067, df=2, p=0.935; F=0.306, df=2, 
p=0.737). The treatment effects are shown in figure 2. In the conditions cognitive 
behaviour therapy, support groups and natural course CFS patients with a current 
psychiatric diagnosis had higher BDI and SCL-scores at each measurement 
compared to patients without a current psychiatric diagnosis. However, patients with 
current psychiatric diagnoses had similar difference scores from baseline to post-test 
and follow-up as patients without current psychiatric diagnoses.
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Figure 2. Effects of study conditions and current psychiatric diagnoses on the secondary outcome variables 
depression (BDI) and psychological distress (SCL-90)
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Comment
Lifetime and current psychiatric diagnoses in respectively one half and one third of 
CFS patients in our sample seem low to moderate compared to proportions of DSM- 
III-R diagnoses found in other studies of CFS patients in hospital settings1. Detailed 
comparisons with other studies are difficult due to the use of different instruments 
and different CFS criteria. In our study lifetime mood disorders, anxiety disorders, 
PTSD and somatoform disorders were present in 50% of CFS patients. Since lifetime 
diagnoses are referring to both the premorbid situation and the period since the onset 
of CFS, interpretation of the lifetime data in our study requires some caution. W ith an
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average duration of complaints of 5.6 years in our sample, no conclusions can be 
drawn about the premorbid psychiatric state of the CFS patients nor about after onset 
psychiatric diagnoses. Most prominent among the lifetime psychiatric disorders were 
major depression (28%) and panic disorder (11%). Corrected for the CFS symptoms 
fatigue and poor concentration, the lifetime proportion was 43%. This proportion 
differs from the one in a recent study in the United Kingdom in which a lower lifetime 
rate of 34% was found, when fatigue was excluded as a criterion22. An explanation 
might be the difference in the female:male ratio in both studies. In the UK study 63% 
of the patients was female compared to 78,5% in our study, in which female patients 
were found to have higher proportions of lifetime psychiatric diagnoses than male 
patients.
Current psychiatric disorders were found in 32% of CFS patients. Dysthymia was 
diagnosed most frequently (11%). Two other studies in which CFS patients were 
assessed with the same instrument showed higher rates of current psychiatric 
diagnoses. In a prevalence study of CFS in an Australian population 43% current 
psychiatric diagnoses were found with a comparable proportion of anxiety disorders 
and 10% more cases of depression23. In a Belgian study a high current prevalence 
rate of 77% was found in a similar setting as our study. Especially high proportions of 
generalised anxiety disorder were reported, which we hardly found24. In our study 
less than 5% of the CFS patients were screened positive for somatisation disorder, a 
rather low percentage compared to most studies in which between 10% and 20% 
fulfil criteria for somatisation disorder1. PTSD was rare, like in other studies24,25.
We had the opportunity to compare our data to a large representative sample of the 
general population with the same age range in the Netherlands. Although slightly 
different structured clinical interviews were used in both studies, the same diagnostic 
categories of DSM-III-R mood and anxiety disorders were obtained during the same 
period. We found no differences in anxiety disorders. Significantly higher 
percentages current and lifetime mood disorders were found in CFS patients than in 
the general population. These results might be explained by a gender effect, since 
almost 80% of the CFS patients in our sample were female. In the general population 
study women were found to have higher prevalence rates of mood and anxiety 
disorders than men. Total proportions of lifetime or current psychiatric disorders 
could not be compared, because PTSD and somatoform disorders were not 
assessed in the general population study and substance use disorders and 
schizophrenia were not assessed in our study.
Considering overlap between symptoms of depression and CFS the question arises if 
overdiagnosis might have occurred in our study. Lower proportions of mood 
disorders were found when we controlled for the CFS symptoms of fatigue and poor 
concentration, resulting in respectively 9% and 5% less lifetime and current mood 
disorders.
One third of the CFS patients with current psychiatric co-morbidity had two or more 
psychiatric disorders. This finding stresses the importance of the role of current
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psychiatric disorders in outcome during the natural course of CFS and in treatment 
outcome or withdrawal in CBT. In contrast to what we expected, the outcomes of 
CBT and support groups as well as the natural course of CFS were not influenced by 
current psychiatric disorders. In view of the significantly better treatment effects of 
CBT compared to the control conditions10, the equal treatment effects of CBT for 
patients with and without current psychiatric disorders are especially interesting. After 
CBT, patients with and without psychiatric co-morbidity improved not only in fatigue 
severity and functional impairment, but also in depression and psychological distress. 
This is remarkable since CBT patients were not allowed other treatments, like 
antidepressants. Apparently, co-morbid psychiatric diagnoses also benefit from CBT 
specially tailored for CFS. These results accord with findings that targeted CBT for 
anxiety disorders is highly effective for treating a single anxiety disorder and at the 
same time lessens co-morbid psychopathology26. Clinical experience with CFS has 
shown that the reverse is not true. Treating psychiatric co-morbidity may relieve 
psychiatric symptoms or psychological distress, but does not alter somatic 
symptoms.
The findings in this study have practical consequences. Psychiatric screening of 
mood and anxiety disorders is no longer relevant for CFS patients referred for CBT, 
since treatment outcome and withdrawal are not affected by the presence of these 
disorders. Now that we found that depressive symptoms considerably benefit from 
CBT, we will continue our routine to refuse CBT to CFS patients not willing to stop 
antidepressant therapy. Antidepressants were not found effective in either treating 
the symptoms of depression of CFS patients or any other outcomes6,27. In our 
opinion antidepressant therapy interferes with the main goal of CBT acquiring control 
over symptoms instead of dependence on medication.
Another remarkable finding concerned the natural course of CFS during 14 months, 
which was not adversely affected by current psychiatric co-morbidity. This finding 
confirms the results of our previous studies, in which current depression was not a 
significant factor in the persistence of CFS28,29.
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Abstract
Although cognitive behaviour therapy (CBT) for chronic fatigue syndrome (CFS) is 
effective in several randomised controlled trials (RCT), little is known about predictors 
of treatment outcome. With the data of our RCT, where CBT for CFS was 
significantly more effective in improving fatigue severity and functional impairment 
than guided support groups and natural course, the predictive value of activity 
pattern, disability claims and psychiatric co-morbidity was tested for outcome of CBT. 
Patients with a passive activity pattern and patients who were engaged in a legal 
procedure concerning financial benefits had a worse outcome. Psychiatric co­
morbidity was not a predictor. For patients with a passive activity pattern another type 
of CBT has to be offered. CBT should not be offered to patients during their 
engagement in legal procedures of disability claims.
Introduction
Most patients with chronic fatigue syndrome (CFS) do not recover. No medical 
treatments have proven to be effective. The effectiveness of cognitive behaviour 
therapy (CBT) and graded exercise for CFS patients has been shown in six out of 
seven randomised controlled trials (RCT). In our opinion, both treatments are 
comparable, since there is no CBT without graded exercise and no graded exercise 
without cognitive therapy.
The conclusion of two reviews was that CBT is effective for CFS patients1,2. Also, the 
first results concerning lasting benefits of CBT after 5 years are promising3. Although 
many CFS patients achieve improved functioning, some patients do not respond at 
all.
However, minimal attention was directed at factors that might influence the treatment 
results. Only in two RCT's predictors of treatment outcome were identified. Poor 
outcome was associated with making a new claim for a disability-related benefit 
during CBT4. In our RCT perpetuating factors in the natural course of CFS5 were 
assessed at baseline and analysed in regression analyses. Predictors for outcome 
after CBT were a higher sense of control predicting more improvement, and a 
passive activity pattern and focusing on bodily symptoms predicting less 
improvement6. For the utility of CBT in routine practice, identification of prognostic 
factors is of major importance.
In our study CBT for CFS was offered in three different centres by 13 newly trained 
therapists6. CFS patients were allocated to CBT, guided support groups or natural 
course. CBT was significantly more effective in improving fatigue severity and 
functional impairment than both control conditions. In this brief report, we will test the 
predictive value of activity pattern, disability claims and psychiatric co-morbidity for 
clinical outcome of all participating CFS patients in our RCT and for outcome of CBT.
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Method
Design, setting, patients, interventions and outcomes
Multicentre randomised controlled trial with 8- and 14-month follow-up in three mental 
health settings in the Netherlands (two based in university medical centres and one 
in a mental health institute). 270 patients between 18 and 60 years of age (mean age 
37 years, 79% women) fulfilling the CDC criteria for CFS or idiopathic chronic fatigue, 
and a score of > 40 on the subscale fatigue severity of the checklist individual 
strength (CIS) and a score of > 800 on the sickness impact profile (SIP). Exclusion 
criteria included previous or current participation in CFS research, and pregnancy. 92 
patients were allocated to CBT (16 one-hour sessions over 8 months), 90 to guided 
support (eleven 1.5-hour meetings over 8 months), and 88 to the control group (no 
intervention). The primary outcomes were fatigue severity and functional impairment. 
Clinical improvement in fatigue severity was defined as a reliable change index > 
1.64 and a score < 36 indicating that the patient had moved to the range of a healthy 
ind iv id u a l7.
Measurement of prognostic factors 
Activity pattern.
At baseline, physical activity was measured by the actometer, a motion-sensing 
device attached to the ankle and worn day and night during 12 days. Accelerometers 
like the actometer are reliable and valid measures of physical activity3. The activity 
pattern of each patient was typified by comparing daily activity scores to the 
reference score of CFS patients. Three categories were defined: pervasively passive 
(90% or more beneath the reference score); moderately active; pervasively active 
(90% or more above the reference score)9.
Claims for disability-related financial benefits.
At 8 months, patients received a post-intervention questionnaire. One of the 
questions was if the patient was engaged in a legal procedure concerning disability- 
related financial benefits during the preceding 8 months.
Psychiatric co-morbidity.
The Dutch translation of the Structured Clinical Interview for DSM-III-R patient 
version (SCID-P)10 was used to assess psychiatric disorder (anxiety disorders, mood 
disorders, eating disorders, posttraumatic stress disorder). A clinical psychologist 
administered the SCID during one session of approximately one and a half-hours. 
The lifetime prevalence was the proportion of patients who reported having 
experienced a given disorder at some time in their lives, and current prevalence 
refers to those that had the disorder at the time of the study.
Results
Activity pattern
In the sample of 270 CFS patients 24% was pervasively passive, 61% was 
moderately active and 1 5% pervasively active9. Fatigue severity at 8 months was 
predicted by interaction of CBT with a pervasively passive activity pattern6.
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Therefore, the percentages of improved and unimproved CFS patients who 
completed CBT were explored. Figure 1 shows that at 8 months none of the patients 
in CBT with a pervasively passive activity pattern was clinically improved compared 
to 40% and 58% of the moderately active and pervasively active CFS patients. At 
follow-up, the improvement rates were respectively 21%, 32% and 60% in the three 
groups.
passive moderately active
Figure 1. Percentages clinically improved CFS patients by CBT in three categories of activity pattern
Claims for disability-related financial benefits
Thirty-one percent of the patients in the trial appeared to be engaged in a legal 
procedure concerning financial benefits of the Disablement Insurance Act in the 
period between baseline and 8 months. In the total sample, the percentage of 
recovered patients was significantly lower in the group of patients engaged in a legal 
procedure compared to the group of patients not engaged in such a procedure 
(Chi2=7.44, p=0.006).
The same effect was found in the group of patients treated with CBT. The percentage 
of clinically improved CFS patients was significantly higher in the group not engaged 
in a legal procedure than in the group claiming financial benefits (49% vs. 19%, 
Chi2=4.37, p=0.034).
Psychiatric co-morbidity
A lifetime prevalence of at least one psychiatric disorder was found in 50% of the 
CFS patients. Most prominent were major depression (28%) and panic disorder 
(11%). At the time of the interview one or more psychiatric disorders were reported 
by 32% of the CFS patients. Current psychiatric disorders were mainly mood
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disorders (19%) and anxiety disorders (13%), and to a lesser extent other 
somatoform disorders (8%). No current somatisation disorders were diagnosed.
For the patients who received CBT, no significant differences in treatment outcomes 
fatigue severity and functional impairment were found between patients with lifetime 
and/or current psychiatric disorders and patients without.
Discussion and conclusion
In CFS patients, cognitive behaviour treatment outcome is negatively affected by a 
passive activity pattern and by engagement in claims for financial benefits. Treatment 
outcome is not influenced by lifetime or current psychiatric diagnoses.
The correlation between the predictors activity pattern and engagement in a claim 
was very low (r=.10, n.s.). Only 10% of the CFS patients was characterised by both 
predictors. Therefore, each of the predictors needs separate attention. Since 45% of 
the patients in the sample was characterised by one of both predictors, these findings 
had implications for our routine practice of CFS patients referred for CBT. First, it was 
concluded that all these patients should be screened for both variables. Second, our 
conclusion was that CBT will not be offered anymore to patients engaged in a claim 
during the time of the legal procedure. These patients have to prove that they are 
disabled in order to gain financial benefits. This is incompatible with recovery, the 
main goal of CBT.
Third, it was concluded that patients with a passive activity pattern were in need of a 
different treatment protocol. The emphasis in CBT as administered in our RCT was 
on a base level of daily activity. This is important for moderately active CFS patients, 
but seemed to increase the fear of physical activity in CFS patients with passive 
activity patterns. In the latter group the subsequent gradual increase of physical 
activity was impeded. Meanwhile, we have developed a CBT protocol for passive 
CFS patients. They start with building up physical activity, whereas more active 
patients still start with a base level of daily activity.
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Social support and the persistence of complaints in chronic fatigue 
syndrome
Abstract
Background Several studies suggested that the surroundings of CFS patients are of 
importance in the persistence of complaints. Contrary to expected, participation in 
support groups has not led to clinical improvement. The purpose of the present study 
was to describe social support in CFS patients as compared to other fatigued and 
non-fatigued groups. Further, changes in social support and the influence of social 
support on the course of CFS over a period of more than one year were studied in 
patients with and without treatment.
Methods Baseline data were assessed in 270 CFS patients, 150 disease-free breast 
cancer patients, 151 fatigued employees on sick leave and 108 healthy subjects 
using the Social Support List and Significant Others Scale. CFS patients were 
followed in cognitive behaviour therapy (CBT), guided support groups and natural 
course at 8 and 14 months.
Results CFS patients and fatigued employees reported more negative interactions 
and insufficiency of supporting interactions than cancer patients and healthy controls. 
No differences in frequency of supporting interactions were found. Negative 
interactions decreased significantly after treatment with CBT, but did not change in 
support groups or natural course. In the natural course, higher fatigue severity at 8 
months was predicted by more negative interactions at baseline.
Conclusions In CFS patients and fatigued employees social support is worse than in 
disease-free cancer patients and healthy controls. Lack of social support was 
identified as a new factor in the model of perpetuating factors of fatigue severity and 
functional impairment in CFS.
Introduction
Chronic fatigue syndrome (CFS) is characterised by persistent or relapsing 
unexplained chronic fatigue of new or definite onset and lasting for at least six 
months. Fatigue is not the result of an organic disease or ongoing exertion, rest does 
not alleviate it, and it results in substantial reduction in previous levels of 
occupational, educational, social and personal activities1. Causes for CFS have not 
been found and most patients do not recover. No somatic or pharmacological 
treatments have proven to be effective. So far, cognitive behaviour therapy (CBT) 
and graded exercise therapy (GET) are the only interventions for CFS patients, which 
consistently have shown positive results2,3. In our study, in which the effectiveness of 
CBT was shown, CBT was compared to guided support groups and the natural 
course4. Guided support groups were intended to control for the absence of specific 
cognitive-behavioural interventions and the presence of therapist’s attention and 
treatment expectations. We assumed that support groups, as in other chronic 
diseases, might contribute to a feeling of mutual understanding, acceptance, and
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support, and thereby would have a healing effect5,6. An unexpected finding was that 
support groups were no more effective than the natural course. However, 80% or 
more of the patients experienced mutual understanding in the support group, and 
rated the contact with the therapist and the atmosphere in the group as good4. This 
discrepancy between the absence of clinical improvement and patients’ satisfaction 
raised questions about the role of social support in CFS.
Social support is a very broad concept referring to the help and protection of others. 
Social support is not a unitary concept, but rather a metaconstruct of conceptually 
different components, ranging from the quantity of social interactions or the size of 
the social network to the perceived availability or quality of supporting interactions7. 
Different types of social support are distinguished, like emotional support, 
instrumental support, esteem support or informational support. Cobb8 was the first to 
describe the positive influence of social support on health, like accelerated recovery 
and enhanced compliance. He saw social support as a buffer against stress. Next, 
several theories were offered to explain the mechanisms, by which social support 
directly or indirectly affects health.
Several studies found a relation between social support and CFS. Prior to illness, 
CFS patients perceived less social support compared to patients with irritable bowel 
syndrome and healthy controls in a retrospective study9. We have hypothesised that 
after onset of CFS perceived social support also may be less, since medical 
professionals consider CFS to be a controversial condition10. The quantity of social 
support also seems affected. CFS patients were found to report a substantial 
reduction of social relationships due to functional impairment in work and pastimes11. 
As a result of changes in social networks, family members and partners have 
become increasingly important resources of social support. CFS patients, whose 
partners were more optimistic about the course of the illness, reported less functional 
impairment12. A solicitous attitude of the partner was associated with worse patient 
functioning13. As to illness course and outcome of CFS, cross-sectional studies have 
shown that perceived social support was associated with improvement14 and with 
less aggravation of CFS complaints after a natural disaster15. In our study of CFS 
patients with a relatively short illness length, we found that persistence of complaints 
after one-year follow-up was associated with higher levels of insufficiency of social 
support at baseline16. Although the results of all these studies suggest that the 
surroundings of CFS patients are of importance in the persistence of complaints, 
many questions concerning the exact relation between social support and CFS 
remain. For example, are demographic characteristics, like age, gender or civil status 
of importance for social support of CFS patients? Does social support of CFS 
patients differ from social support of other patients with fatigue complaints, patients 
with a chronic disease or healthy controls? Does social support of CFS patients 
change as a result of treatment with CBT or after participation in support groups?
The objectives of the present study were to assess the relation between social 
support and several demographic characteristics and to describe quantitative and
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qualitative aspects of social support in CFS patients. Further, we were interested in 
comparing social support of CFS patients to other patients with fatigue complaints, to 
other patients with a chronic disease and to healthy subjects. In addition, we 
intended to study changes in social support of CFS patients over a period of more 
than one year and the relation between social support and the course of CFS in 
patients with and without treatment.
Patients and methods
Patients, design and procedure
The sample consisted of 270 CFS patients, who entered a multicentre randomised 
controlled trial of cognitive behaviour therapy4. All patients had a major complaint of 
fatigue and were referred to the outpatient clinic of the departments of internal 
medicine of two university medical centres in the Netherlands. Patients aged 
between 18 and 60 years were assessed by means of detailed history, physical 
examination and computer assessment of questionnaires and had to fulfil criteria for 
CFS1, with the exception of the criterion of four out of eight additional symptoms17. 
Severe fatigue was assessed with a score of 40 or more on the subscale fatigue 
severity of the Checklist Individual Strength and severe impairment with a score of 
800 or more on the Sickness Impact Profile.
Comparison groups
The sample of disease-free cancer patients consisted of 150 patients who 
participated in a cross-sectional study on determinants of chronic fatigue18. The 151 
fatigued employees on sick leave had severe fatigue for more than four months 
without a somatic explanation and complete absenteeism from work for 6 to 26 
weeks19. Healthy control subjects were family members, friends or colleagues of the 
patients participating in one of the above mentioned studies on CFS or breast
4,18cancer4,18.
Assessments
Fatigue severity, functional impairment and social support were assessed at 
baseline, 8 months and 14 months. Relations with significant others were assessed 
at baseline.
Fatigue severity A subscale of the Checklist Individual Strength (CIS) assessed 
fatigue severity. In this questionnaire, the patient is asked about fatigue in the two 
weeks preceding the assessment. The subscale consists of eight items, each scored 
on a 7-point Likert scale (range 8-56). The CIS has good reliability and discriminative 
validity420'22.
Functional impairment The Sickness Impact Profile (SIP) measured functional 
impairment. A total score was calculated by addition of the weights of items in eight 
subscales: home management, mobility, alertness behaviour, sleep/rest, ambulation, 
social interactions, work, and recreation and pastimes (S IP -8). This measure has 
good reliability and content validity4,23.
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Social support Social support was measured by the Social Support List24, consisting 
of two 34-item questionnaires, interactions (SSL-I) and discrepancies (SSL-D), and a 
7-item questionnaire negative interactions (SSL-N). Both SSL-I and SSL-D assess 
six types of social support: emotional interactions (range 4-16), problem-focused 
emotional support (range 8-32), esteem support (range 6-24), instrumental 
interactions (range 7-28), social companionship (range 5-20) and informational 
support (range 4-16). In the SSL-I, the frequency of supporting interactions is 
assessed. The SSL-D measures the perceived discrepancy in actual support and 
wanted support, further called insufficiency of supporting interactions. Total scores of 
SSL-I and SSL-D range from 34-136, total score of SSL-N from 7-28. The SSL has 
good reliability (Cronbach’s alpha 0.93 (SSL-I) and 0.95 (SSL-D)) and content 
validity25.
Significant others Twelve questions concerning the relationship with spouse/partner, 
relatives, friends, chief, colleagues, and general practitioner were administered and 
subjected to an exploratory principal component analysis with a subsequent 
orthogonal rotation. One item concerning the spouse/partner was too skewed and 
was therefore excluded. With an eigenvalue over 1, factor analysis resulted in 3 
factors explaining 66% of the variance. Items that loaded at least .45 on one factor 
and a difference in loading on another factor of >.30 were retained. All items had a 
sufficient factor loading. The first factor consisting of 4 items explained 24% of the 
variance and was described as ‘relationship with general practitioner’ (REL-GP). The 
score ranged from 4 to 16, with a higher score reflecting a better relationship 
(Cronbach’s alpha 0.91). 17% of the variance was explained by the second factor, 
which consisted of 4 items and reflected the ‘relationship with family and friends’ 
(REL-FF). The score ranged from 5 to 21, with a higher score reflecting a better 
relationship (Cronbach’s alpha 0.63). The third factor consisting of 2 items explained 
15% of the variance and was described as ‘empathy from colleagues and chief’ 
(EMP-CC). The score ranged from 4 to 8, with a higher score reflecting more 
empathy (Cronbach’s alpha 0.75). If a patient did not work, no score was obtained for 
this factor.
Statistical analyses
The relation between baseline data of social support and several demographic 
characteristics, like age, gender, education, civil status, job status and illness length 
was analysed by comparing categories of the demographic variables using t-tests. 
Baseline social support data of CFS patients were compared with data of disease- 
free breast cancer patients, fatigued employees on sick leave and healthy controls. 
Since these samples were not similar in age and gender, pairwise group 
comparisons were made with estimated marginal means standardised for age and 
gender using ANCOVA with Bonferroni corrections.
Changes in social support during the 14 months of the study were analysed with a 
multivariate analysis of variance (GLM) repeated measures within-subjects design.
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Predictors of treatment outcome were selected by computing correlations between 
the variables concerning social support and significant others, and the primary 
outcome variables fatigue severity and functional impairment at 8 months for each of 
the three conditions. The baseline value of the dependent variable and significantly 
correlating variables were entered as independent variables in two blocks in separate 
multiple regression analyses for each of the dependent variables using the method 
enter. Variables not adding substantially to the variance in the dependent variable 
were removed. Factors were entered in the multiple regression which related to the 
outcome measures at p<0.05 or added substantially to the variance in the dependent 
variable.
Results
Relation between social support and demographic characteristics 
In table 1 the baseline characteristics of the CFS sample concerning social support 
and significant others are shown. Female patients reported significantly more 
supporting interactions and a better relationship with family and friends than male 
patients. Patients older than 35 years had significantly less supporting interactions, 
reported significantly more insufficiency of social support, but had a significantly 
better relation with the general practitioner than younger patients. Lower educated 
patients had a significantly better relation with the general practitioner than higher 
educated patients. No differences were found between patients with and without a 
partner, with and without a job, or with a shorter or longer illness length.
Comparisons between CFS patients, disease-free breast cancer patients, fatigued 
employees on sick leave and healthy controls
In table 2 the means and standard deviations of supporting interactions and negative 
interactions of CFS patients, disease-free breast cancer patients, fatigued employees 
on sick leave and healthy controls are shown. In the three mixed samples, gender 
differences were found in the total score of supporting interactions, in social 
companionship, problem-focused emotional support and emotional interactions. 
Females reported significantly more supporting interactions than males. In the two 
samples of patients selected on fatigue severity, equal gender differences were also 
observed in instrumental interactions. Esteem support was significantly higher for 
female than for male fatigued employees on sick leave. No gender differences 
occurred for informational support and negative interactions.
Table 2 also depicts group differences while controlling for age and gender. No 
significant differences between the groups were found in the total score of supporting 
interactions and in esteem support and informational support. However, significant 
differences were found in some other types of supporting interactions. CFS patients 
had significantly more instrumental interactions than disease-free breast cancer 
patients and healthy controls. Fatigued employees on sick leave had significantly 
less emotional interactions compared to the other three groups. The three patient
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groups had significantly more problem-focused emotional support than healthy 
controls. CFS patients had significantly less social companionship than disease-free 
breast cancer patients and healthy controls, and fatigued employees on sick leave 
less than healthy controls. CFS patients and fatigued employees on sick leave 
reported significantly more negative interactions than disease-free breast cancer 
patients and healthy controls.
Table 1. Baseline scores of social support and relation with significant others
Social support Significant others
% of 
sample
SSL-I
mean(sd)
n=270
SSL-D
mean(sd)
n=270
SSL-N
mean(sd)
n=270
REL-GP REL-FF EMP-CC 
mean(sd) mean(sd) mean(sd) 
n=268 n=269 n=149
Condition
CBT 34% 79.6(11.3) 46.9(10.5) 11.1(3.5) 12.6(3.1) 14.9(2.6) 6.2(1.6)
SG 33% 78.9(12.9) 47.9(12.1) 11.8(3.0) 12.7(2.7) 14.7(2.9) 6.4(1.5)
NC 33% 81.3(12.4) 46.4(10.8) 11.0(2.8) 12.8(2.9) 14.9(2.5) 6.4(1.5)
p 0.410 0.626 0.209 0.912 0.844 0.734
Gender
male 21.5% 73.4( 9.9) 46.9(11.2) 11.3(2.9) 12.6 14.2 6.3
female 78.5% 81.7(12.2) 47.1(11.1) 11.3(3.2) 12.7 15.0 6.4
p 0.000*** 0.904 0.920 0.742 0.042* 0.799
Age
< 35 years 44.8% 82.7(11.1) 45.5( 9.3) 11.4(3.0) 12.3 15.1 6.4
>= 35 years 55.2% 77.7(12.6) 48.3(12.3) 11.3(3.2) 13.1 14.6 6.3
p 0.001** 0.036* 0.842 0.019* 0.093 0.540
Civil status
partner 69.9% 79.7(12.4) 46.4(10.6) 11.2(3.2) 12.9 14.9 6.3
no partner 30.1% 80.5(11.9) 48.7(12.3) 11.5(3.0) 12.3 14.8 6.4
p 0.629 0.126 0.520 0.114 0.768 0.916
Education
lower 33.5% 78.6(11.5) 45.3(10.2) 11.1(3.2) 13.3 15.1 6.2
higher 66.5% 80.6(12.5) 48.0(11.5) 11.4(3.1) 12.4 14.7 6.4
p 0.207 0.061 0.471 0.017* 0.308 0.337
Job
no 48.3% 80.3(13.3) 47.2(11.5) 11.6(3.3) 12.8 14.7 6.0
yes 51.7% 79.5(11.3) 47.1(11.0) 11.2(3.1) 12.6 14.9 6.5
p 0.618 0.923 0.341 0.477 0.728 0.083
Illness length
<= 2 years 35.6% 81.8(12.1) 46.2(10.5) 10.9(3.1) 12.7 15.2 6.2
> 2 years 64.4% 78.9(12.2) 47.5(11.5) 11.5(3.2) 12.7 14.5 6.5
p 0.061 0.356 0.109 0.967 0.054 0.252
CBT: cognitive behaviour therapy - SG: guided support groups - NC: natural course 
*p<0.05, **p<0.01, ***p<0.001
Table 2. Means and standard deviations of supporting interactions (SSL-I) and negative interactions (SSL-N) for patients with CFS, disease-free breast cancer patients, 
fatigued employees on sick leave and healthy controls, and pairwise group comparisons of estimated marginal means standardised for age and gender
CFS Disease-free Fatigued employees Healthy controls Significant pairwise
breast cancer comparisons between
37 yr 46 yr 43yr 45 yr estimated marginal means standardised
1 2 3 4 for age and gender
Supporting interactions Female Male Female Female Male Female Male
n=211 n=58 n=149 n=83 n=68 n=99 n=9 groups p
M (sd) M (sd) M (sd) M (sd) M (sd) M (sd) M (sd)
Emotional interactions 11.2 ( 2.4) 10.0 ( 2.3)*** 11.1 ( 2.5) 10.1 ( 2.2) 9.2 ( 2.2)* 11.1 ( 1.9) 9.4 ( 1.7)* 1 vs 3
2 vs 3
3 vs 4
<0.001
<0.01
<0.05
Esteem support 15.9 ( 2.8) 15.1 ( 2.5) 15.7 ( 2.9) 16.5 ( 3.2) 14.6 ( 3.3)** 15.7 ( 2.7) 14.5 ( 2.1)
Emotional support problems 19.1 ( 3.7) 16.2 (3.2)*** 18.2 ( 4.1) 18.8 ( 4.3) 16.7 ( 4.0)** 16.9 ( 3.4) 13.1 ( 3.6)** 1 vs 4, 3 vs 4
2 vs 4
<0.001
<0.05
Informational support 8.4 ( 1.7) 8.0 ( 1.7) 8.1 ( 2.1) 8.4 ( 2.1) 8.0 ( 2.3) 8.4 ( 1.8) 7.3 ( 2.0)
Instrumental interactions 14.4 ( 3.3) 12.6 ( 2.8)*** 12.8 ( 2.9) 13.6 ( 3.6) 12.1 ( 2.9)** 12.9 ( 3.1) 10.9 ( 2.6) 1 vs 2,1 vs 4 <0.05
Social companionship 12.7 ( 2.7) 11.6 ( 2.3)** 13.9 ( 2.5) 13.4 ( 2.9) 11.6 ( 2.9)*** 14.2 ( 2.5) 11.3 ( 2.1)*** 1 vs 2,1 vs 4 
3 vs 4
<0.001
<0.05
Total (SSL-I) 81.7 (12.2) 73.4 ( 9.9)*** 79.8 (12.5) 80.7 (13.8) 72.2 (13.3)*** 79.2 (11.6) 66.7 ( 9.7)**
Negative interactions 11.3 ( 3.2) 11.3 ( 2.9) 9.8 ( 2.5) 11.5 ( 3.5) 11.6 ( 3.4) 9.5 ( 2.0) 9.0 ( 1.8) 1 vs 2,1 vs 4
2 vs 3,3 vs 4
<0.001
<0.001
gender differences *p<0.05, **p<0.01, ***p<0.001
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Table 3. Means and standard deviations of insufficiency o f supporting interactions (SSL-D) for patients with CFS, disease-free breast cancer patients, fatigued employees 
on sick leave and healthy controls, and pairwise group comparisons of estimated marginal means standardised for age and gender.
Insufficiency of supporting 
interactions
CFS
37 yr 
1
Disease-free 
breast cancer 
46 yr
2
Fatigued employees
43yr
3
Healthy controls
45 yr 
4
Significant pairwise 
comparisons between 
estimated marginal 
means standardised 
for age and gender
Female 
n=211 
M (sd)
Male 
n=58 
M (sd)
Female 
n=149 
M (sd)
Female 
n=83 
M (sd)
Male 
n=68 
M (sd)
Female 
n=99 
M (sd)
Male 
n=9 
M (sd)
groups p
Emotional interactions 5.8 ( 2.3) 5.9 ( 2.3) 5.7 ( 2.3) 6.1 ( 2.3) 6.5 ( 2.1) 5.4 ( 2.0) 5.8 ( 1.6) 3 vs 4 <0.05
Esteem support 7.7 ( 2.0) 7.6 ( 1.9) 7.6 ( 2.1) 7.4 ( 1.7) 8.6 ( 2.6)** 7.2 ( 1.6) 7.1 ( 1.2)
Emotional support problems 11.9 ( 3.9) 11.9 ( 4.1) 10.7 ( 3.3) 11.9 ( 3.9) 13.0 ( 3.9) 10.6 ( 3.0) 9.7 ( 2.7) 1 vs 2 <0.05
1 vs 4, 2 vs 3 <0.01
3 vs 4 <0.01
Informational support 5.5 ( 1.7) 5.2 ( 1.4) 5.6 ( 1.8) 5.7 ( 2.0) 6.0 ( 2.0) 5.4 ( 1.5) 5.4 ( 1.9)
Instrumental interactions 9.1 ( 2.4) 9.3 ( 2.4) 8.7 ( 2.2) 9.4 ( 2.9) 9.7 ( 2.5) 8.5 ( 1.8) 7.7 ( 1.3) 1 vs 4, 2 vs 3 <0.05
3 vs 4 <0.01
Social companionship 7.1 ( 2.6) 7.0 ( 2.1) 6.2 ( 2.1) 6.5 ( 2.2) 7.0 ( 2.1) 5.8 ( 1.6) 6.7 ( 1.7) 1 vs 2 <0.01
1 vs 4 <0.001
3 vs 4 <0.05
Total (SSL-D) 47.1 (11.1) 46.9 (11.2) 44.5 (11.0) 47.1 (11.1) 50.7 (12.2) 42.9 ( 8.5) 42.3 ( 9.1) 1 vs 4 <0.01
2 vs 3 <0.05
3 vs 4 <0.001
gender differences **p<0.01
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Data pertaining to insufficiency of supporting interactions are shown in table 3. CFS 
patients had a significantly higher total score of insufficiency of supporting 
interactions than healthy controls, and employees with work-related fatigue had a 
higher total score than disease-free breast cancer patients and healthy controls. As 
to the different types of insufficiency of supporting interactions, CFS patients 
experienced significantly more insufficiency of social companionship and problem- 
focused emotional support than both disease-free breast cancer patients and healthy 
controls. The same pattern was found in fatigued employees on sick leave, although 
the comparison of social companionship with disease-free breast cancer patients did 
not reach significance. CFS patients experienced significantly more insufficiency of 
instrumental interactions than healthy controls and fatigued employees on sick leave 
significantly more than disease-free breast cancer patients and healthy controls. 
Fatigued employees on sick leave reported more insufficiency of emotional 
interactions than healthy controls. No group differences in esteem support and 
informational support were found. No gender differences occurred for the total score 
of insufficiency of supporting interactions.
Table 4. Course of supporting interactions (SSL-I), insufficiency of supporting interactions (SSL-D), and negative 
interactions (SSL-N) over 14 months for each of the three treatment arms
baseline 
mean (sd)
8 months 
mean (sd)
14 mont hs 
mean (sd)
Repeated measures 
F p
CBT (n=57)
SSL-I 82.3 (10.0) 80.6 (12.0) 79.7 (11.7) 4.661 0.013*
SSL-D 45.5 ( 8.8) 43.3 ( 8.4) 43.0 ( 8.9) 2.830 0.068
SSL-N 10.9 ( 3.1) 9.9 ( 2.0) 9.6 ( 2.4) 4.705 0.013*
SG (n= 62)
SSL-I 78.9 (12.2) 78.3 (11.4) 78.1 (11.9) 0.326 0.723
SSL-D 48.2 (12.5) 47.3 (11.8) 45.7 (10.7) 1.820 0.171
SSL-N 11.6 ( 3.1) 11.2 ( 3.4) 11.2 ( 3.0) 0.707 0.497
NC (n=75)
SSL-I 81.9 (12.0) 79.9 (10.2) 78.7 (11.6) 3.244 0.045*
SSL-D 46.2 (10.9) 46.7 (10.2) 45.0 (10.6) 1.741 0.183
SSL-N 10.8 ( 2.7) 10.5 ( 2.8) 10.4 ( 3.1) 1.460 0.239
CBT: cognitive behaviour therapy - SG: guided support groups - NC: natural course
* p<0.05
Course of social support over 14 months in CFS patients
Table 4 shows the mean scores of supporting interactions, negative interactions and 
insufficiency of supporting interactions of CFS patients at baseline, 8 months and 14 
months in each of the treatment groups, as well as differences within groups
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reflecting changes over time. In patients treated with CBT, supporting interactions 
and negative interactions decreased significantly after 14 months. In this group a 
decrease in insufficiency of supporting interactions was also found, although this 
change did not reach significance. Patients in guided support groups showed no 
significant changes during 14 months. Patients in the natural course group reported 
significantly less supporting interactions after 14 months. Insufficiency of supporting 
interactions and negative interactions did not change significantly in this group. 
Significant differences between groups after 14 months were only found in negative 
interactions (F=4.555, df=2, p=0.012), and not in supporting interactions (F=0.107, 
df=2, p=0.898) or insufficiency of supporting interactions (F=1.193, df=2, p=0.305). 
Post-hoc analyses showed a significant difference in negative interactions between 
patients treated with CBT and patients in guided support groups (p=0.009).
Table 5. Predictors of fatigue severity and functional impairment after 8 months
adj R2 beta
Fatigue severity 
Cognitive behaviour therapy
model 1: baseline fatigue severity 0.073** 0.290**
model 2: baseline fatigue severity 0.126** 0.285*
insufficiency emotional support problems 0.252*
Natural course
model 1: baseline fatigue severity 0.046* 0.243*
model 2: baseline fatigue severity 0.106** 0.260*
negative interactions 0.257*
Functional impairment 
Cognitive behaviour therapy
model 1: baseline functional impairment 0.250*** 0.509***
model 2: baseline functional impairment 0.325*** 0.460***
relationship with family and friends -0.172
insufficiency emotional interactions 0.190
Guided support groups
model 1: baseline functional impairment 0.288*** 0.556***
model 2: baseline functional impairment 0.355*** 0.491***
social companionship -0.190
empathy from colleagues and chief -0.196
Natural course
model 1: baseline functional impairment 0.193*** 0.451***
model 2: baseline functional impairment 0.271*** 0.454***
relationship with general practitioner 0.294**
* p<0.05, **p<0.01, ***p<0.001
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Predictors of fatigue severity and functional impairment
Higher fatigue severity after CBT was predicted by higher fatigue severity (7%) and 
more insufficiency of problem-focused emotional support (5%) at baseline (table 5). 
No predictors were found for fatigue severity after guided support groups. In the 
natural course group, higher fatigue severity (5%) and more negative interactions at 
baseline (6%) predicted fatigue severity at 8 months. Higher functional impairment 
after CBT was predicted by higher functional impairment (25%) and by a worse 
relationship with family and friends and more insufficiency of emotional interactions at 
baseline. Although the latter variables just did not reach significance, together they 
added 7.5% to the variance in fatigue severity. After guided support groups, higher 
functional impairment was predicted by higher functional impairment (29%) and by 
less social companionship and less empathy from colleagues and friends at baseline. 
Together these variables added 6.5% to the explained variance in fatigue severity, 
although they did not reach significance. In the natural course group, baseline 
functional impairment (19%) and a better relationship with the general practitioner 
(8%) predicted functional impairment.
Discussion
Our study of social support in CFS patients revealed several new findings.
Relation between social support and demographic characteristics 
Demographic variables, like age, gender, and education, appeared to represent 
relevant factors in the quantitative and qualitative aspects of social support of CFS 
patients. Female CFS patients did report more supporting interactions than males. In 
this respect, CFS patients did not differ from other samples in our study in which 
similar gender differences were found. Insufficiency of supporting interactions and 
negative interactions were similar for both genders, in CFS patients and in both other 
mixed samples. Marriage and work are both sources for social support, and were 
therefore expected to coincide with higher levels of social support. However, the 
presence of a partner or a job seemed not to be related to the quantity or quality of 
social support of CFS patients. Nor did illness length, while we supposed that 
changes in social networks due to increasing illness length would result in a 
decrease of social support.
Comparisons between CFS patients, disease-free breast cancer patients, fatigued 
employees on sick leave and healthy controls
Based on the group comparisons, we concluded that CFS patients and fatigued 
employees differed in qualitative aspects of social support from disease-free breast 
cancer patients and healthy controls and not in quantitative aspects. CFS patients 
and fatigued employees on sick leave reported more negative interactions and more 
insufficiency of supporting interactions than disease-free breast cancer patients and 
healthy controls. In the sample of disease-free breast cancer patients 38% was 
severely fatigued. These patients also had significantly more negative interactions 
and insufficiency of supporting interactions than those patients who were not
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fatigued18. Severe fatigue seems to be related to a worse quality of social support.
No significant differences between the four samples in the frequency of supporting 
interactions were found, although some differences in types of supporting 
interactions were identified. Roughly, fatigued persons, CFS patients as well as 
fatigued employees on sick leave, had more instrumental and problem-focused 
interactions and less social or emotional interactions than one or both of the other 
groups, which were not selected on fatigue severity. CFS patients reported more 
instrumental support, but at the same time also experienced more insufficiency of 
instrumental support than healthy subjects. Evidently, they were not fulfilled in their 
need for instrumental support.
As to the quality of social support, fatigued patients had more negative interactions 
and more insufficiency of support than healthy controls. This finding is of interest, 
because negative aspects of social relationships are supposed to reduce the helpful 
effect of social support.
There is one methodological point which should be considered. The way of recruiting 
healthy control subjects, who were family members, friends or colleagues of the 
patients participating in our studies, might have introduced some selection bias. 
Since these subjects were willing to join the patient in the study and thereby were 
showing support, they possibly had a more positive network interaction than other 
people in the normal population.
Course of social support over 14 months in CFS patients
Perceived support rather than quantity of social relationships is considered to affect 
health-related behaviours7. Therefore, we were especially interested in the effect of 
CBT and guided support groups on negative interactions and insufficiency of 
supporting interactions. We found that negative interactions and to a lesser extent 
insufficiency of supporting interactions decreased after CBT. The statistically 
significant decrease of negative interactions was also clinically significant, since the 
mean score at 14 months was similar to the mean score of healthy subjects. 
Insufficiency of supporting interactions and negative interactions did not change 
significantly during natural course and guided support groups. Supporting 
interactions decreased after CBT, as was the case in the natural course group. 
Clinically, this finding was of little importance, since after 14 months the frequency of 
supporting interactions was still at a level considered as normal for healthy subjects. 
The new contacts in the guided support groups may explain the finding that the 
supporting interactions of the patients in the guided support groups did not decrease 
significantly. In addition to our former conclusion that guided support groups were not 
effective in decreasing fatigue and functional impairment in CFS patients, we 
concluded that support groups also did not contribute to a decrease of negative 
interactions or insufficiency of supporting interactions. Higher levels of functional 
impairment, less social companionship and less empathy from colleagues and chief 
at baseline were found to predict higher levels of functional impairment in the support 
groups. Apparently, participation in support groups did not satisfy the need for
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companionship and empathy. There might be another explanation for the 
ineffectiveness of support groups for CFS patients. Despite the fact that only in the 
first two meetings attention was paid to symptoms and functional impairment, in all of 
the subsequent meetings CFS patients remained focused on each other’s symptoms 
and frequently exchanged information about aids to facilitate daily life. A strong focus 
on bodily symptoms was found to predict a worse outcome in our trial4.
Predictors of fatigue severity and functional impairment
In the patients with CBT, insufficiency of supporting interactions and a worse 
relationship with family and friends predicted higher fatigue severity or functional 
impairment. Therefore, in the treatment protocol of cognitive behaviour therapy for 
CFS patients more attention for insufficiency of social support is needed. In the 
patients without treatment more negative interactions predicted higher fatigue 
severity.
Our conclusion was that insufficiency of social support and negative interactions are 
important factors in the persistence of CFS. Lack of social support should be added 
as a new factor to the model of perpetuating factors of fatigue and functional 
impairment in CFS26. Until now, the model was limited to complaint-related cognitions 
and behaviours, like somatic attributions, sense of control over complaints, physical 
activity and a strong focus on bodily symptoms. From the results of this study it is 
obvious that cognitions and behaviours concerning the individual’s support system 
need equal attention. Further studies especially should pay attention to different ways 
in which social support might be of influence for CFS patients, helping them to accept 
and tolerate symptoms and disability or reinforcing illness behaviour. Also the 
mediating role of psychological distress should be considered. In general, patients 
with low levels of perceived social support report more psychological distress.
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Doctor-patient relationship in primary care of chronic fatigue 
syndrome: perspectives of the doctor and the patient
Abstract
Background. Chronic Fatigue Syndrome (CFS) is characterized by severe debilitating 
fatigue for at least six months. The lack of a known origin could have consequences 
for the way general practitioners deal with the diagnosis CFS and their perception of 
CFS patients.
The aims of the study were to investigate the use of the diagnosis CFS by GPs and 
their reactions to self-diagnosis and to explore opinions of GPs about causes of CFS 
and the communication with CFS patients as well as opinions of CFS patients about 
their GPs.
Method. 121 GPs completed questionnaires and 12 were interviewed. Data of 211 
CFS patients were analyzed as well.
Results. Only half of the GPs used the diagnosis CFS. The main reason for not 
diagnosing CFS was ignorance of the criteria. GPs reported self-diagnosis in 68% of 
the CFS patients. More than half of the GPs could sympathize less with the 
complaints of CFS patients compared with other patients. These GPs experienced 
more problems in communicating with CFS patients and judged co-operation and 
contact as poor. As to the causes for CFS a discrepancy was found. GPs mainly 
attributed the complaints to psychosocial factors, whereas patients mainly had 
physical attributions.
Conclusion. In CFS, GPs should be explicit about the diagnosis. As to the 
discrepancy in presumed causes of CFS between GPs and CFS patients, it may be 
helpful for GPs to discuss the distinction between initiating and perpetuating factors 
of CFS. We argue that this attitude of GPs would be beneficial to the course of the 
complaints of CFS patients.
Introduction
Fatigue is a complaint regularly presented by patients attending general practitioners 
(GPs)1. Fatigue is the third symptom on the list of most frequently presented 
complaints in general practices in the Netherlands2. If complaints of fatigue persist for 
more than six months and no somatic explanation can be found, chronic fatigue has 
developed3. Chronic fatigue syndrome (CFS) is defined by the presence of persistent 
or relapsing unexplained chronic fatigue that is of new or definite onset and lasting 
for at least six months. Fatigue is not the result of ongoing exertion, it is not alleviated 
by rest and results in substantial reduction in previous levels of occupational, 
educational, social and personal activities.
In prevalence studies among all GPs in the Netherlands the estimated prevalence of 
CFS was 1.1 per 1000 inhabitants4,5. This means an average of 2 CFS patients per 
GP, corresponding with Irish primary care6. In the UK GPs reported a prevalence of 
1.3 per 1000 patients7. The results in these prevalence studies are in probability an
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underestimation of true prevalence as not all CFS is presented to and diagnosed by 
GPs. In CFS, GPs may not be familiar with the criteria for the diagnosis or do not 
acknowledge the disease as a distinct clinical entity8, which may contribute to the 
iceberg of complaints. If patients confront the practitioner with the self-diagnosis of 
myalgic encephalomyelitis (ME) or CFS, GPs consider these patients less likely to 
comply with treatment and more likely to pose difficult management problems and to 
take up a lot of time9. CFS patients report that doctors do not understand or accept 
their symptoms10,11.
It seems obvious that the perspectives of CFS held by GPs and patients are quite 
different. However, it is not clear to what extent opinions about CFS differ. Diagnosis 
and self-diagnosis may be perceived from a different perspective, as well as opinions 
about causes of CFS, which will have its consequences for the communication 
between medical practitioners and CFS patients. The role of the GP seems 
especially important, because often the GP is the first professional confronted with 
the complaints of chronic fatigue. How this first consultation passes off may 
determine the future course of the CFS patient considerably12. Will the patient accept 
the fact that no known cause is available and no effective treatment? Or will the 
patient persist in further medical examinations and the testing of all kinds of non­
proven treatments? In our opinion the GP has a crucial role in the further course of 
the complaints of chronic fatigue. More information about the behavior and opinions 
of GPs in cases of CFS is necessary for the development of management programs 
in primary care.
The aims of the present study were to investigate the use of the diagnosis CFS by 
GPs and their reactions to self-diagnosis. Furthermore, it was explored if 
discrepancies exist between the ideas of GPs and CFS patients about possible 
causes of CFS and about communication and mutual understanding.
Method
Questionnaires for GPs
In figure 1 the questionnaire developed for GPs is shown. The questionnaire was 
presented to 121 GPs preceding courses about CFS, 73 GPs in 1995 and 48 GPs in 
1997. All of them agreed to complete the questionnaire. The GPs varied in years 
working as GP (range 1-28, mean 11.5). The questions concerned frequency of 
diagnosing cases of CFS, causes and attributions for the complaints, expectations of 
patients, the opinions about the communication with CFS patients and the need for 
expert knowledge. Completion of the questionnaire lasted about four minutes.
Questionnaires for CFS patients
Questionnaire data of 211 patients, not being the patients of the GPs in the study, 
were analyzed as well. These patients were consecutively referred from a university 
hospital outpatient clinic and met the criteria for CFS13. Data were gathered before 
participation in a randomized clinical trial. The questions concerned the doctor- 
patient relationship and attributions for the complaints.
Figure 1. Questionnaire for general practitioners about Chronic Fatigue Syndrome
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This questionnaire contains 15 multiple-choice questions. These questions concern the relationship of 
general practitioners and patients with Chronic Fatigue Syndrome (CFS). CFS patients also use the 
name Myalgic Encephalomyelitis (ME). We should be grateful if you fulfilled this questionnaire. If there 
are no CFS patients in your practice, please fulfil the answer you would expect in the relationship with 
CFS patients.
1 Did you ever diagnose Chronic Fatigue Syndrome (CFS)? 
o No
o Yes, namely............. patients
2 If not, what is the reason? (you may select several answers) 
o These complaints do not occur in my practice
o CFS is unknown to me
o The diagnosis CFS does not exist (I disbelieve in CFS)
o I am not familiar with the criteria to diagnose CFS
o another reason, namely..............................................................
3 Did any of your patients had a selfdiagnosis of CFS or ME? 
o None
o Yes, namely................ patients
3b If yes, did you agree with the patients? 
o Yes 
o No
4 In your opinion, what is the main cause of CFS? 
o Only psychological
o Mainly psychological and physical as well 
o Mainly physical and psychological as well 
o Only physical
5 To which of the following aspects are the complaints of CFS patients related?
(You may select several answers)
o Virus
o Immune system 
o Physical abnormalities 
o Situation at work or at home 
o Consequence of a busy daily life 
o Distress
o Problems in childhood 
o Too much worrying
6 Do you think CFS patients can be treated ? 
o Yes
o Sometimes 
o I do not know 
o No
7 What do you think a CFS patient expects from the general practitioner?
(You may select several answers)
A CFS patient feels the general practitioner to be a person: 
o to whom one may give vent to one's feelings 
o who gives advice 
o who prescribes an evident treatment 
o who prescribes a doctor's referral
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How is your relationship with CFS patients compared with other patients? If you do not have any CFS 
patients in your practice, please try to answer these questions according to your present opinion. 
Please mark the box corresponding to your answer. The middle box means ‘equal to other patients'.
8 Consultation of a CFS patient takes more / less time
more time less time
9 In your opinion CFS patients give more / less problems in communicating 
more problems less problems
10 The complaints of CFS patients are more / less empathising to you 
more empathising less empathising
11 Co-operation with CFS patients is better / worse
better
12 Contact with CFS patients is more flexible / tense
flexible
worse
tense
13 Are there any difficulties you encounter regularly with CFS patients? 
o No 
o Yes
Could you please mention these difficulties?...................................
14 Do you feel capable of informing CFS patients sufficiently? 
o Yes
o Could be better 
o No
15 Do you want more information about CFS? 
o Yes
o No
16 For how many years have you been practising as a general practitioner? 
....... years
Interview of GPs
Twelve GPs were extensively interviewed. They were not among the GPs who 
attended the courses and filled in the questionnaire. The practices of the GPs were 
located throughout the Netherlands, in cities as well as the country. The sem i­
structured interview consisted of 33 questions covering the same subjects as the 
questionnaire for GPs, but more extensively. Especially, the acknowledgement of 
CFS as a distinct clinical entity and the attitude to CFS patients were paid attention 
to. The tape-recorded interviews took place in 1995 and lasted about 45 minutes 
each.
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Comparison of data from interviews and questionnaires
The answers of the interviewed GPs were in agreement with those given in the 
questionnaires. The data of the questionnaires will be used to answer the research 
questions. The content of the interviews will be used to explain and clarify the results.
Results
Diagnosis, self-diagnosis and need for expert knowledge
As is shown in table 1, half of the 121 GPs reported to use the diagnosis CFS. GPs 
diagnosing CFS had an average of 3.3 CFS patients in their practice. Reasons for 
not diagnosing CFS were ignorance of the criteria for CFS (69%) and not 
acknowledging CFS as a diagnosis (20%). Eleven percent gave no reason. In the 
interviews, half of the 12 GPs reported reluctance to the diagnosis, and this appeared 
to be an important reason for not diagnosing CFS. Interviewed GPs with reluctance 
to the diagnosis CFS had fewer CFS patients in their practice (3.2 vs. 5.5 patients). 
Differences between 1995 and 1997 showed an increased percentage of GPs 
diagnosing cases of CFS (45% vs. 62%).
Table 1. Percentage of GPs diagnosing CFS, reporting self-diagnosis and agreeing with self-diagnosis
Did the GP ever diagnose CFS?
yes no
n/total n/total
63/121 (52%) 58/121 (48%) Chi2 P
Self-diagnosis of CFS/ME present? 
n = 113
yes 
49/60 (82%)
yes 
33/53 (62%) 5.27 <0.05
Agreement of GP with selfdiagnosis? yes yes
n = 67 28/36 (78%) 14/31 (45%) 7.46 <0.01
In the questionnaires 121 GPs reported self-diagnosis in 68% of the CFS patients. 
Table 1 shows that GPs not diagnosing CFS reported significantly less self­
diagnoses than GPs diagnosing CFS (82% vs. 62%; Chi2=5.27, p<0.05). Agreement 
with the self-diagnosis was mentioned by 35% of the GPs (n=42), whereas 21% 
disagreed (n=25); 44% (n=54) did not answer this question. Table 1 shows that GPs 
not diagnosing CFS reported significantly less agreement with self-diagnoses than 
GPs diagnosing CFS (78% vs. 45%; Chi2=7.46, p<0.01).
Only 10% of the GPs felt capable of giving sufficient information about CFS to 
patients. GPs not diagnosing CFS felt significantly less capable of informing patients 
than GPs diagnosing CFS (Chi2=9.22; p<0.01). Not surprisingly, nearly all of the GPs 
participating in the courses about CFS wanted more information about CFS (94%).
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Doctor-patient relationship: perspective of the doctor
GPs’ opinions about the relationship with CFS patients compared with other patients 
were analyzed as well. Most of the GPs (89%) reported that the visits of CFS patients 
took more time, 73% regularly experienced all kinds of problems with these patients, 
43% reported problems in the communication and 31% rated the contact and co­
operation as bad. Comparing their attitude to CFS patients with the attitude to other 
patients, 54% of the GPs reported less empathy to CFS patients. Less empathizing 
GPs had significantly more problems in communicating with CFS patients than more 
empathizing GPs (t=2.49, p=0.014) and the quality of the contact (t=4.20, p=0.000) 
and co-operation was significantly worse (t=4.14, p=0.000). Consultations of CFS 
patients by empathizing GPs did not take more time. A strong tendency was found 
that GPs working more years in general practice (12.7 vs. 10.5, p=0.08) and having 
more CFS patients in their practice (4.0 vs. 2.7, p=0.09) are more empathizing than 
less experienced colleagues.
Statements from the interviews were analyzed to illustrate the kind of problems GPs 
experience with CFS patients. The strong tendency to somatization, the vagueness 
of the complaints and the compelling attitude of CFS patients were mentioned as 
most problematic.
Questionnaire items about the expectations of CFS patients revealed that three- 
quarters of the GPs believed that CFS patients want to give vent to their feelings and 
take medical advice as well. One third of the GPs believed that CFS patients expect 
a treatment for their complaints or want to be referred to a specialist.
Doctor-patient relationship: perspective of the patient
In 43% CFS patients rated their relationship with the GP as good, as rather good in 
37% and as not good or even bad in 20%. Seventeen percent of the CFS patients 
reported to have no confidence in the GP. Patients’ opinions about the degree to 
which doctors take their complaints seriously and sympathize with them differed for 
categories of doctors. According to the opinion of 21% of the CFS patients GPs did 
not take their complaints seriously and 23% of the patients stated that the GP does 
not sympathize with them. In the patients’ opinions more than half of medical 
specialists did not take their complaints seriously and did not sympathize with CFS 
patients (53% and 54%). Contrary, according to patients, doctors in a university 
outpatient clinic with a dedicated program for CFS nearly always took the complaints 
seriously and sympathized with the patient (both 99%). It should be noted that these 
last observations concerned the doctors who gave the diagnosis CFS to the patient.
Opinions about causes
As to the presumed causes for CFS a large discrepancy between GPs and CFS 
patients was found. Table 2 shows to which specific aspects CFS is attributed.
It is obvious that patients mainly have physical attributions for their complaints, 
whereas GPs mainly attribute the complaints to psychological factors. However, a
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significant difference exists between GPs not diagnosing CFS and GPs diagnosing 
CFS. Ninety-one percent of GPs not diagnosing CFS attributed complaints to 
psychological factors compared to 76% of GPs diagnosing CFS (Chi2=4.65, p<0.05).
Table 2. Percentage of GPs and CFS patients believing that CFS is related to one of the following aspects
Causes for CFS GPs 
n = 121
CFS patients 
n = 211
Physical
virus 41 63
immune deficiency 37 78
physical abnormalities 23 77
Psychological
distress 82 — *
work or family 58 9
being busy 37 27
worrying 23 24
problems in childhood 23 12
* data not available for CFS patients
Discussion
In 1994 guidelines for the clinical evaluation of fatigued persons and a case definition 
of the chronic fatigue syndrome were provided13. However, the results in our study 
indicate that GPs are not familiar with the diagnosis CFS. In CFS, self-diagnoses are 
even more prominent than diagnoses by GPs. An exceptional situation in general 
practices.
Nearly half of the GPs never diagnose CFS. These GPs report fewer self-diagnoses 
of CFS and are less inclined to agree with self-diagnoses. Also, these GPs feel less 
capable of giving information about CFS to patients and are more inclined to attribute 
complaints of CFS patients to psychological causes. These results indicate that GPs 
never diagnosing CFS differ from GPs occasionally diagnosing CFS in knowledge of 
the disease and attitudes to CFS patients. Although there appear some problems in 
diagnosing CFS, there are indications from our comparisons at 1995 and 1997 of a 
substantial and rapid change in this respect.
Self-diagnosis is reported by GPs in 68% of the CFS patients. Confronted with a self­
diagnosis nearly half of the GPs do not agree or disagree with the patient in a 
straightforward fashion. In cases of self-diagnosis, the tables are turned: the patient 
diagnoses in stead of the doctor. The self-diagnosis may easily evoke irritation of 
GPs, especially if the GP is uncertain about the diagnosis14. In our study nearly all 
GPs reported insufficient knowledge of CFS. However, CFS patients expect a 
diagnosis. Most CFS patients attribute complaints to a physical disease and may 
therefore expect an effective treatment as well.
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Differences between GPs and CFS patients in causal attributions were found. 
Patients mainly had physical attributions for their complaints. GPs mainly attributed 
the complaints to psychological factors. Although no data are available about the 
reactions of GPs to physical attributions of CFS patients, caution is advised. Denial 
or resistance of the patient’s opinion about physical causes by the GP may easily 
strengthen the patient’s physical attributions. Strong physical attributions were found 
to be unfavorable for the prognosis15. Paying attention to somatic attributions and to 
the meaning of the diagnosis for the patient will be more beneficial to the patient than 
arguing about possible causes.
Although the GPs and the CFS patients in this study do not in anyway relate to each 
other, it is worthwhile to compare their views about clinical encounters. GPs’ opinions 
about the relationship with CFS patients compared to other patients were not 
favorable. It is of interest that GPs experience more problems in the doctor-patient 
relationship than CFS patients. This may be due to self-diagnoses. A vicious circle of 
debating about causes and diagnosis may easily develop. Not diagnosing CFS when 
the patient fulfils the criteria, resistance to the patient’s opinion as well as the 
unfavorable attitude of GPs to CFS patients may be important factors in determining 
the doctor-patient relationship. GPs may therefore decide to refer CFS patients to a 
medical specialist. However, patients will not profit from referral to a medical 
specialist, because of the lack of adequate medical treatments and the risk of 
increasing somatic fixation by further medical examinations. Moreover, CFS patients 
in this study reported that GPs took their complaints more seriously than most 
medical specialists did.
Despite these interesting results some side-notes should be discussed. The GPs 
involved in the study were not a representative sample, being those who had gone 
on courses about CFS and thus being more interested in CFS. The CFS patients in 
this study were all involved in a randomized clinical trial, perhaps indicating that they 
are a more co-operative and satisfied group than usual. However, in the case of 
interested doctors and co-operative patients the study highlights the most optimistic 
view of how CFS is dealt with in primary care. The methodological limitations of two 
separate samples of doctors and patients prevents us from presenting evidence for 
the supposed relation between not acknowledging the diagnosis CFS and an 
unfavorable doctor-patient relationship. Despite these shortcomings some 
recommendations may be drawn from the study.
The diagnosis and management of CFS patients in primary care seems of crucial 
importance in the future course of the illness. More specific guidelines for GPs in the 
identification and management of CFS patients are definitely needed. GPs capable of 
diagnosing CFS and adequate counseling may be able to prevent worsening of the 
complaints and long-term disability in CFS patients. Fuller and Morrison16 described 
in detail a primary care approach to diagnosis and management of CFS. Although 
this approach will be of great support in the relationship with all patients in general 
practice and especially those with unexplained complaints, it is far too general for
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patients with CFS.
In our opinion extensive evaluation of patients complaining of chronic fatigue is also 
necessary to be certain about the diagnosis CFS. Moreover, such evaluation of the 
patient’s complaints has the advantage that the patient feels taken seriously by the 
GP and that a solid foundation is laid for management of the complaints in general 
practice.
A solution to the huge discrepancies in causal attributions between GPs and CFS 
patients may be found in the empirical fact that the cause of CFS is still unknown. 
GPs capable of distinguishing initiating and perpetuating factors in CFS may refrain 
from conflicts about presumed causes of CFS.
Objections made by GPs that these approaches to diagnosis and presumed causes 
are too time-consuming are refuted by the findings in this study that CFS patients 
already take more time of the GP than other patients in general practice. Moreover, 
the investment of the GPs valuable time will be recompensed by fewer conflicts with 
CFS patients about diagnosis and causes. Both willingness to diagnose CFS and 
expert knowledge of CFS seem to be important factors for improvement of the 
perceived relationship with CFS patients. This attitude may be beneficial to the 
course of the complaints too.
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The transferability of the treatment protocol ‘Cognitive Behaviour 
Therapy for Chronic Fatigue Syndrome’
Abstract
Recently, the treatment manual ‘Cognitive behaviour therapy for Chronic Fatigue 
Syndrome’ (CBT for CFS) was published. In the context of a research programme 
thirteen therapists applied an earlier version of this manual in 82 CFS patients. The 
results of this study showed that the treatment is effective. Hence, it was opportune 
to investigate whether the treatment manual was suitable to be transferred to 
peripheral therapists. The therapists participating in the research programme were 
thoroughly trained and supervised. But did they actually do what they were supposed 
to do? And what did they think of the usability of the treatment manual? In order to 
shed some light on these issues, following completion of the study the thirteen 
therapists were asked to complete a questionnaire. Also, analyses of audiotaped 
sessions were conducted to verify whether the therapists had complied with the 
various treatment aspects included in the manual. In 89% of the sessions this 
appeared to be the case. The questionnaire revealed that the therapists found it 
more difficult to treat CFS patients than patients with psychological or other physical 
problems. The treatment aspects posing the most problems were integrating 
individual problems into the standardised treatment, dealing with the patients’ lack of 
confidence in the treatment and handling insufficient motivation. For these aspects in 
particular, extra training seems necessary. The treatment manual will have to be 
revised in such a way that it will leave therapists room to individualise the prescribed 
interventions and it will need to provide them with guidelines for interventions aimed 
at motivating patients.
Introduction
There have been manual-based psychotherapy treatments, for both research 
purposes and training and practice, for well over 25 years1. In 1993 the American 
Psychological Association (APA) appointed a task force to advise on the use of 
empirically validated treatments in the clinical practice and in the training of 
psychotherapists. The report of this Task Force on Promotion and Dissemination of 
Psychological Procedures2 formed the starting point of a heated debate about the 
desirability and/or introduction of research-based treatment manuals in the clinical 
practice.
Much of the debate concerned the strengths and weaknesses of such ‘evidence- 
based treatments’ and the differences between research and practice3-6. The 
discussions revealed that resistance to the use of standardised treatments was 
highest in psychotherapists working in clinical practice. It is their impression that the 
limitations of scientific research, the implications of the differences between client 
and therapist characteristics, the role of non-specific factors and the necessity to 
adjust the therapeutic interventions to the client- or patient-specific complaints are
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not sufficiently taken into account7. Objections to manual-based treatments have 
been discussed and refuted frequently3,6,8-10. The arguments challenging 
standardised treatments include:
- their failure to take comorbidity and the more complex problems of the clinical 
practice into account;
- their lack of flexibility and adjustability preventing customisation;
- the idea that the patient or client is not served adequately by a standardised 
treatment;
- their failure to do justice to the role of the holistic theory and function analysis;
- the negative effect they have on the patient-therapist relationship;
- their negative impact on the competency and work satisfaction of the therapist;
- their poor practicability.
Despite these realistic objections many defend the notion that the clinical practice 
should nevertheless take advantage of the empirical evidence on the effectiveness of 
treatment procedures or manuals, even though further research is needed9,11-15. 
Recently, an American study investigated the attitude of psychotherapists toward 
treatment manuals16. Of the 2970 psychologists approached, all of who were APA 
members, 30% responded by returning the questionnaire they had been sent. Such a 
response can be said to be low and this raises doubts as to whether the collected 
data accurately reflect the general attitude of therapists. Nevertheless, a striking 
result was that the majority of the respondents had expressed an opinion about 
treatment manuals even though 25% of them were unfamiliar with the existence of 
such manuals and nearly 50% had never worked with them. This led the authors to 
conclude that the attitude of therapists regarding treatment manuals seems, to a 
great extent, to be based on what the psychologist has heard or read, rather than on 
any hands-on experience. The respondents’ attitudes could be differentiated 
according to those who emphasised the negative aspects of the treatment process 
and those who underlined a positive treatment outcome. The negatively inclined 
respondents characterised a standardised treatment as dehumanising the 
psychotherapeutic process and focusing solely on the technical aspects at the 
expense of treatment flexibility and the patient-therapist relationship. Those 
psychologists emphasising a positive treatment outcome regarded the manuals more 
as guidelines provided to help the therapist to apply empirically validated 
interventions16.
The debate on the pros and cons of standardised treatments in the clinical practice 
has also yielded suggestions as to the desired content of such a treatment manual. 
Many of these suggestions underpin the importance of a manual that leaves room for 
customisation and flexible application. In Schulte’s view17 for instance, the use of 
particular treatment techniques for specific symptomatology or disorders should be 
standardised as much as possible. Translating this general strategy into an actual 
intervention for a specific client or patient, however, will always involve tailoring the 
therapy to an individual patient, taking the patient-specific perpetuating factors into
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account. According to Schulte17, this also holds for establishing a workable basic 
attitude in the patient and motivating him or her, thus ensuring that interventions can 
be successfully applied. Davison18 advocates basing interventions both on the 
treatment manual and the individual function analysis. According to Eifert, Schulte, 
Zvolensky, Lejuez, & Lau19 a treatment manual should incorporate optional modules 
that may or may not be used depending on the patient’s function analysis. Wilson6 
finds that many manuals would be more user-friendly if they would provide practical 
examples and specify non-specific factors.
Kendall, Chu, Gifford, Hayes, & Nauta20 state that a manual should offer a general 
framework outlining the treatment and treatment goals per session, that the manual 
should specify strategies and means to achieve these goals and that it should 
provide the therapist with guidelines to challenge problems that may arise in the 
course of the treatment. It is also desirable that the manual provides examples on 
how to customise the treatment. Addis11 argues that in order to facilitate a successful 
transfer of a manual-based treatment, a systematic description of the non-specific 
factors (such as the patient-therapist interaction and the generation of positive 
expectations) and the clinical techniques to be used should be included in the 
manual.
Some authors seem to be under the impression that learning to work according to a 
manual is easier than learning to apply other psychotherapeutic methods. Vakoch 
and Strupp21, for instance, are concerned that when, during training, too much 
attention is paid to learning to apply manual-based treatments, this will go at the 
expense of acquiring the ability to make more complex clinical judgments. By 
contrast, Heimberg8 claims that learning to apply manual-based therapies requires 
more training. On the one hand the therapist needs to be able to fit his or her 
activities within the framework of the manual, while on the other hand he or she also 
needs to be able to improvise, but again within these boundaries. To be able to 
accomplish this requires experience with the symptomatology or disorders to be 
treated, the treatment itself and its theoretical context. Addis11 suggests a training 
with one level addressing the more technical aspects of the treatment and a level 
dedicated to the non-specific factors. Iwamasa and Orsillo22 state that before 
therapists are to apply manual-based treatments, they first need to acquire general 
cognitive-behavioural therapeutic skills. And finally, Addis, Wade, & Hatgis3 mention 
that making an inventory of the therapists’ objections to standardised treatments is 
an important ingredient for future training courses. Apart from teaching therapeutic 
techniques, attention needs to be paid to the patient-therapist relationship.
Recently, the treatment manual ‘Cognitive behaviour therapy for Chronic Fatigue 
Syndrome’, CBT for CFS, was published23. In the context of a research programme 
considerable practical experience had been acquired using an earlier version of the 
manuaP4. In a multicentre randomised controlled trial cognitive behaviour therapy 
was compared with guided support groups and natural course25. The study included 
270 CFS patients. Intention-to-treat analyses showed CBT to be more effective than
136 Chapter 10
the two other conditions for both of the two main outcome measures, i.e. fatigue 
severity and functional impairment.
Since the standardised treatment has proved effective, it has become opportune to 
try and investigate whether the manual is also suitable for transferral. Two questions 
are relevant in this context.
First, to what extent did the therapists, who were extensively trained and supervised, 
comply with the various aspects of the treatment manual during the actual sessions? 
In other words, did they do what they were expected to do? This is the so-called 
integrity check. Secondly, what is their judgment as to the manual’s suitability for 
transfer? What are, in their views, the difficult and less difficult aspects of the 
prescribed treatment, what are the manual’s shortcomings, and which of the 
treatment aspects do they think are suitable to be applied by therapists without 
additional training? To find answers to these questions, following conclusion of all 
treatment sessions, each of the therapists was presented with a questionnaire.
Method
Treatment manual
The treatment manual 'CBT for CFS' was founded on empirical knowledge and 
experience with CFS patients in the clinical practice. The rationale of the intervention 
was based on the model of perpetuating factors in CFS24,26,27. This model claims that 
a negative self-efficacy (the idea the patient has that he/she has no control over the 
complaints), strong somatic attributions, a low activity level and a tendency to focus 
on bodily sensations negatively affect fatigue severity and functional impairment in 
CFS patients. When complaints are attributed to a somatic cause (somatic 
attributions) this will lead to a reduced level of physical activity, which in turn affects 
the severity of the fatigue. A negative self-efficacy and strong focus on physical 
sensations will, again according to the model, have a direct impact on the severity of 
the fatigue. The standardised cognitive behaviour therapy for the treatment of CFS 
was therefore aimed at decreasing somatic attributions, increasing self-efficacy, and 
restoring the balance in activity patterns. The underlying principle of the treatment 
was that although we do not know what actually causes the complaints, we do know 
which factors help maintain the symptoms. The treatment therefore challenged the 
perpetuating factors. The final treatment goal was the patient’s full recovery and a 
resumption of his or her normal activities.
The manual starts with a general outline of the treatment (table 1). Next, for each 
session the goal is described, together with the associated target cognitions for the 
patient, the therapist’s aims and objectives, and the session’s programme. Also, an 
indication of time, in minutes, to be allotted to each treatment aspect was provided. 
The manual further contained practical suggestions on how to effectuate the various 
interventions, sometimes with verbatim descriptions and detailed examples using the 
same two fictitious patients throughout the manual. The treatment consisted of 16 
sessions distributed over a period of eight months. The first sessions were on a
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weekly basis with the frequency of the subsequent sessions decreasing from once 
every two to once every three weeks down to once a month.
Table 1. Outline of the treatment manual
Step 11 Session Methodology Homework assignment
1. Referral and intake 1 - introduction
- discussion report
- fine-tuning expectations
- role spouse
- modus operandi
2. Preparing patient for 
treatment and 
explanation of 
treatment goal
1, 2 - discussion goal
- return to work
3. Explanation of the 
model
1, 2 - views on somatic factors
- role of cognitions and 
behaviours
4. Exercises to prevent 
the fatigue from 
getting worse
1, 2, 3 ... 
(through-out)
- learning to think differently
- accepting cognitions
- peak-stop exercise
- registration of 
cognitions
- peak-stop exercise
5. Learning to recognise 
and respect 
limitations, and 
following this through
2, 3, 4 ... 
(through-out)
- peak-stop exercise, learning 
to rest, base level
- rationale activity programme
- coping with the environment: 
learning to say no
- lowering demands: changing 
way of thinking
- registration of 
cognitions
- peak-stop exercise
- writing down base 
level
6. Practising gradual 
expansion of limits
5, 6, 7 ... 
(through-out)
- activity programme: graphs
- drawing up a plan for a 
return to work
- peak-stop exercise
- activity programme: 
graphs
- plan for return to 
work
7. Changing lifestyle 
and relapse 
prevention
8, 9, 10, 11, 
12,...
(through-out)
13, 14, 15, 
16
- first step return-to-work plan
- discussion of impeding 
circumstances, environmental 
factors, cognitions and other 
likely problems
- dealing with setbacks
- preparing for therapy 
completion
- evaluation
- activity programme: 
graphs
- steps for return to 
work
11 These steps refer to the treatment aspects as described on pages 14 to 17 of the chapter on Chronic fatigue 
from 'Handboek Klinische Psychologie' (Bleijenberg, Vercoulen, & Bazelmans, 1996)
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The content of the first eight sessions was fully structured. The subsequent sessions 
left more room to allow them to be tailored to the individual patient. The manual 
comprised 79 pages. Preparation and evaluation forms were provided separately. 
With these forms the therapists were encouraged to reflect, both prior to and 
following each session, on how to integrate the patient’s complaints with the manual.
Therapists, training and supervision
Thirteen psychotherapists participated in the research project 'Cognitive behaviour 
therapy for chronic fatigue syndrome: a multicentre randomised controlled trial'25. The 
therapists worked at three different locations, viz. Leiden, Maastricht and Nijmegen. 
They were psychologists, psychiatrists or health scientists and all were qualified or 
assistant behaviour therapists. At the start of the project none had any earlier 
experience with CBT for CFS. Prior to the start of the treatments all therapists 
received extensive training in the use of the manual 'CBT for CFS'. The training 
course lasted two two-day meetings, followed by several follow-up sessions.
Table 2. The main topics discussed during the plenary supervison sessions
- recognising individual cognitions, defining new (target) cognitions, and achieving the desired 
changes in cognitions (Socratic dialogue)
- enhancing the patient’s self-efficacy
- use of a wheelchair
- use of medication
- sleeping problems and sleeping during the day
- base level and peak-stop exercise: balancing periods of rest and activity
- what constitutes a good programme to build up activity levels, and how to respond to the activity 
graphs
- passive patients
- company doctors and work-related problems
- what is improvement, what is recovery?
- how flexible can/are you allowed to be with the manual?
- making function analyses
- integrating additional patient-specific problems and comorbidity in the CBS treatment
- balancing permissiveness and authoritativeness
- the therapist’s cognitions regarding the treatment
- emotions patients may evoke in the therapist
- resistance and motivation of therapist and patient_____________________________________
Preceding the training sessions all therapists had studied the treatment manual as 
well as literature on CFS and cognitive behaviour therapy24. For the training sessions 
and subsequent supervisions use was made of, among other techniques, video 
recordings, audiotapes, fictitious problems, role plays with simulated patients and the 
therapists’ own cases. The in-situ supervisions were initially conducted on a weekly 
basis and, at a later stage, every other week. Every other month a plenary
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supervision was arranged to discuss those issues that had caused the therapists 
problems. The therapists of one of the three locations selected these topics, together 
with their supervisor, and they provided their own CFS cases. During these central 
supervisions, additionally, role plays were practised or the supervisor raised specific 
points for discussion based on the experience of the preceding months. In total eight 
such plenary sessions were held over a period of 18 months. The main topics 
discussed in these sessions are listed in table 2. Together, the participating 
therapists treated 82 CFS patients.
Integrity check
For evaluation purposes, i.e. to verify whether the therapists had complied with the 
guiding principles of the treatment manual, all therapy sessions were audiotaped. In 
total 1,097 sessions were conducted. A random sample of 61 audiotapes (a good 
5%) was analysed by an independent rater. In 49 of the cases the tapes comprised a 
full session; 12 of the recordings were incomplete. The manual was subdivided and 
scored for the following treatment aspects: cognitive restructuring, setting limits, 
activity programme, return to work (or resumption of other personal goals) and other 
CBT. The sessions were analysed by means of the audiotapes, their so-called 
verbatims, and a checklist. For each of the treatment aspects the time dedicated to 
this aspect during a session was noted down. In addition, the checklist was used to 
indicate on a five-point scale (minimal, some, reasonable, considerable, extensive) 
for each session how much attention the therapist had paid to the treatment aspect 
the manual prescribed for that session. An overall judgment on the session as a 
whole was given using a three-point scale (insufficient, sufficient, good).
Questionnaire for the psychotherapists
As regards the questions about the treatment to be put to the therapists, the manual 
was subdivided into the same treatment aspects as used for the integrity check, i.e. 
cognitive restructuring, setting limits, activity programme, return to work or 
resumption of other personal goals, and other CBT. In addition, for the questionnaire 
these aspects were further subdivided into subcategories (table 3).
The therapists were asked to evaluate the CBT for CFS manual for these 
subcategories on a scale ranging from 1 (agree) to 6 (disagree) on the basis of the 
following statements:
- I think this is important fo r a successful treatment
- I can adequately apply this myself
- In my view, patients understand the rationale of this aspect well 
(this item was not assessed for the questions relating to 'other CBT')
- Can, in my view, be adequately applied by an untrained psychotherapist, i.e. a 
(cognitive) behaviour therapist working solely on the basis of the manual
- How this aspect is to be effected, is sufficiently described in the manual.
In addition, the following statements were included:
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- CFS patients are more difficult to treat than other patients with somatic complaints.
- CFS patients are more difficult to treat than patients with psychological complaints. 
Similarly, these statements were scored on a scale from 1 (agree) to 6 (disagree).
Of this 6-point scale the therapists primarily used score 1 (40% of the answers). The 
scores 2 (26% of the answers) and 3 (17% of the answers) and 4, 5 and 6 (together 
17% of the answers) were used far less frequently. This is why, except for the overall 
judgment, in the representation of the therapists’ evaluations we only show the 
percentages of score 1, reflecting the proportion of therapists who fully agreed with 
that specific statement.
Table 3. The therapists' views on the CBT for CFS treatment manual
doable in 
my opinion
understood 
well by the 
patient
important for 
a successful 
treatment
sufficiently 
described 
in the 
manual
not practicable 
for an 
untrained 
therapist
Cognitive restructuring 
explanation rationale 85% 54% 100% 39% 23%
making an inventory of 
cognitions 31% 8% 62% 15% 23%
challenging cognitions 39% 8% 69% 8% 46%
Setting limits 
explanation limits 69% 62% 92% 46% 23%
implementing peak-stop 
exercise 54% 46% 62% 15% 15%
Activity programme
explanation activity 
programme 69% 62% 85% 31% 15%
implementing activity 
programme 46% 31% 77% 15% 23%
Return to work / 
Other personal goals 
defining goals 39% 31% 77% 23% 15%
action plan return to work 
/ personal goals 31% 23% 62% 8% 23%
implementing plan return 
to work / personal goals 31% 23% 69% 15% 31%
Other CBT
lack of confidence 31% 85% 8% 54%
insufficient motivation 23% 92% 8% 46%
integrating individual 
problems 31% 77% 8% 39%
dealing with comorbidity 18% 85% 0% 31%
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Results
Did the therapists do what they were expected to do?
During all sessions themes were dealt with as described by the manual. In 89% of 
the sessions this was rated as sufficient. In 25% of the sessions issues were raised 
that were not related to CBT for CFS (other non-CBT). The proportion of time allotted 
to these non-relevant topics was, on average, 8%. The overall judgment revealed 
that the rater considered 87% of the sessions to be sufficient or good.
A comparison of the proportion of time to be allocated to the various subjects as 
stipulated in the manual with the time actually spent on these themes showed many 
similarities, particularly with respect to the aspects cognitive restructuring, setting 
limits and building up activity levels (figure 1).
As regards the percentage of time allocated to return to work and other CBT the 
differences were greater. Compared to the manual, less time was dedicated to a 
return to work and more time was spent on other CBT.
other CBT 
12%
plan for 
a return 
to work 
27%
challenging 
and defining 
cognitions 
29%
setting limits 
14%
other non-CBT 
8%
other CBT 
22%
plan for 
a return 
to work 
10%
challenging 
and defining 
cognitions 
31%
activity
programme
18%
activity
programme
12%
setting limits 
17%
MANUAL PRACTICE
Figure 1. Discrepancy between what the therapists practised and what was prescribed by the manual
Overall judgment of CBT for CFS
Many of the therapists indicated that they found CFS patients more difficult to treat 
than other patients with somatic complaints and patients with psychological 
complaints (figures 2a and 2b).
Which treatment aspects were practicable for the therapists?
It was remarkable that for a majority of therapists explaining the treatment’s rationale, 
the activity programme and setting limits posed the least problems, whereas at the 
stage of having the patient comply with the peak-stop exercises and activity
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programme already fewer therapists stated this was practicable. Moreover, with 
respect to challenging and defining cognitions, formulating the final goal, drawing up 
and realising a plan for a return to work, integrating individual problems and dealing 
with a lack of confidence, only a third of the therapists indicated that the manual was 
workable. Merely 18% reported that challenging insufficient motivation and dealing 
with comorbidity was viable.
38%
agree agree
Figure 2 a. CFS patients are more difficult to treat than Figure 2 b. CFS patients are more difficult to treat th 
other patients with somatic complaints than other patients with psychological complaints
Which aspects were understood adequately by the patients?
Again, the explanation of the rationale, setting limits and the activity programme 
come top of the list, followed by maintaining the peak-stop exercise and activity 
programme, defining targets and drawing up and executing a plan for a return to 
work. The most striking finding is that a mere 8% (a single therapist) had the 
impression that the patients grasped what defining and challenging cognitions 
entailed.
Which aspects did the therapists regard as important for a successful treatment? 
When we look at which aspects of the treatment were important or less important in 
the eyes of the therapists to ensure a successful treatment outcome, it is surprising 
that for the element rated as the least significant still 62% of the therapists indicated 
this as important. In addition to explaining the treatment, 75% of the therapists 
regarded coping with low motivation, handling comorbidity and integrating individual 
problems as central to the treatment. Compared to the other treatment elements, 
particularly defining and challenging cognitions and making and having the patient 
follow up the plan aimed at a return to work was considered less relevant.
What was described adequately in the manual?
Only with respect to the aspects explaining limits, the rationale and activity
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programme did 31% to 46% of the therapists state that these were amply described 
in the manual. For the aspects having the patient comply with the peak-stop exercise 
and activity programme, and also for work resumption, cognitive restructuring, and 
the elements categorised as ‘other CBT’, only one therapist indicated these as 
having been adequately described in the manual.
Which aspects would pose problems for an untrained therapist?
Table 3 lists for each treatment aspect the percentage of psychotherapists who 
thought that the particular aspect could not be applied by an untrained therapist. 
Specifically lack of confidence, insufficient motivation and challenging cognitions was 
seen by 50% of the therapist as likely to pose problems for an untrained therapist. 
Only two therapists (15%) were convinced that an untrained therapist would not be 
capable to apply the activity programme and have the patient comply with the peak­
stop exercise and achieve the targets set.
Discussion
As evidenced by the integrity check, the therapists have overall applied the treatment 
as prescribed by the manual and, as shown by the effect study, successfully25. 
However, it needs to be said that the therapists found several aspects of the manual- 
based CBT for CFS treatment hard to administer.
They managed explaining the treatment rationale and having the patients comply 
with their limits and activity programme quite well. However, with respect to bringing 
about a change in the patient’s behaviour and cognitions, as well as having the 
patients draw up and follow up on the action plan aimed at a return to work (or 
reaching other personal goals), already fewer therapists indicated that they had 
found this viable. Integrating patient-specific problems and managing a lack of 
confidence and motivation had posed them the most problems. Particularly for 
comorbidity and dealing with lack of motivation the therapists expressed a need for 
the manual to be more explicit. These aspects, together with challenging cognitions, 
were also the treatment components of which the therapists stated that these could 
not be easily applied without additional training in the use of the manual. Since it is 
difficult to describe these aspects explicitly in a manual, we feel that specifically these 
components of the therapy need to be mastered through training and supervision. It 
needs to be noted that the results as derived from the questionnaire are in line with 
the topics discussed in the plenary supervision sessions. These frequently involved 
cognitive restructuring, tailoring the programme to the individual patient, and the 
patient-therapist interaction.
This study has several methodological limitations. For instance, since the 
questionnaire could only be put to the 13 therapists who had participated in the 
study, our sample was small. In addition, only a limited number of scores of the six- 
point scale were used. This may possibly be due to the respondents’ desire to give 
socially acceptable answers. Nevertheless, the scores clearly indicated at which
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aspects the manual was found to be lacking. The responses to the various items, 
moreover, are consistent in that they show which treatment aspects the therapists 
considered less or more difficult. Despite these limitations, we can safely say that the 
responses to the questionnaire constitute a useful supplement to the acquired clinical 
experience in the use of the manual and the associated training and supervision.
The fact that defining and challenging cognitions posed serious problems may also 
be attributed to the therapists’ prior training and experience. They had been selected 
on the basis of their experience in behavioural therapy, but the extent of practical 
experience with cognitive therapy was not the same for all therapists. Similarly, their 
therapeutic experience with patients suffering form somatic complaints was quite 
diverse and ranged from 0 to 24 years. Furthermore, the fact that the therapists 
indicated that putting the manual to practice had not always been easy may also be 
related to the version of the manual they were working with; this first version did not 
yet differentiate between passive and active CFS patients28. The effect study25 had 
shown that the standardised treatment had proved specifically suitable for the 
treatment of the relatively active CFS patients but had hardly worked for the passive 
CFS patients. As passive CFS patients are characterised by a fear and avoidance of 
activity, complying with preset activity limits proved to be of no use to these patients. 
We now know that for this group the stage at which activity levels are raised needs to 
be brought forward drastically. In contrast, active CFS patients still undertake too 
many activities regularly. Since they exceed their limits, for them learning to observe 
the limits agreed upon is useful. Passive CFS patients already undertake so little that 
maintaining limits only perpetuates their pattern of complaints. Because during the 
study the passive patients were also required to comply with this aspect of the 
treatment, this may have frustrated the therapeutic process.
On the basis of the experiences as reported by the 13 participating therapists, their 
supervisions and the results of the effect study, the treatment manual has been 
revised. In the most recent version23 the manual now makes a distinction between 
the treatment of passive and relatively active CFS patients. Also with respect to 
flexibility the manual has been modified. It is now stressed that the therapist will 
always need to investigate for each individual patient which the key factors are that 
help maintain the complaints. Is this a passive or a relatively active CFS patient? Is 
there any comorbidity? In the course of the treatment a function analysis of the 
patient-specific perpetuating factors is recommended. The manual may be used to 
support this process of differentiating the essentials from the side issues. It describes 
the treatment in broad outlines and offers suggestions and examples, founded on 
empirical evidence, of possible cognitions and behaviours, the appropriate 
interventions and the likely problems to be encountered. Pivotal to the treatment will, 
however, always be to relate to each individual patient.
It is our view that a sound treatment manual should provide insight into and contain 
detailed information about the function analysis of the patient group as a whole, the 
specific cognitions and behaviours of the patient or client population, the
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interventions specifically targeted at these specific symptoms, likely motivational and 
interaction problems, as well as provide strategies, interventions and additional 
recommendations illustrating ways to deal with such problems. The function analysis 
and the specific cognitions and behaviours of the patient group as a whole need to 
be founded on scientific findings. Furthermore, a treatment manual should offer a 
solid framework and firm foothold, and should provide the psychotherapist with a 
sound basis for the individual function analysis and the subsequent interventions29,30. 
This facilitates the treatment for the therapist, but he or she will, however, always 
have to tailor the treatment to the individual patient. The difficulty here is that in order 
to integrate the patient-specific function analysis with the manual the therapist needs 
to have full control over two different aspects. He or she will need to combine both 
the manual and the individualised treatment on the basis of a therapeutic programme 
that has only been defined in broad terms. This implies that the therapist may need 
specific, additional skills and the process will always place high demands on his or 
her basic technical and interaction skills, as well as on the preparation and evaluation 
of the sessions.
Applying a standardised, manual-based therapy may seem straightforward. It is 
ready-made and everything is primed and as long as you stick to the manual, the 
treatment will run its course. Nothing is further from the truth. Although the outlines 
are provided, it is vital that the therapist fine-tunes the manual to each individual 
patient. For the developers of manuals it is essential that they allow enough room for 
manoeuvre in the manual so that the therapist is able to cater for each specific 
patient, but the manual should also offer sufficient degrees of freedom to provide for 
differences between therapists. Working with the present manual requires solid 
cognitive behavioural and interaction skills of the therapist, as well as a sound 
knowledge of the scientific state of affairs concerning CFS. A standardised, 
empirically validated practice does not necessarily make treatment easier, but it may 
at least enhance the quality.
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Cost effectiveness analysis of cognitive behaviour therapy for 
patients with chronic fatigue syndrome
Abstract
Cognitive behaviour therapy (CBT) can be considered to be an efficacious treatment 
for chronic fatigue syndrome (CFS). This study reports a cost-effectiveness analysis 
as part of a randomised controlled trial of CBT for CFS patients compared to guided 
support groups (SG) and the natural course (NC, no protocolised intervention). 
Patients were treated for 8 months and followed up for another 6 months. Both a 
health care and a societal perspective were used, indicating either cost per patient 
clinically significant improved based on the CIS-fatigue scale or cost per quality 
adjusted life year. One way sensitivity analyses and bootstrap simulations were 
performed to study cost-effectiveness uncertainty.
Of the 270 patients complete cost and effectiveness data were available of 171 
patients at 8 months and 128 at 14 months. At 8 and 14 months the percentages of 
improved patients were 31% and 27% for CBT, 9% and 11% for SG, and 12% and 
20% for NC. The mean QALY gained until 14 months was for CBT, SG and NC 
respectively 0.0737, -0.0018, and 0.0458. CBT and SG mean treatment costs were 
€1,490 and €424. Other medical cost for CBT, SG, and NC for the first period were 
€324, €623, and €412 and for the second period €232, €561, and €378 respectively. 
The non-medical costs for the distinguished periods for CBT, SG and NC were €262, 
€550, €427 and €226, €439, €287. Productivity costs were considerable but not 
statistically significant different between groups. CBT was dominant over SG. 
Compared to NC, the baseline incremental cost-effectiveness of CBT is €20,516 
CFS-patient clinically significant improved and €21,375 per QALY. The bootstrap per 
ratios indicate that compared to the current situation (NC) CBT can be dominant as 
well as inferior, or that an incremental cost-effectiveness has to be judged about. 
Future research should focus on productivity costs and use a longer period of 
prospectively following patients.
Introduction
Principles of economic evaluations in health care
Because of the tension between budget constraints and the growing possibilities of 
diagnosing and treating patients, economic evaluations of interventions in health care 
become more and more important. These economic evaluations intend to generate 
information about the relative efficiency of a diagnostic or therapeutic intervention on 
the basis of which decision-makers can decide about the implementation of this 
technology. After the efficacy of a health care technology has been established in a 
highly controlled situation for selected patients, the effectiveness and efficiency (or 
cost-effectiveness) has to be studied empirically in order to judge about the 
usefulness and possibilities of the technology in day-to-day health care.
The basic principle of an economic evaluation is the comparison of at least two
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alternative courses of action, either being pharmaceutical products, medical devices 
or treatment procedures1. Because of this explicit comparison the difference in 
effectiveness and the differences in costs between the alternatives can be related to 
each other in order to be able to determine the relative efficiency of, in most 
economic evaluations, a newly introduced health care intervention. A comparison of 
the new intervention can be made with the regular intervention for the specific patient 
population, the most effective intervention so far, the cheapest, the intervention of 
first choice and so on. Of course, the choice of the comparator intervention is 
essential for the usefulness of the study findings to decision-makers2.
Chronic fatigue syndrome
Chronic fatigue syndrome (CFS) is characterised by persistent or relapsing 
unexplained fatigue, of new or definite onset and lasting for at least six months, 
resulting in substantial reduction in previous levels of occupational, educational, 
social and personal activities3. Other symptoms such as musculoskeletal pain, sleep 
disturbance, impaired concentration and headaches might be present as well4. A 
large economic burden related to disability and health care use induced by CFS 
underscores the need for analysis of costs involved5. Cognitive behaviour therapy 
(CBT) can be considered to be an efficacious treatment for CFS. However, in the first 
randomised controlled trials6,7, the therapy was administered by a highly skilled 
therapist in a specialised centre and therefore the generalisibility of these findings is 
subject to discussion4. Thus, before CBT for the treatment of CFS can be 
implemented in day-to-day health care practice, nowadays instead of efficacy only, 
information about effectiveness and cost-effectiveness is desirable.
A full economic evaluation aimed to determine the cost-effectiveness of health care 
interventions is only possible in case besides effectiveness measurement a cost 
analysis is integral part of the study. In this study we report the results of a cost- 
effectiveness analysis which was part of a randomised controlled trial. In this study 
we evaluate the differences in both costs and effectiveness of CBT for CFS patients 
compared to first another treatment, guided support groups, and secondly a control 
group, the natural course.
Methods
Study design 
Design
The methods of the clinical part of this study have been previously described.8. The 
study was designed as a prospective, controlled, randomised multicentre clinical trial 
and was approved by the institutional review board.
Patients and treatment
The inclusion criteria for participation in the trial were as follows. Besides informed 
consent, the patients, between 18 and 60 years old, had to have a score of 40 or 
more on the subscale fatigue severity of the Checklist Individual Strength (criteria for
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CFS or idiopathic chronic fatigue according to Fukuda et al.3), and a score of 800 or 
more on the Sickness Impact Profile. Exclusion criteria were previous or current 
engagement in CFS research, pregnancy or engaged in pregnancy- stimulating 
techniques and living more than one-and-a-half hour travelling time of one of the 
three centres. Between October 1996 and January 1998, consecutive patients with a 
major complaint of fatigue, referred to the outpatient departments of internal medicine 
of the University Medical Centre Nijmegen and the University Hospital Maastricht 
were enrolled in the study.
After inclusion in the study and baseline measurements, patients w ere randomised to 
cognitive behavioural therapy (CBT), guided support groups (SG) or natural course 
(NC). CBT lasted 8 months and consisted of 16 one-hour sessions by trained 
therapists. Patients in this group had to meet the requirements of no further medical 
examinations or additional treatments for CFS during the study. The SG group (11 
one-and-a-half-hour meetings during 8 months) was introduced to show the 
additional effect of CBT next to therapist attention. The NC group (no protocolised 
intervention) was established to make comparison possible between the protocolised 
CBT intervention and the medical care seeking behaviour of CFS patients as is 
current practice. CBT and SG were performed in three treatment centres (Dept. 
Medical Psychology, University Medical Centre Nijmegen; Dept. Psychiatry, Leiden 
University Medical Centre; Dept. Psychotherapy, Maastricht Mental Health Institute). 
Thirteen therapists were available for CBT, one social worker for SG.
Before randomisation, at 8 months follow up (shortly after finalising CBT or SG), and 
at 14 months follow up (6 months after finalising CBT or SG) patient assessments 
were performed. Because fatigue is the main symptom of CFS patients, for the cost- 
effectiveness analysis we used the subscale CIS-fatigue (Checklist Individual 
Strength) as a disease-specific outcome measure to determine the fatigue severity 
during the last two weeks9,10. Besides this, because health related quality of life was 
considered to be an important outcome, the EuroQol was used as a preference- 
based measure11. Using the patients’ answers on the EuroQo-questions indicating 
their health state of the past two weeks, a single utility value was calculated as an 
indicator for the quality of life12.
Cost-effectiveness analysis 
Study perspective and time horizon
In our study we used two perspectives. First, a health care perspective was basis for 
the cost-effectiveness analysis, indicating that only medical costs were relevant 
(either paid for by an insurance company or the patients themselves). Secondly, a 
societal perspective was used, which implies that also non-medical costs, such as 
travelling expenses and productivity costs (costs related to absence from work due to 
illness) were considered to be relevant. Both perspectives implied that the cost 
analysis was performed on the basis of real costs instead of using charges paid for 
treatment (for instance, neither patients nor insurance companies had to pay for the
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experimental CBT and SG treatment, although these costs are a relevant part of our 
analysis). Costs initiated in the context of the study, but not related to day to day 
patient treatment, the so-called protocol-driven costs were left out of the cost 
analysis1. The time horizon used for the analyses was equal to the follow up of 
patients, thus 14 months after inclusion in the study. Given this short time horizon, 
the principle of discounting was not applied.
The cost analysis consisted of two main components: first, the measurement of the 
volumes of the resources used by each patient and second, the financial valuation 
(cost price) of the volumes measured. The volumes of care and other cost items that 
were not related to the protocolised CBT and SG treatment were measured by 
means of a monthly diary. Patients indicated on the monthly diary cards the number 
of CFS related visits to their GP, medical specialists, physical therapists, and 
practitioners for alternative medicine, number of hours of formal and informal home 
care support, hospital admission and number of days in hospital, and use of 
prescribed medication. Out-of-pocket costs, for instance OTC-medication, were 
based on actual expenses. The number of days not being able to perform paid or 
unpaid work was registered as well. Regarding the cost price analyses we followed 
the Dutch guidelines for costs analyses in health care13. Cost prices that were based 
on the 1998 price level and converted into Euros were used to value the registered 
volumes (table 1).
Table 1. Cost prices used to value the different volumes measured in the cost-effectiveness analyses (in Euro, €)
Volume parameter Cost price (€)
General practitioner (per visit) 14.98
Medical specialist (per visit) 59.90
Physical therapist (per visit) 16.34
Company doctor (per visit) 83.05
Non-physician alternative medicine practitioner (per visit) 44.47
Prescribed medication (average costs per day) 2.27
Unprescribed medication (average costs per day) 2.41
Home care (per hour) 14.48
Informal home care support (per hour) 6.13
Regarding CBT and SG integral prices were determined, thus costs were based on 
actual therapist time, use of medical materials and including overhead costs such as 
costs for therapist training and facilities. The cost prices for GP visits, medical 
specialist visits, physical therapists, and travelling were based on the guidelines. 
Visits to psychotherapists, home care, and use of alternative treatment were based 
on reported expenses or recommended prices from the professional associations. 
Market prices were used for valuing medication. In order to prevent coincidental 
differences in productivity costs between the trial groups, the days of lost work were
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valued using the Dutch general wage rate rather than the actual wages of individuals. 
The diagnostic protocol was identical for all participating patients. However, in daily 
practice only patients who are eligible for CBT will be diagnosed extensively, thus 
these costs were only relevant for the CBT-patients and were left out of the cost 
analysis for the other groups. For SG, the costs for an intake visit were calculated, as 
is current practice.
For each patient, the volumes measured were multiplied by the specific cost price, 
leading to the cost of CFS. A distinction was made between the costs of CFS 
diagnosis and treatment, other medical costs being reimbursed by the insurance 
company, patients’ expenses, and costs of lost productivity. Besides this, the phases 
of the therapy period (intake to 8 months) and the follow-up (9 to 14 months) were 
discerned.
Analyses
Analyses were performed on the basis of intention to treat. The patients who were 
included in our analyses had to have complete data regarding the effectiveness 
measures and at least 75% of the cost diaries had to be available. Missing cost data 
due to missing diaries were constructed by using the patient year approach, thus 
extrapolating the available cost data to the end of follow-up14. The CIS-fatigue was 
used to determine the percentage of patients for each randomisation group that was 
clinically significant improved. As a criterion for improvement we used both a 
significant change index and a cut off score of 36 or lower of the CIS-fatigue8. The 
EuroQol utility score was used to calculate the quality adjusted life years (QALY) 
regarding the period of follow-up. In the QALY concept, the quality of life is 
expressed in a utility figure between 0 (health state equal to death) and 1 (perfect 
health) and multiplying time in a health state with this figure leads to the QALY score. 
Costs were expected to be skewed and therefore the non-parametric Mann Whitney 
U test was used to detect differences in costs between the groups. The analyses of 
the cost-effectiveness data were aimed to compare CBT to both SG and NC. For the 
effectiveness regarding the percentage of patients that clinically significantly 
improved, the incremental cost-effectiveness ratio (ICER) was based on the total 
treatment costs for each specific patient group. The ICER regarding quality of life 
was calculated based on the difference in mean costs and difference in mean 
effectiveness between groups. These ratios indicate the financial investment that is 
needed to gain the additional effectiveness. To test the robustness of the findings of 
the cost-effectiveness analysis regarding deterministic variables such as cost prices, 
one way sensitivity analyses were performed by varying the values of these 
parameters15. For this analysis, we used the most important cost prices in these 
analyses, being the costs of the CBT therapist and the overhead costs for training. 
Besides, the uncertainty of an ICER was estimated by using non-parametric 
bootstrapping, a method that is based on randomly sampling with replacement of the 
number of the patients in the trial from the original data16. For each of the 1,000
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bootstrap replicates a bootstrap ICER was calculated. Following, this information is 
translated and readily presented to decision-makers using the cost-effectiveness 
acceptability curve which plots the probability that a particular intervention is optimal, 
over a range of cost-effectiveness values17. For the bootstrap analyses we used the 
costs and effectiveness data regarding the 14 months follow up.
Results
In the study 270 patients were included (for CBT, SG, and NC respectively 92, 90, 
and 88). The effectiveness and costs data were complete for 171 patients until the 8 
months measurement (52, 55, and 64 for CBT, SG, and NC respectively) and for 128 
patients until the 14 months measurement (for CBT, SG, and NC respectively 37, 36, 
and 55). The missing data were related to 10 patients in CBT and 8 patients in SG 
who did not start therapy. Lost to follow-up for the clinical assessments for CBT, SG, 
and NC were 28%, 21%, and 10% respectively during the eight months period, and 
7%, 6%, and 11% between the 8 to 14 months follow-up. Missing cost diaries were 
the reason for additional lost to follow-up of 7 of 59 remaining patients in CBT, 10 of 
65 SG, and 15 of 79 in NC at 8 months follow-up and, respectively, 18 of 55, 25 of 
61, and 15 of 70 at 14 months follow-up. Extensive analysis of differences between 
patients who completed the study and patients who were lost to follow-up for the 
cost-effectiveness analysis showed no differences at baseline measurement 
regarding age, sex, duration of CFS complaints, treatment centre, CIS fatigue score 
and the clinical assessment measures.
From the clinical results of the study it was concluded that there were no centre 
effects on the main outcome variables. CBT proved to be statistically significant more 
effective regarding improvement on CIS fatigue and other measures such as 
Karnofsky performance status and Sickness Impact Profile as described in detail 
elsewhere8. Regarding the criterion clinical significant improvement as defined by the 
cut off score of 36 or lower of the CIS-fatigue, at 8 and 14 months the percentages of 
improved patients in the cost-effectiveness study were 31% and 27% for CBT, 9% 
and 11% for SG, and 12% and 20% for NC. The utility at intake, 8, and 14 months of 
follow up are reported in table 2. Based on these utility scores the mean QALY 
gained from intake until 14 months follow up was for the three groups respectively 
0.0737, -0.0018, and 0.0458.
Table 2. Mean utility scores at intake, 8, and 14 months of follow up and the differences between the measuring 
moments
Intake 8 months
Difference 
0 - 8 months 14 months
Difference 
8 -  14 months
CBT 0.4859 0.5817 0.0958 0.6014 0.0197
SG 0.5036 0.4930 - 0.0106 0.5035 0.0105
NC 0.5257 0.5779 0.0522 0.5999 0.0220
CBT: cognitive behaviour therapy - SG: guided support groups - NC: natural course
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Cost results
The analysis of the cost involved in diagnosis and both protocolised treatment 
strategies, e.g. CBT and SG resulted in €1,490 and €424 respectively. In detail, for 
the treatment modality SG the diagnostic activities were considered to be limited to 
one intake session by a social worker, costing €34. The cost for the more extensive 
diagnostic protocol before CBT treatment were €411, consisting of €265 for 
personnel, €48 for the use of medical equipment and materials, and €65 overhead 
costs. €34 considered travelling costs by patients. In both cases, main component of 
the diagnosis and treatment costs were costs for personnel €830 (of which €192 was 
related to the training CBT-therapists) and €194 (for SG).
Table 3. Volumes of care used
CBT SG NC
Mn Md IQR Mn Md IQR Mn Md IQR
0-8 months
General practitioner 1.3 1 0-2 2.2 1 1-4 2.2 1 0-3
Medical specialist 0.4 0 0-0 0.9 0 0-1 0.7 0 0-0
Physiotherapist 1.4 0 0-0 5.1 0 0-7 3.7 0 0-6
Psychologist 0.5 0 0-0 2.1 0 0-3 1.3 0 0-0
Alternative caregiver 0.3 0 0-0 4.9 0 0-9 3.4 1 0-5
9-14 months
General practitioner 1.0 0 0-1 1.8 1 0-2 1.4 1 0-2
Medical specialist 0.2 0 0-0 0.8 0 0-2 0.6 0 0-0
Physiotherapist 1.9 0 0-0 3.2 0 0-3 2.9 0 0-4
Psychologist 0.0 0 0-0 1.3 0 0-1 1.5 0 0-0
Alternative caregiver 1.3 0 0-0 4.2 0 0-7 1.4 0 0-2
CBT: cognitive behaviour therapy -  SG: guided support groups -  NC: natural course 
Mn: mean -  Md: median -  IQR: interquartile range
In table 3 the volumes of non-protocolised care used are reported. These volumes 
were the basis for calculating the mean medical cost per patient (the above 
mentioned treatment costs excluded): for CBT, SG, and NC for the period from 0 to 8 
months €324, €623, and €412 respectively and for the period from 9 to 14 months 
€232, €561, and €378. The non-medical costs for the distinguished periods for CBT, 
SG and NC were €262, €550, €427 and €226, €439, €287. In table 4 a more detailed 
break-down is given regarding these figures. Thus, the 8 months average total costs 
(productivity costs excluded) for the three groups were €2,487, €1,631, and €839, 
and for the whole 14 months period €2,534 for CBT, €2,597 for SG and €1,504 for 
NC.
In the three groups the percentage of patients having a paid job at the start of the 
study were 36.8%, 23.5% and 39.7% and the mean number of working hours were 
28.0, 31.7, and 24.7. Based on the absence from paid work (mean number of hours
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Table 4. Mean and median cost (€) per patient and interquartile range regarding the 14 months study period, 
distinguishing the 'treatment’ period of 8 months and 6 months 'follow up’
0-8 months CBT NC SG
Mn Md IRQ Mn Md IRQ Mn Md IRQ
Medical costs
General practitioner 20 15 0- 30 34 15 15- 60 34 15 0- 45
Specialist 22 0 0- 0 55 0 0- 60 39 0 0- 0
Physiotherapist 24 0 0- 0 83 0 0- 114 62 0 0- 98
Company doctor 38 0 0- 0 177 0 0- 249 105 0 0- 0
Prescribed medicine 35 0 0- 3 80 22 0- 85 70 10 0- 93
Home care 173 0 0- 0 182 0 0- 0 94 0 0- 0
Non-medical costs
Non physician 
alternative practitioner 17 0 0- 0 128 0 0- 152 137 11 0- 189
Unprescribed medicine 32 0 0- 11 70 8 0- 90 62 12 0- 90
Informal home care 97 0 0- 25 155 0 0- 230 104 0 0- 57
Other costs 79 0 0- 0 166 0 0- 45 71 0 0- 18
Travelling costs 51 0 0- 50 44 9 0- 48 61 0 0- 70
Total medical costs 324 51 0- 373 623 349 75- 883 412 176 34- 554
Total non-medical costs 262 34 1- 422 550 342 851-3728 427 243 5- 771
Total 0 -  8 months 586 1173 839
9 - 14 months
Medical costs
General practitioner 15 0 0- 15 26 15 0- 30 20 15 0- 30
Specialist 13 0 0- 0 45 0 0- 90 35 0 0- 0
Physiotherapist 31 0 0- 0 52 0 0- 41 48 0 0- 65
Company doctor 2 0 0- 0 104 0 0- 42 121 0 0- 0
Prescribed medicine 29 0 0- 9 75 16 0- 94 93 5 0- 44
Home care 132 0 0- 0 250 0 0- 0 101 0 0- 0
Non-medical costs
Non physician 
alternative practitioner 33 0 0- 0 94 0 0- 179 55 0 0- 68
Unprescribed medicine 19 0 0- 2 55 1 0- 14 23 0 0- 14
Informal home care 82 0 0- 0 146 0 0- 208 75 0 0- 0
Other costs 69 0 0- 0 115 0 0- 0 89 0 0- 0
Travelling costs 31 0 0- 5 40 9 0- 48 44 12 0- 70
Total medical costs 232 561 378
Total non-medical costs 226 439 287
Total 9 -  14 months 458 1000 665
0-14 months (sum of means)
Medical costs 556 1184 790
Non-medical costs 488 989 714
Total 0-14 months 1044 2173 1504
CBT: cognitive behaviour therapy -  SG: guided support groups -  NC: natural course 
Mn: mean -  Md: median -  IQR: interquartile range
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absence from paid work during 4 weeks for CBT, SG and NC were 33.4 and 23.1, 
23.1 and 20.1, and 37.0 and 25.3 for the two periods respectively), the productivity 
costs from intake to 8 month and for the 9 to14 months period were calculated, but 
due to the large, overlapping ranges no significant difference were found (table 5)
Table 5. Productivity costs in Euro (€)
Intake to 8 months 9 to 14 months 0 to 14 months
Mn Md IQR Mn Md IQR Sum of means
CBT 13,248 4,030 0 -  26,838 7,242 1,072 0 -  12,325 20,490
SG 8,728 0 0 -  10,896 6,437 0 0 -  13,168 15,165
NC 14,564 3,684 0 -  28,177 7,788 2,322 0 -  10,717 22,353
CBT: cognitive behaviour therapy -  SG: guided support groups -  NC: natural course 
Mn: mean -  Md: median -  IQR: interquartile range
Incremental ratios
An important finding before calculating incremental cost-effectiveness ratios is that 
SG is more expensive and less effective, both regarding percentages of improved 
patients and QALYs , than the experimental treatment (CBT). Therefore SG can be 
considered to be inferior to CBT and only the incremental cost-effectiveness of CBT 
versus NC was calculated.
Table 6. Incremental cost-effectiveness of CBT versus NC based on the number of CFS patients showing 
clinically significant improvement and costs regarding treatment and other medical costs at 8 months and 14 
months follow up
Costs
CBT
Explanation Costs
NC
Explanation Cost
difference
Effectiveness
difference
Costs
CFS-
patient
improved
8 months €159,168 64* €2,487 €53,696 64*€ 839 €105,472 11.69 € 9,024
14 months €161,975 55* €2,945 €82,720 55* €1,504 € 79,255 3.86 €20,532
CBT: cognitive behaviour therapy -  SG: guided support groups -  NC: natural course
The incremental cost-effectiveness regarding the percentage of patients that clinically 
significant improved showed that an investment of respectively €9,024 and €20,516 
was needed to have one CFS patient clinically significant improve at 8 months and 
14 months follow up. In table 6 the underlying calculation is explained in detail. The 
cost per QALY using the 14 month follow up related to respectively 1) treatment 
costs, 2) treatment costs, other medical costs and patients costs, and 3) these costs 
including productivity costs are respectively €60,108, €51,642 and €21,375.
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Table 7. Distribution of the bootstrapped incremental cost-effectiveness ratios over the four quadrants of the cost- 
effectiveness plane
1st quadrant 2nd quadrant 3rd quadrant 4th quadrant
Medical and patient cost per 
CFS-patient improved 78% 22% 0% 0%
Medical- patient and productivity 
cost per CFS-patient improved 37% 10% 13% 40%
Medical and patient cost per 
QALY 64% 36% 0% 0%
Medical- patient and productivity 
cost per Qa LY 31% 15% 20% 34%
CBT: cognitive behaviour therapy; NC: natural course
1st quadrant: CBT more effective and more costly than NC 2nd quadrant: CBT inferior compared to NC 
3rd quadrant: CBT less effective and less costly than NC 4th quadrant: CBT dominant over NC
Figure 1. Acceptability curve showing the probability that CBT is cost-effective over a range of cost-effectiveness 
thresholds regarding medical-, patient-, and productivity costs per QALY
Varying the costs of the CBT therapist and costs for training in a sensitivity analysis 
showed that this did influence the cost-effectiveness estimates. In the situation that 
training costs are set at zero, the additional treatment cost per extra patient clinically 
significant improved changed from €9,024 to €7,971 regarding the 8 months time 
horizon and from €20,516 to €17,778 for the 14 months time horizon. The cost per 
QALY based on total costs (productivity costs included) changed into €14,482.
The bootstrap simulations based on the costs and effectiveness data regarding the 
14 months follow up showed that the uncertainty surrounding the incremental cost- 
effectiveness ratios is considerable. The bootstrap ratios indicate that compared 
tothe current situation (NC) CBT can be dominant as well as inferior, that it is 
necessary to invest cost to gain effectiveness, or to accept effectiveness loss at
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lowerlower cost (table 7). However, from the cost-effectiveness acceptability curve it 
can be seen that regarding prefering CBT over NC, uncertainty remains over a wide 
range of cost-effectiveness thresholds (figure 1).
Discussion
To our knowledge, cost-effectiveness of CBT in CFS patients has not been studied 
prospectively before. An extensive literature review did not reveal any prospective 
randomised study reporting the cost-effectiveness of CBT in CFS patients (our 
search strategy is available on request). Especially since CBT is the only therapy for 
CFS with evidence based efficacy, cost-effectiveness information is relevant18. Our 
main finding suggests that CBT leads to a higher clinical efficacy and that total costs 
to society are lower than the natural course, however, the statistical uncertainty of 
this finding is considerable.
Compared to the results of the clinical study as reported by Prins et a l8 our results 
are based on a smaller number of patients due to the cost diaries lost to follow up in 
a larger number of participants, in the treatment period as well as the whole study 
period. Although this is a known phenomenon when using cost diaries, this method to 
collect cost-effectiveness data is considered to be feasible and valid19. An extensive 
comparison between participants in the cost-effectiveness analyse (N=171) and the 
remaining clinical study participants (N=99) did not reveal any statistically significant 
differences regarding age, duration of CFS-complaints, and scores on Sickness 
Impact Profile, Karnofsky score, physical activity, a self-efficacy scale, a causal 
attribution list, and functional impairment. Selection bias due to missing data is not 
expected, and we regard the cost estimates to be a valid reflection of the medical 
costs of CFS patients.
In our study, we found that CBT resulted in a better outcome and a lower use of 
medical care facilities than the control treatment (SG) and the natural course (NC). 
The phenomenon that patients receiving active treatment for disorders manifest 
reduced utilization of other medical services is referred to as the medical-offset. This 
is explained by, first, the situation that patients with untreated mental disorders 
frequently present with physical symptoms and persistent complaints that resolve 
with appropriate mental health treatment and, second, the idea that physical 
disorders may contribute to emotional distress, which in turn may exacerbate 
patients' symptoms or delay recovery. In the literature a medical-offset was reported 
for patients who were treated for depression and had CFS complaints, thus bringing 
about less reimbursed costs compared to the period before they were actively 
treated20. Health care visits to either GP and specialists or non-physician 
practitioners were found to be higher in SG than in CBT and control. During CBT, as 
part of the therapy, patients were discouraged to use other treatment in order to 
facilitate attribution of improvement to themselves in stead of other treatments. Some 
CBT patients violated this advice given the fact that the range of medical costs (CBT 
costs excluded) was zero to €4,122 (mean €324) during the first 8 months. However,
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given a sim ilar period of follow-up, the number of visits to GP and specialist in our 
control group was considerably less than found in the literature5,21. This might be 
explained by the Dutch yearly subscription payment system, which discourages 
physician-induced follow-up visits. The number of non-physician alternative medicine 
practitioner visits, characterised by a fee for service payment was comparable. In our 
study no patient reported CFS-related hospital admission. Lloyd et al.21 found a mean 
CFS-related hospital stay of 0.7 days after making a correction for three exceptional 
situations. It can be assumed that the costs we reported are underestimations of the 
total costs involved in current CFS treatment because, since besides visits to care 
providers and use of drugs we were not able to examine other services and non­
drugs costs such as special diets. However, it can be argued that including these 
costs would enlarge the cost difference between successfully and unsuccessfully 
treated patients. Besides this, an important contribution to the reduction in costs was 
generated by the ability of successfully treated patients to return to their work. This 
finding was in accordance with previous studies because resuming work was clearly 
related to improvement of CFS symptoms. The best predictors to explain resuming 
work were found to be changes in the number of physical signs and psychiatric 
diagnosis22. Regarding our limited follow up we expect the cost-effectiveness to 
improve in case of a longer time horizon. Besides this, on an experimental basis CBT 
is offered as a group therapy which reduces costs and in case effectiveness persists, 
this might lead to a more favourable cost-effectiveness.
However, the statistical uncertainty of the cost-effectiveness estimates we found is 
considerable as the bootstrap simulations showed. This might be due to the fact that 
the clinical trial that was basis for this economic evaluation was powered to show an 
effect on physical activity, a measure that is not ideal for a cost-effectiveness 
analysis because its focus may be too narrow1. Using a societal perspective, thus 
including productivity costs, has a large impact on the cost-effectiveness estimates. 
However not statistically significant, the differences in productivity costs between the 
groups were considerable due to the fact that a small number of patients that were 
employed were absent from work during a longer period. Therefore, the results have 
to be interpreted with caution and we intend to further investigate the longer term 
working situation of our patients. The societal perspective is of importance, since in 
the trial of 270 CFS patients 76% had been employed before the onset of CFS, 
whereas only 33% had a job at the start of the study8. In the mean time the 
conclusions of this work should be based on the health care perspective as 
expressed in the medical and patient costs per CFS patient clinically significant 
improved, being €20,516. The difference in utility between the experimental 
treatment and the current situation is small. Given this fact and the short time 
horizon, the cost per QALY seem high. However, extrapolating the utility values and 
the cost figures another four years indicates that the cost per QALY will become 
more acceptable and even indicates dominance in case the productivity costs are 
included. This finding has to be interpreted with caution because in our study the
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productivity costs were based on a small number of patients. Thus, to be able to 
estimate the cost-effectiveness of treatment of CFS patients more accurately, future 
research should give more focus on productivity costs and use a longer period of 
prospectively following patients.
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Introduction
In this thesis, we concluded that cognitive behaviour therapy (CBT) is an effective 
treatment for patients with chronic fatigue syndrome (CFS). The effectiveness of CBT 
was found by comparing the treatment with guided support groups and the natural 
course of CFS in a randomised controlled trial (Chapter 4). Three systematic reviews 
endorsed effectiveness of CBT for patients with CFS1-3. The conclusion of these 
reviews was that CBT and graded exercise therapy (GET) are beneficial 
interventions for CFS patients, while for immunological therapy the evidence was 
inconclusive and for all other interventions insufficient evidence of effectiveness was 
found. In our opinion, CBT and GET are similar therapies, since there is no CBT 
without exposure to graded exercise and no GET without cognitive interventions 
needed to encourage graded exercise. All forms of CBT and GET encompassed a 
graded exercise programme, in which the main exercise was daily walking or cycling. 
In both CBT and GET, therapists express the opinion and entertain the expectation 
that exercise is helpful, the cognitive aspect that motivates patients to continue 
graded exercise for several weeks or months.
In other trials reporting positive results of CBT/GET a single therapist4-6 or only a few 
highly skilled therapists7-9 administered CBT in specialist centres. Therefore the 
generalisability of the positive results to settings outside specialist centres remained 
uncertain1. In our study 13 therapists with no prior experience in CBT for CFS who 
were participating in three different centres established the effectiveness of CBT. We 
showed that CBT could be transferred from CFS research clinics to therapists 
working in different settings with no previous experience in CBT for CFS patients 
(Chapter 10).
Our conclusion that CBT is an effective treatment for CFS patients brought about 
reactions both in scientific journa ls10-16 and in letters and comments by patient 
organisations17,18. In several comments patient selection was questioned and 
methodological issues concerning our study came up. Compared to other studies we 
reported lower percentages of improved patients, which raised questions about the 
effectiveness of CBT. The curative intention of CBT was under discussion as well as 
our choice for a psychological model of CFS as the basis for therapy.
In this chapter, we will discuss these comments and questions. Furthermore 
suggestions for implementation of CBT and for future directions of CFS research will 
be made.
Patient selection
A frequently raised objection was that in our study less impaired patients with chronic 
fatigue had been selected and that therefore the results could not be generalised to 
patients with CFS. The suggestion that we selected relatively healthy patients with 
chronic fatigue without additional symptoms rather than patients with CFS was
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incorrect19. Apparently our statement that we did not include the CDC criterion of four 
additional symptoms led to misunderstanding. In previous studies we showed that 
the number of additional symptoms is highly dependent of the assessment method 
and more importantly there are no differences in fatigue severity between chronic 
fatigue syndrome patients fulfilling the CDC criteria and patients who did not20. 
Besides, we did assess additional symptoms at baseline. In our sample 252 patients 
had the diagnosis CFS and 18 the condition idiopathic chronic fatigue19. Cut-off 
scores for fatigue severity and functional impairment guaranteed that all these 
patients were severely disabled. We agree that we can only generalise the results of 
our study to patients who are able to attend an outpatient clinic. However, this is a 
large group. During the trial we were never short of CFS patients and still there is a 
steady flow of patients to our chronic fatigue outpatient clinic. Large numbers of 
bedridden or homebound CFS patients are claimed by patient organisations. One of 
our studies concerned non-institutionalised bedridden CFS patients. The Dutch ME- 
association was asked to contact CFS patients among their thousands of members 
who were willing to participate in CFS-related research, but were incapable to visit 
the research centre because of severe functional limitations. We received 
participation forms of 29 patients living all over the Netherlands, of whom 20 were 
included after screening21.
It was also suggested that patients in our study suffered from other somatic or 
psychiatric diagnoses than CFS10,15. All patients with a major complaint of fatigue, 
referred to the outpatient clinic of the departments of internal medicine, were eligible 
for the study. Extensive screening of patients with a CFS protocol, consisting of 
guidelines for the anamnesis and physical examinations as well as supplementary 
diagnostics, prevented misdiagnosis of CFS before they were approached for 
participation in the trial. First, before we diagnosed a patient as CFS, according to the 
CDC criteria22 a thorough medical examination was being done to rule out somatic 
disorders, which might explain the complaint of chronic fatigue. Further, patients with 
complaints of chronic fatigue were screened with computerised questionnaires to 
verify whether they fulfilled the CDC-criteria for CFS (Chapter 2). In addition, a 
structured clinical interview for DSM-III-R was done to prevent confounding of CFS 
and psychiatric diagnoses. Nevertheless, like in other CFS samples23, we found 
psychiatric co-morbidity in the CFS patients in our study. Compared to the general 
population, CFS patients reported significantly more lifetime and current mood 
disorders, while the prevalence of anxiety disorders did not differ (Chapter 6). We 
also found somatic co-morbidity in our CFS sample, but the internists evaluated the 
somatic co-morbidity as insufficiently accounting for the complaint of chronic fatigue 
and diagnosed these patients as CFS (publication in preparation).
Study methods
Also methodological aspects of our study were criticised. Our choice of control 
conditions was questioned. It was suggested that active management in a primary-
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care situation would have been better as a control condition12. This might have been 
true for studies in the United Kingdom. In our study concerning the use of the 
diagnosis CFS by general practitioners (GPs) and their attitude towards CFS we 
found that GPs in the Netherlands were not familiar with CFS and reported 
insufficient knowledge of CFS (Chapter 9). Support groups and natural course were 
chosen as control conditions, since these were closest to the health care situation of 
CFS patients in the Netherlands. Our choice of control groups yielded the interesting 
finding that support groups were significantly less effective than CBT and no more 
effective that the natural course. Similar results were found in a study showing that 
membership of support groups of CFS patients was predictive of a worse outcome 
after GET. The authors suggested that these groups might play a part in reinforcing 
illness beliefs and advising against graded exercise interventions24.
Our statistical analyses raised questions, since there was a large dropout rate in the 
trial, especially in both treatment arms. However, most patients dropping out were 
willing to participate in assessment. There was a post-treatment dropout rate of 25%, 
but only 11% of the patients had missing data. Before the trial we decided that no 
imputation techniques would be used to estimate missing data, since as in leaving 
out patients with missing data bias may also result from using imputed data. 
Regarding the intention-to-treat (ITT) population we used the usual definition: all 
patients randomised. Since the variables we analysed were differences from baseline 
values, the actual ITT population did not include patients with missing values at 8 
and/or 14 months. Patients who withdrew from treatment were included in the 
analyses10,11. We provided enough circumstantial evidence to substantiate our 
results and "explain" the missing data. Proper methodology was used in our study, 
and the results clearly show that patients receiving CBT improved more than patients 
in both other conditions, also in blinded functional assessments like the Karnofsky 
performance status16.
The cost-effectiveness study of CBT for CFS patients was under discussion. The 
cost-effectiveness estimates appeared to vary largely, depending of the choice of a 
health-care perspective or a societal perspective. The prevailing method is the 
health-care perspective. Therefore, conclusions were based on the assessment of 
medical and patient costs. However, we assumed that these were underestimations 
of the total costs involved in the treatment of CFS. Productivity costs were not 
included, although these have a large impact in CFS (Chapter 11). In our opinion, the 
societal perspective would have shed more light on the costs of CFS patients. The 
amount of sick leave of CFS patients was impressively higher than in other general 
medical outpatients25. In our trial of 270 CFS patients 76% had been employed 
before the onset of CFS, whereas only 33% had a job at the start of the study.
Clinical significant improvement
Less patients showed clinically significant improvement in our trial than in the two 
comparable CBT studies5,7. Various aspects may account for this finding. Our criteria
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for clinical significant improvement were more stringent than in both other CBT trials. 
To define clinical significant improvement in fatigue severity, first a reliable change 
index was calculated for each patient to decide if statistical significant improvement 
occurred. Second, a cut-off score was calculated to decide if a patient’s score had 
moved from the range of CFS patients to the range of healthy subjects. Normative 
comparisons of CFS patients and healthy subjects perhaps have led to an overly 
stringent criterion for improvement. In an evaluation of the concept of clinically 
significant improvement26 it was questioned if patients should be compared to a non­
representative "supernormal” sample of healthy subjects, from which all (psycho)- 
pathology is excluded (Chapter 4). Further, therapists in our study had no clinical 
experience with CFS patients at the onset of the trial, while the therapists in the two 
other CBT studies were very experienced. After participating in the trial, many of our 
therapists agreed with the statement that CFS patients were more difficult to treat 
than patients with psychological complaints and than patients with somatic 
complaints (Chapter 10). Finally, predictors of treatment outcome showed that the 
treatment protocol was not suitable for CFS patients with a passive activity pattern 
and for CFS patients engaged in a claim for disability related financial benefits.
Predictors of treatment outcome
We agree with suggestions for further identification of subgroups of CFS patients 
benefiting from CBT12. In our studies we found several predictors of treatment 
outcome. Some of these predictors pointed in the direction of subgroups, like patients 
with a passive activity pattern or patients engaged in claims for disability related 
benefits, while other predictors highlighted weaknesses in the treatment protocol or in 
the way CBT was performed by the therapists. Starting with the latter, patients with a 
strong focus on bodily symptoms or with a low sense of control had a worse outcome 
in respectively functional impairment and fatigue severity after CBT (Chapter 4). We 
did not expect these factors as predictors of a worse outcome, since both were 
factors in the model of CFS, which was the basis for CBT. This might indicate that 
CFS patients characterised by a strong focus on bodily symptoms or by a lower 
sense of control were less sensitive to the treatment protocol we developed or that 
therapists were less competent in handling aspects of the treatment concerning 
these characteristics of patients. It might have been difficult for therapists to detract 
patients from complaining about bodily symptoms to more health-promoting 
cognitions and behaviours. To facilitate this aspect for both therapists and patients, in 
the later revised treatment protocol we skipped the daily registration of fatigue during 
the first sessions of CBT. The emphasis came on impeding cognitions and 
behaviours rather than on symptoms. Further, therapists might have experienced 
problems in establishing sense of control in CFS patients with a relatively long 
duration of somatic complaints who used to be dependent on treatments rather than 
taking the initiative for active participation in therapy. Pre-therapy assessment of 
sense of control might alert the therapist to pay special attention to this important
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aspect before starting CBT.
Of all 270 CFS patients in our study 24% was subtyped as pervasively passive 
(Chapter 5). For the subgroup of patients with a passive activity pattern a new 
treatment protocol was developed27. The early accent in CBT on a base level of daily 
activity, so important for relatively active CFS patients, seemed to enhance the fear 
of physical activity in patients with a passive activity pattern and might be impeding 
for the subsequent gradual increase of physical activity. In the new treatment 
protocol, CBT for passive patients directly starts with building up physical, mental and 
social activities, whereas relatively active patients still start with attaining and 
maintaining a base level of physical activity.
During the trial, we noticed the impact for CFS patients of being engaged in a claim 
for disability related benefits of the Disablement Insurance Act. Thirty-one percent of 
the patients in our study appeared to be engaged in a claim between the baseline 
and post-treatment assessments Chapter 7). Afterwards, it turned out that these 
patients had significantly less improvement than CFS patients not engaged in claim. 
In our opinion, it was impossible to benefit from a treatment directed at recovery of 
complaints, while in the meantime a patient was convincing work-related institutions 
of complaints and the need of financial benefits. Therefore, in our outpatient clinic 
patients engaged in disability claims only are assigned to CBT after finishing these 
legal procedures.
Variables failing to predict treatment outcome were as interesting as the predictive 
factors we identified. Demographic variables like age, gender and education were not 
found to be of importance for clinical response. Treatment outcome also was not 
predicted by duration of complaints suggesting that CBT is equally effective for 
patients with differing duration of illness. This finding was supported by recent results 
of a similar outcome study24. The majority of CBT/GET studies in CFS pertained to 
samples with median illness duration of about five years. In one of our natural course 
studies we found that prognosis for total recovery was poor from 18 months after 
onset of CFS28. If CBT will be offered to CFS patients in an earlier stage of the 
illness, medical and societal costs might be reduced importantly.
We found that CFS patients with and without lifetime or current psychiatric co­
morbidity equally benefited from CBT (Chapter 6). Similar results were reported in a 
previous CBT trial5. Therapists’ attention for psychiatric diagnoses might explain this 
finding. From the start of our study therapists were trained to deal with psychiatric co­
morbidity during CBT. In one of the GET studies with considerably less face-to-face 
sessions, concurrent emotional difficulties were predictive of a worse outcome24. 
Since in our sample of CFS patients treated with CBT psychological wellbeing and 
depressive symptoms also considerably improved, we continued our routine to refuse 
CBT to those CFS patients who were not willing to stop antidepressant 
pharmacotherapy. In earlier studies, antidepressants were not found effective in 
either treating the symptoms of depression of CFS patients or any other outcomes29. 
In our opinion, antidepressant therapy interferes with one of the main goals of CBT
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acquiring control over symptoms instead of dependence on medication.
The identification of the above predictors of treatment outcome prompted us to clarify 
indications and contra-indications of CBT for patients with CFS30. CBT is not 
recommended if patients disagree with the diagnosis and insist on further medical 
examinations, if patients are not willing to co-operate in CBT, if they are engaged in 
other therapies or if they are involved in legal procedures for disease- related 
financial benefits. Activity pattern and psychiatric co-morbidity have to be considered 
to optimise the treatment plan.
Cognitive behaviour therapy: rehabilitation or cure
Patient organisations and colleagues questioned the curative intention of our therapy 
and claimed that the ultimate goal could be rehabilitation16,31. However, the intention 
of CBT as practised in our research group was definitely curative. We elaborated our 
opinion in a reaction to Christopher Clark and colleagues’ commentary on the Report 
of the Working Party on CFS/ME to the Chief Medical Officer for England and Wales, 
in which they state that none of the rehabilitation approaches is intended to be 
curative31,32. With each CFS patient who enters CBT, the therapist discusses the 
individual and specific meaning of recovery. As in other chronic diseases the 
meaning of cure differs tremendously among patients. At the beginning of CBT 
recovery seems vague and unattainable for most CFS patients. By contemplating life 
after recovery, a CFS patient is formulating his own personal goals for CBT. Under 
which conditions will a patient consider himself as basically healthy? Which activities 
would he undertake in this situation? Too often therapists agree to far less concrete 
and less achievable aims, still within the scope of chronically ill patients. The art of 
CBT is to broaden the patients’ vision to a future life as a well person. After reaching 
most of the personal goals, one of the last cognitive interventions in CBT is to stop 
labelling oneself as a CFS patient. Our case study of a patient with CFS who was 
treated with CBT and was followed up two-and-a-half years after the start of CBT is a 
good example of the way we deal with cure in CBT (Chapter 3). In our opinion it 
helps CFS patients to strive for a cure, since a personal goal can never be completed 
if it is not aimed for. By questioning or denying the curative intentions of CBT 
therapists may deprive CFS patients from a potential cure. We agree that CBT may 
not be a cure for all CFS patients. As in other chronic diseases not one therapy is 
effective in curing all patients or in establishing the same effect for all patients. 
However, CBT certainly has been effective for at least thirty five percent of the CFS 
patients who fulfilled the stringent criteria for recovery in our trial. Recovered patients 
returned to work and other activities. Everyday bodily signs and symptoms were no 
longer interpreted as indicating CFS. Most importantly, these persons no longer 
labelled themselves as having CFS. If this is not cure, what is?
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The psychological model of CFS
CBT for patients with CFS was based on a statistically tested model of perpetuating 
factors in CFS33. Our use of this model was questioned. Unlike correspondents10,12,13 
and patients’ organisations13,14 suggested, the use of a psychological model does not 
preclude neurobiological components. There is still little consistent evidence for 
underlying organic pathology in CFS. The findings in CFS concerning subtle changes 
in the hypothalamus-pituitary adrenal axis (of which pathogenetically the importance 
is unknown), have led to two randomised controlled trials , from which neither we nor 
the investigators of these tria ls34,35 do derive the suggested conclusion that steroids 
are treatment of choice15. Adherents of biopsychosocial models and pathological 
models made some slight steps towards agreement on definition and diagnosis, but 
large gaps concerning treatment still remain31. Patients’ organisations in the 
Netherlands share the opinion that the success of CBT affirms the bias that CFS has 
a psychogenic cause17. This argument enforces the old paradigm, in which diseases 
or complaints were considered as either somatic or psychiatric in origin. In modern 
medicine, the biopsychosocial approach guarantees that both aspects are equally 
attended to36. Problems with a somatic cause, like diabetes may be aggravated or 
alleviated by psychological consequences (medication adherence or lifestyle). 
Psychological factors were involved in the persistence of fatigue in patients with a 
known somatic cause as multiple sclerosis33. Initiating psychological factors, like a 
reactive depression following bereavement, may be aggravated by somatic 
consequences (fatigue, weight loss) or alleviated by medical therapy.
A known somatic or psychic cause is not conditional for an effective treatment of a 
disorder. In our study on co-morbid psychiatric disorders (Chapter 6), we showed that 
CFS patients with and without current or lifetime psychiatric disorders equally 
benefited from CBT, not only concerning physical symptoms, like fatigue severity and 
functional impairment, but also in psychological symptoms, like depression and 
psychological distress. The atter results are remarkable since CFS patients treated 
with CBT were not allowed to use anti-depressants. Apparently, co-morbid 
psychiatric diagnoses, like anxiety disorder or depression, also benefit from CBT 
specially tailored for the somatic complaint of fatigue.
Our model of perpetuating factors in CFS was limited to complaint-related cognitions 
and behaviours, like somatic attributions, sense of control over complaints, physical 
activity and a strong focus on bodily symptoms. From the results of our study of 
social support in CFS patients it is obvious that cognitions and behaviours 
concerning the individual’s support system need equal attention (Chapter 8). 
Insufficiency of social support and negative interactions were found to be important 
factors in the persistence of CFS. Lack of social support should be added as a new 
factor to the model of perpetuating factors of fatigue and functional impairment in 
CFS.
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Implementing CBT for CFS patients
The effectiveness of CBT for patients with CFS was proven. We showed that CBT 
could be transferred from a CFS research clinic to therapists with no previous 
experience in treating CFS patients with CBT. This transfer is essential to detach the 
treatment from medical research settings, in which only a limited number of CFS 
patients can be treated. To increase accessibility of this treatment for more CFS 
patients, CBT will have to be implemented in general (mental) health settings.
The societal costs of CFS are high and consist of medical costs, productivity costs 
and costs as a result of legal procedures concerning claims. Extrapolating cost- 
effectiveness estimations over four years indicated dominance of CBT compared to 
the natural course if case productivity costs were included (Chapter 11).
Based on these results we proposed to make CBT available for CFS patients in the 
Netherlands. In comparing two prevalence studies among general practitioners we 
found that the population of CFS patients was growing37,38. The estimated prevalence 
of CFS patients in 1999 was 27.000. The incidence was estimated at 6000 new 
patients every year17. To increase accessibility of CBT for all CFS patients in future, 
this treatment will have to be implemented outside university medical settings. 
Ideally, general practitioners should diagnose CFS, without detours to medical 
specialists, and refer CFS patients to general mental health settings for CBT. During 
several years CFS expert centres should transfer expertise to both general 
practitioners and mental health settings.
Acceptance of CBT as an effective treatment for CFS patients by both CFS patients 
and general practitioners is a crucial condition for implementation. There is evidence 
from several sources that CBT is an acceptable treatment for half to three-quarter of 
CFS patients. First, in our trial 75% of the eligible patients in the general internal 
medicine outpatient clinic was willing to participate in a psychotherapy study. Next, 
after informed consent and before randomisation patients’ preference for one of the 
treatment arms was investigated. Sixty-two percent of the patients preferred CBT 
compared to 19% expressing preference for each of the control conditions17. Further, 
in a study among members of the Dutch ME-association 54% of 2600 respondents 
reported previous psychosocial treatments39. Acceptance by general practitioners of 
CFS as a medical diagnosis and of CBT as a treatment seemed also favourable. In 
1997, we concluded that in the majority of cases general practitioners should 
diagnose CFS40, only a small percentage of patients needed to be referred for further 
diagnostics. The willingness among general practitioners to diagnose CFS was 
growing. Compared to our first prevalence study the percentage general practitioners 
reporting to have no CFS patients dropped from 27% in 1993 to 13% in 199937,38. In 
the latest prevalence study we found that 75% of the general practitioners still 
referred CFS patients to medical specialists. At the same time half of the general 
practitioners reported to counsel CFS patients. However, almost all of the general 
practitioners were willing to refer CFS patients in case of an evidence-based 
treatment38.
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Future directions
Like others we are interested in the long-term results of CBT. Since at the end of our 
study CBT was offered to all patients in the control conditions, a long-term 
comparison between CBT and natural course was not possible. In a retrospective 
study of the effects of CBT after 5 years the first results concerning lasting benefits of 
CBT were promising41. In future CBT studies, fatigue and physical functioning of CFS 
patients should be monitored during several years to elucidate patterns of cure and 
relapse. To estimate the cost-effectiveness of CBT in CFS patients more accurately, 
future research should give more focus on productivity costs and use a longer period 
of prospectively following patients.
The essential mechanisms responsible for improvement after CBT are still unknown. 
Do cognitive and behavioural interventions equally need attention? Is graded 
exposure to exercise essential to recovery? Or do illness beliefs or a strong focus on 
bodily symptoms need to be changed first? Does a changed sense of control over 
symptoms precedes or results from these changes? Once we know which 
mechanisms mainly cause improvement, more efficient and less expensive 
treatments can be developed.
In a CFS expert centre, GET with minimal individual treatment sessions and 
telephone follow-up calls showed promising results for patients without strong illness 
beliefs and without concurrent emotional difficulties4,24. Active management of CFS 
patients in a primary-care situation by family physicians or members of primary-care 
health teams might be another alternative12. Co-operation with patient support groups 
was suggested as a way to spread evidence-based advices among CFS patients24. 
Perhaps in some patients, group CBT might be a more effective alternative in 
combining patients’ support and evidence-based interventions. Our first clinical 
results showed effectiveness in symptom reduction and improved physical 
functioning42.
Essential mechanisms of improvement might be located in the patient’s functioning 
as well as in the patient’s surroundings. Lack of social support was identified as a 
new perpetuating factor in CFS. Support might come from the general practitioner 
diagnosing CFS, the psychotherapist offering CBT, other CFS patients in a therapy 
group, family members and friends. All these support systems deserve more 
attention in future studies concerning the natural course or treatment of CFS patients.
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Summary
Chronic fatigue syndrome (CFS) is the term that is usually accepted by clinicians and 
scientists for the range of complaints that patients often refer to as ME (myalgic 
encefalomyelitis). CFS is characterised by severe disabling fatigue, for which no 
somatic explanation can be offered, lasting for more than six months and resulting in 
severe impairment in daily functioning. Health care costs are high and productivity 
loss occurs frequently.
From 1990, the Nijmegen Fatigue Research Group studied causes, natural course, 
consequences and treatments of CFS. No cause of CFS was found and most 
patients did not recover. Pharmacological treatment was not effective. Psychological 
processes were found to be involved in perpetuating fatigue and functional 
impairment in CFS patients. Based on these findings a model of CFS was developed, 
which showed that a low sense of control, low levels of physical activity and strongly 
focusing on bodily symptoms contribute to increasing severity of fatigue and 
functional impairment. Factors in the model concern psychological processes, which 
can be treated with cognitive behaviour therapy (CBT). CBT is a psychotherapeutic 
method directed at changing condition-related cognitions and behaviours.
The studies presented in this thesis are primarily concerned with the effectiveness of 
cognitive behaviour therapy for CFS patients and factors influencing the outcome in 
CFS patients with and without treatment.
In Chapter 2 we describe how the patients for these studies were selected. During 
the last decade our outpatient clinic has seen large numbers of patients suffering 
from chronic fatigue, both in the context of outpatient care and within the framework 
of scientific research. In both settings guidelines and measuring instruments have 
been developed to help improve CFS diagnostics. At our outpatient clinic a chronic 
fatigue protocol is applied. In our scientific studies patients fill in several 
computerised questionnaires (MID TestOrganizer) to establish whether they meet the 
operational and CDC (Centers for Disease Control) criteria for CFS. Retrospectively 
the medical records and the computerised questionnaires of 516 patients referred to 
an internal medicine outpatient clinic with complaints of chronic fatigue, were 
checked separately and compared to see whether the diagnosis of CFS had been 
met. Agreement between the physicians’ and the researchers’ evaluations was 84%. 
Disagreement mostly concerned severity of fatigue and functional impairment, or 
premorbid exclusion criteria.
Studying CBT for CFS, we first subjected the treatment protocol for CFS patients to 
systematic evaluation in several case studies. In Chapter 3 the case of a 26-year old 
woman with CFS is presented. Multidimensional assessment showing severe 
debilitating fatigue and considerable psychological, social and occupational 
impairment confirmed the diagnosis. CBT was based on a tested causal model of 
CFS and individual behavioural analyses. Key elements in CBT were process
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variables from the CFS model, like sense of control, causal attributions, physical 
activity and focusing on bodily functions. Goals were recovery of fatigue, returning to 
work and relapse prevention. The course of therapy is described in detail to illustrate 
difficulties in treating CFS. Assessments were made five times, at baseline and at 8, 
14, 21 and 33 months. Comparison of the pretest, post-test and follow-up scores of 
the outcome variables, fatigue and functional impairment and of the process 
variables showed clinically significant improvement from the range of CFS patients to 
the range of healthy controls. CBT was successful and resulted in clinically significant 
improvement.
Our next step was studying the effectiveness of CBT for patients with CFS. This 
study is presented in Chapter 4 In a multicentre randomised controlled trial we 
compared CBT with guided support groups and the natural course. CBT was 
administered in three different settings by 13 recently trained behaviour therapists of 
three different disciplines. CBT consisted of 16 sessions of one hour during eight 
months. Central components of CBT were explanation of the model of perpetuating 
factors, motivating for CBT, challenging fatigue-related cognitions, attaining and 
maintaining a base level of physical activity, gradual increase of physical activity, and 
planning work rehabilitation or rehabilitation in other personal activities. The CFS 
patient learned to acquire control over symptoms instead of dependence on 
physicians prescribing treatments or medications. Multidimensional assessments 
were done at baseline, 8 months, and 14 months. Results showed that CBT was 
significantly more effective than both control conditions for the two primary outcome 
variables fatigue severity and functional impairment. Depending of the different 
criteria, one third of the patients was clinically significant improved and half of the 
patients was more improved in the ratings by an independent judge or in the self­
rated improvement. Prognostic factors for outcome after CBT were higher sense of 
control predicting more improvement, and a passive activity pattern and focusing on 
bodily symptoms predicting less improvement.
Changes in physical activity are thought to play an important role in maintaining 
symptoms in CFS. The aim of the study presented in Chapter 5 was to describe intra­
individual physical activity patterns in more detail and to identify pervasively passive 
patients. With help of a movement-sensing device (ActiLog), physical activity levels 
were registered continuously over a 12-day period in CFS patients. Within this 
registration period, the ten largest activity peaks were computed. The intensity and 
duration of these activity peaks and their subsequent rest periods were described 
and compared to those of healthy controls. In addition, the patients’ 12 daily activity 
scores were used to identify patients who were characterised by low levels of 
physical activity throughout the registration period. The results showed that the CFS 
sample had less intense and shorter activity peaks than the healthy controls, while 
the average rest periods that followed these peaks lasted longer. Approximately one 
fourth of the CFS sample differed distinctly from the control group and was labelled 
as pervasively passive. We concluded that the measurements and classification of
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actual physical activity levels reduced heterogeneity in the CFS population and 
therefore could provide the opportunity to optimise behavioural intervention protocols 
for CFS.
Lifetime and current psychiatric disorders have been associated with poor outcome in 
the prognosis of patients with CFS. The impact of psychiatric disorders on treatment 
withdrawal and outcome of CBT for CFS patients is not known. In Chapter 6 lifetime 
and current psychiatric diagnoses were assessed at baseline with a structured 
psychiatric interview in a multicentre randomised controlled trial of 270 patients 
allocated to CBT, support groups or natural course during 14 months. The 
proportions of psychiatric diagnoses in CFS patients were compared to data of a 
general population study. Proportions of patients with and without psychiatric 
diagnoses were compared concerning treatment withdrawal and clinical 
improvement. Outcomes of patients with and without current psychiatric diagnoses 
were examined in general linear models. Lifetime and current psychiatric disorders 
were found in 50% and 32% of the CFS patients. The proportions of mood disorders 
were higher than in the general population. No significant differences were found 
between patients with and without current or lifetime psychiatric diagnoses in 
treatment adherence or clinical improvement in each of the conditions. In CBT, 
support groups and natural course patients with a current psychiatric diagnosis had 
outcomes of fatigue severity and functional impairment identical to patients without a 
current psychiatric diagnosis. CFS patients with psychiatric co-morbidity have not a 
higher withdrawal rate or worse outcome than patients without, when treated with 
cognitive behaviour therapy.
In Chapter 7 two categories of CFS patients are described which did not benefit from 
CBT. One third of the CFS patients appeared to be engaged in a legal procedure 
concerning financial benefits. We found that patients engaged in disability claims had 
a worse outcome after CBT han those patients to whom this did not apply. We 
concluded that patients who are involved in legal procedures in connection with their 
illness -  involving insurance issues and/or invalidity benefit claims -  should not be 
offered CBT. During such procedures patients need to convince the medical board of 
the severity of their complaints and impairments and this does not accord with a 
treatment aimed at improvement or recovery from the symptoms involved. Based on 
these findings CFS patients still actively involved in such procedures are no longer 
prescribed CBT in clinical practice. In Chapters 4 and 5 we described that the quarter 
of CFS patients characterized by a passive activity pattern had a worse outcome. 
None of the patients in CBT with a passive activity pattern was clinically improved 
after treatment. We concluded that patients with a passive activity pattern were in 
need of a different treatment protocol, which we have developed by now.
Several studies suggested that the surroundings of CFS patients are of importance in 
the persistence of complaints. Contrary to expected, in Chapter 4 we found that 
participation in support groups did not result in more clinical improvement than the 
natural course. The purpose of the study presented in Chapter 8 was to describe
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social support in CFS patients as compared to other fatigued and non-fatigued 
groups. Social support data were assessed in 270 CFS patients, 150 disease-free 
breast cancer patients, 151 fatigued employees on sick leave and 108 healthy 
subjects. The results showed that CFS patients and fatigued employees reported 
more negative interactions and insufficiency of supporting interactions than cancer 
patients and healthy controls. In CFS patients and fatigued employees the quality of 
social support was worse than in disease-free cancer patients and healthy controls. 
However, no differences in quantity of supporting interactions were found. Further, 
changes in social support of CFS patients and the influence of social support on the 
course of CFS over a period of more than one year were studied in patients with and 
without treatment. CFS patients were followed in CBT, guided support groups and 
natural course at 8 and 14 months. Negative interactions decreased significantly after 
treatment with CBT, but did not change in support groups or natural course. In the 
natural course, higher fatigue severity at 8 months was predicted by more negative 
interactions at baseline. Lack of social support was identified as a new factor in the 
model of perpetuating factors o f fatigue severity and functional impairment in CFS. 
The general practitioner (GP) is part of the social environment too. The role of the GP 
seems especially important, because often the GP is the first professional confronted 
with the complaints of chronic fatigue. How this first consultation goes may determine 
the future course of CFS considerably. The lack of a known origin for chronic fatigue 
could have consequences for the way GPs deal with the diagnosis CFS and their 
perception of CFS patients. The aims of the study presented in Chapter 9 were to 
investigate the use of the diagnosis CFS by GPs and their reactions to self-diagnosis 
and to explore opinions of GPs about causes of CFS and the communication with 
CFS patients as well as opinions of CFS patients about their GPs. The results 
showed that only half of the GPs used the diagnosis CFS. The main reason for not 
diagnosing CFS was ignorance of the criteria. GPs reported self-diagnosis in 68% of 
the CFS patients. More than half of the GPs could sympathize less with the 
complaints of CFS patients compared to those of other patients. These GPs 
experienced more problems in communicating with CFS patients and judged co­
operation and contact as poor. As to the causes for CFS a discrepancy was found. 
GPs mainly attributed the complaints to psychosocial factors, whereas patients 
mainly had physical attributions. In communicating with the CFS patient it may be 
helpful for GPs to discuss the distinction between initiating and perpetuating factors 
of CFS.
In Chapter 10 the transferability of CBT for patients with CFS is considered. The 
results of the trial in Chapter 4 showed that CBT can be transferred from CFS 
research clinics to therapists with no previous experience in CBT. In order to 
implement CBT in general health settings, transferability of the treatment is essential. 
The therapists in the effect-study were thoroughly trained and supervised. The 
question was if they sufficiently followed the treatment protocol. Analyses of 
audiotaped sessions were conducted to verify whether the therapists had complied
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with the various treatment aspects included in the manual. In 89% of the sessions 
this appeared to be the case. The opinions of the therapists concerning the usability 
of the treatment manual were investigated with questionnaires completed by the 
thirteen therapists following completion of the study. The questionnaire revealed that 
the therapists found it more difficult to treat CFS patients than patients with 
psychological or other physical problems. The treatment aspects posing the most 
problems were integrating individual problems into the standardised treatment, 
dealing with the patients’ lack of confidence in the treatment and handling insufficient 
motivation. For these aspects in particular, extra training seems necessary. The 
treatment manual will have to be revised in such a way that it will leave therapists 
room to individualise the prescribed interventions and it will need to provide them 
with guidelines for interventions aimed at motivating patients.
Implementation of CBT for CFS not only depends on transferability of the treatment 
to other therapists, but also on the economic evaluation of the intervention. In 
Chapter 11, the first prospective randomised study reporting the cost-effectiveness of 
CBT in CFS-patients is presented. Especially since CBT is the only therapy for CFS 
that is evidence based, cost-effectiveness information is relevant. The cost- 
effectiveness analysis was part of the randomised controlled trial of CBT for CFS 
patients, presented in Chapter 4. Both a health care and a societal perspective were 
used, indicating either cost per patient clinically significant improved or cost per 
quality adjusted life year (QALY). CBT resulted in a better outcome and a lower use 
of medical care facilities than both control conditions. Regarding our limited follow up 
we expect the cost-effectiveness to improve in case of a longer time horizon. 
However, the statistical uncertainty of the cost-effectiveness estimates we found is 
considerable, as the bootstrap simulations showed. The use of a societal 
perspective, thus including productivity costs, has a large impact on the cost- 
effectiveness estimates. Although not statistically significant, the differences in 
productivity costs between the groups was considerable due to the fact that a small 
number of patients that were employed were absent from work during a longer 
period. Therefore the results have to be interpreted with caution and we intend to 
investigate the longer term working situation of our patients further. The societal 
perspective is of importance, since in the trial of 270 CFS patients 76% had been 
employed before the onset of CFS, whereas only 33% had a job at the start of the 
study. In the meantime the conclusions of this work should be based on the health 
care perspective. The difference between utility in the experimental treatment and the 
current situation is small. Given this fact and the short time horizon, the costs per 
QALY seem high. However, extrapolating the utility values and the cost figures 
another four years indicates, that the cost per QALY will become more acceptable 
and even indicates dominance of CBT in case the productivity costs are included. 
Finally, in Chapter 12 the results of the studies in this thesis are considered as a 
whole. We go into questions and critical remarks which our studies evoked, discuss 
practical implications of our studies and our ideas concerning implementation of CBT
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for CFS, and indicate the direction for future studies. It was concluded that with 
proper indications CBT may be a cure for a considerable part of the CFS population. 
Future research should be directed at long-term effectiveness and cost-effectiveness 
to give implementation a fair chance of succeeding. Essential mechanisms of CBT 
should be investigated to contribute to further improvement of effectiveness and cost- 
effectiveness.
Samenvatting 187
Samenvatting
Chronisch vermoeidheidssyndroom (CVS) is de door clinici en wetenschappers 
algemeen aanvaarde naam voor het geheel van klachten, dat door patiënten vaak 
ME (myalgische encefalomyelitis) wordt genoemd. CVS wordt gekenmerkt door 
ernstige invaliderende vermoeidheid, die minimaal zes maanden bestaat, waarvoor 
geen lichamelijke verklaring gevonden kan worden en die heeft geleid tot ernstige 
beperkingen in het dagelijks functioneren. De medische consumptie van CVS 
patiënten is hoog en arbeidsongeschiktheid komt veel voor.
Dit proefschrift bouwt voort op onderzoek vanaf 1990 verricht door de Nijmeegse 
Onderzoeksgroep Chronisch Vermoeidheidssyndroom naar de oorzaken, het beloop, 
de gevolgen en de behandelingsmogelijkheden van CVS. Lichamelijke oorzaken 
voor CVS werden niet gevonden en spontaan herstel bleek weinig voor te komen. 
Behandelingen met medicijnen waren niet effectief. Het onderzoek liet wel zien dat 
psychologische factoren een rol spelen bij het in stand blijven van de klachten. Op 
basis van deze bevindingen werd een model voor CVS ontwikkeld, dat liet zien dat 
het idee dat men zelf weinig aan de klachten kan doen, het blijven toeschrijven van 
de klachten aan een lichamelijke oorzaak en daarmee samenhangende verminderde 
lichamelijke activiteit, en een sterke gerichtheid op lichamelijke symptomen bijdragen 
aan het in stand blijven van vermoeidheid en beperkingen van CVS patiënten. De 
factoren in het model betreffen psychologische processen. Dergelijke processen zijn 
met cognitieve gedragstherapie (CGT) te beïnvloeden, waardoor de klachten van 
CVS patiënten kunnen verminderen. CGT is een vorm van psychotherapie die 
gericht is op het veranderen van cognities en gedragingen die met de lichamelijke 
klachten samenhangen.
De onderzoeken in dit proefschrift hebben betrekking op het bepalen van de 
effectiviteit van CGT voor patiënten met CVS en op factoren die het verloop van de 
klachten bij patiënten met en zonder deze behandeling beïnvloeden.
In Hoofdstuk 2 wordt beschreven hoe patiënten voor deze onderzoeken geselecteerd 
werden. Op de polikliniek Algemeen Interne Geneeskunde (AIG) van het Universitair 
Medisch Centrum Nijmegen zijn in het afgelopen decennium zeer veel patiënten 
gezien met klachten van chronische vermoeidheid, zowel in de patiëntenzorg als in 
het kader van wetenschappelijk onderzoek. Vanuit beide invalshoeken werden 
richtlijnen en meetinstrumenten ontwikkeld om de diagnostiek te verbeteren. Op de 
polikliniek AIG gebruiken de artsen een protocol om de diagnose CVS te stellen. 
Daarnaast vullen de patiënten enkele vragenlijsten op de computer in met de MID 
TestOrganizer, een software programma ontwikkeld door de Medisch Instrumentele 
Dienst in samenwerking met de afdeling Medische Psychologie, om vast te stellen of 
zij voldoen aan de operationele criteria en CDC criteria (Centers for Disease Control) 
voor CVS. Bij 516 patiënten werden de uitkomsten van het onderzoek door de arts 
met behulp van het protocol en het geautomatiseerde vragenlijstonderzoek met
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elkaar vergeleken. In 84% van de gevallen bestond overeenstemming over de aan- 
of afwezigheid van de diagnose CVS tussen de arts en de vragenlijsten. In de 
gevallen met tegenstrijdige bevindingen bleek meestal onduidelijkheid over de ernst 
van de vermoeidheid of de beperkingen een rol te spelen. De ernst van de klachten 
is goed in kaart te brengen met vragenlijstonderzoek. Twee korte vragenlijsten 
zouden als aanvulling op het protocol door artsen gebruikt kunnen worden om de 
diagnose CVS te stellen.
De behandeling met CGT voor patiënten met CVS werd systematisch geëvalueerd in 
enkele casestudies. In Hoofdstuk 3 wordt verslag gedaan van CGT bij een 26-jarige 
vrouw met CVS. Haar vermoeidheidsklachten hebben geleid tot ernstige beperkingen 
in het beroepsmatig, sociaal en psychisch functioneren. Patiënte is volledig 
arbeidsongeschikt geraakt. De diagnose CVS werd gesteld en met multidimensioneel 
vragenlijstonderzoek bevestigd. Uit de metingen bleek dat de klachten van patiënte 
in vergelijking met andere CVS patiënten ernstig waren. De behandeling werd 
gebaseerd op zowel een wetenschappelijk model als individuele functionele 
analyses. Cognitieve herstructurering en activiteitenopbouw waren de belangrijkste 
elementen van de behandeling. Behandeldoelen waren herstel, werkhervatting en 
terugvalpreventie. Vergelijkingen van de metingen van vermoeidheid en beperkingen 
voor en na de behandeling lieten zien dat het niveau van functioneren van patiënte 
na de behandeling dichter bij het gemiddelde van gezonde proefpersonen lag dan bij 
het gemiddelde van CVS patiënten. Cognitieve gedragstherapie had succes en 
resulteerde in klinisch significante verbetering.
De volgende stap was het onderzoeken van de effectiviteit van CGT voor patiënten 
met CVS in wetenschappelijk onderzoek. Deze studie wordt in Hoofdstuk 4 
gepresenteerd. In een gerandomiseerd gecontroleerd onderzoek uitgevoerd in drie 
verschillende centra werd bij 278 CVS patiënten het effect van CGT vergeleken met 
lotgenotencontact en met de gangbare praktijk. Dertien therapeuten zonder ervaring 
met CVS kregen een training in het behandelen van patiënten met CVS. CGT 
bestond uit 16 sessies van één uur gedurende acht maanden. Belangrijke elementen 
in de behandeling waren uitleg van het model van instandhoudende factoren, 
motiveren voor CGT, herstructureren van aan moeheid gerelateerde cognities, tot 
stand brengen van een basisniveau van dagelijkse activiteiten, geleidelijk ophogen 
van lichamelijke activiteit en hervatting van werk of persoonlijke doelen. De CVS 
patiënt leerde zelf controle te krijgen over de klachten, in plaats van afhankelijk te 
blijven van voorschriften van artsen of andere behandelaars. Multidimensionele 
metingen hadden op drie momenten plaats: bij de start van het onderzoek, na 8 
maanden (nameting) en na 14 maanden (follow-up). De resultaten lieten zien dat 
CGT effectiever is dan beide andere onderzoekscondities op de twee primaire 
uitkomstmaten vermoeidheid en beperkingen. Afhankelijk van het gehanteerde 
criterium was ruim een derde of de helft van de patiënten klinisch significant hersteld 
of verbeterd volgens de onafhankelijk beoordelaar en naar het eigen oordeel van de 
patiënt. Een positieve self-efficacy, het idee dat men zelf iets aan de klachten kan
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doen, bleek meer verbetering na CGT te voorspellen, terwijl een passief 
activiteitenpatroon en een sterke gerichtheid op lichamelijke symptomen voorspellers 
waren van minder verbetering na CGT.
In Hoofdstuk 5 wordt een onderzoek gepresenteerd over de lichamelijke activiteit van 
CVS patiënten. Doel van dit onderzoek was het gedetailleerd beschrijven van intra- 
individuele patronen van fysieke activiteit en het identificeren van patiënten met een 
passief activiteitenpatroon. Met behulp van de aktometer (ActiLog, Medisch 
Instrumentele Dienst), een apparaat ter grootte van een luciferdoosje dat dag en 
nacht om de enkel wordt gedragen, werden gedurende twaalf dagen niveaus van 
fysieke activiteit gemeten bij alle CVS patiënten die eerder beschreven werden in 
Hoofdstuk 4. Gedurende de periode van registratie werden de tien grootste pieken 
van activiteit berekend. De intensiteit en duur van deze pieken van activiteit werden 
beschreven, evenals de erop volgende periodes van rust. Deze werden vergeleken 
met dezelfde gegevens van gezonde proefpersonen. De resultaten van dit onderzoek 
lieten zien dat CVS patiënten minder intense en kortere pieken van activiteit hadden 
en langere periodes van rust dan de controlegroep met gezonde proefpersonen. 
Daarnaast werden de dagelijkse activiteitsscores van de CVS patiënten gebruikt om 
patiënten te identificeren met een voortdurend laag activiteitenpatroon. Een kwart 
van de CVS patiënten bleek een voortdurende lage lichamelijke activiteit gedurende 
twaalf dagen te vertonen. De classificatie in activiteitenpatronen werd in Hoofdstuk 4 
gebruikt om het behandelingsresultaat van CGT te voorspellen.
In Hoofdstuk 6 wordt een onderzoek gepresenteerd naar psychiatrische co- 
morbiditeit van de patiënten met CVS die deelnamen aan het onderzoek beschreven 
in Hoofdstuk 4. Psychiatrische stoornissen zijn in sommige onderzoeken 
geassocieerd met een ongunstig beloop van de klachten van patiënten met CVS. 
Niet bekend is de invloed van psychiatrische stoornissen op het resultaat van 
behandeling met CGT of op uitval tijdens de behandeling. Voordat de CVS patiënten 
startten met het gerandomiseerd gecontroleerd onderzoek naar het effect van CGT 
werd de aanwezigheid van eerdere of huidige psychiatrische stoornissen vastgesteld 
met een gestructureerd psychiatrisch interview. Psychiatrische stoornissen bleken bij 
50% van de CVS patiënten in de loop van het leven voor te komen en waren 
aanwezig bij 32% van de patiënten op het moment van het onderzoek. De 
percentages stemmingsstoornissen en angststoornissen bij patiënten met CVS 
werden vergeleken met de resultaten uit een onderzoek bij de Nederlandse 
bevolking. Stemmingsstoornissen kwamen bij CVS patiënten meer voor dan in de 
algemene bevolking, maar angststoornissen waren in gelijke mate aanwezig bij beide 
groepen. In de drie onderzoekscondities CGT, lotgenotencontact en natuurlijk beloop 
werden tussen patiënten met en zonder psychiatrische stoornissen geen verschillen 
gevonden in behandelingsresultaat of in uitval tijdens de behandeling. Vermoeidheid 
en beperkingen waren in gelijke mate afgenomen. Op basis van deze bevindingen 
concludeerden wij dat psychiatrische co-morbiditeit geen voorspeller is van het 
behandelingsresultaat van CGT.
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In Hoofdstuk 7 worden twee categorieën patiënten beschreven die niet of nauweijks 
bleken te verbeteren na behandeling met CGT. Een derde van de CVS patiënten 
was betrokken bij een beroepsprocedure met betrekking tot een W AO/AAW  of WW- 
uitkering. In ons onderzoek naar het effect van CGT werd vastgesteld dat patiënten 
die tijdens behandeling betrokken zijn bij een dergelijke beroepsprocedure een 
significant slechter behandelingsresultaat hadden dan patiënten waarbij dit niet het 
geval is. Dit heeft er in de klinische praktijk toe geleid dat CGT voor CVS niet meer 
aangeboden wordt aan patiënten die nog actief bezig zijn met een 
beroepsprocedure. In een dergelijke procedure moeten patiënten de tegenpartij 
overtuigen van de ernst van hun klachten en beperkingen. Dit blijkt moeilijk samen te 
gaan met een behandeling die gericht is op herstel. Zoals in Hoofdstuk 4 en 5 werd 
beschreven had een kwart van de CVS patiënten in ons onderzoek een passief 
activiteitenpatroon. Na de behandeling met CGT bleek geen van deze patiënten 
hersteld te zijn. Op basis van deze resultaten werd voor de patiënten met een passief 
activiteitenpatroon een andere vorm van cognitieve gedragstherapie ontwikkeld.
In de literatuur wordt gesuggereerd dat de omgeving van CVS patiënten een rol 
speelt bij het in stand blijven van de klachten, zonder dat dit goed onderzocht is. In 
Hoofdstuk 8 wordt een studie gepresenteerd, waarin de sociale steun van CVS 
patiënten wordt beschreven en vergeleken met andere groepen patiënten en met 
gezonde proefpersonen. Gegevens over sociale steun werden verzameld van 270 
CVS patiënten, 150 ziektevrije borstkankerpatiënten, 151 zieke werknemers met 
vermoeidheidsklachten en 108 gezonde proefpersonen. De resultaten lieten zien dat 
CVS patiënten en vermoeide werknemers meer negatieve interacties en een groter 
tekort aan ondersteunende interacties rapporteerden dan kankerpatiënten en 
gezonde controles. De kwaliteit van sociale steun van CVS patiënten en vermoeide 
werknemers was slechter dan die van ziektevrije borstkankerpatiënten en gezonden, 
maar tussen deze groepen werden geen verschillen in de kwantiteit van sociale 
steun gevonden. Verder werden gedurende een periode van ruim een jaar 
veranderingen in sociale steun van CVS patiënten onderzocht en werd de invloed 
van sociale steun op het beloop van CVS nagegaan bij patiënten behandeld met en 
zonder CGT. Na behandeling met CGT namen de negatieve interacties van CVS 
patiënten significant af, terwijl dit niet het geval was in de lotgenotencontactgroepen 
en het natuurlijk beloop. In het natuurlijk beloop werd hogere vermoeidheid na acht 
maanden voorspeld door meer negatieve interacties bij de start van het onderzoek. 
De resultaten lieten zien dat sociale steun als variabele opgenomen moet worden in 
het model van vermoeidheid.
De huisarts maakt ook deel uit van de sociale omgeving van de patiënt. De rol van 
de huisarts is van belang, omdat de huisarts meestal de eerste professional is die 
geconfronteerd wordt met de klachten van chronische vermoeidheid. Hoe dit consult 
verloopt, kan mede het beloop van CVS bepalen. Het ontbreken van een somatische 
verklaring voor chronische vermoeidheid zou consequenties kunnen hebben voor de 
wijze waarop huisartsen omgaan met de diagnose CVS en voor hun perceptie van
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CVS patiënten. Doel van het onderzoek gepresenteerd in Hoofdstuk 9 was om te 
onderzoeken of huisartsen de diagnose CVS gebruiken en hoe zij reageren op een 
door de patiënt zelf gestelde diagnose. Verder was het onderzoek gericht op de 
opvattingen van huisartsen over oorzaken van CVS en over de communicatie met 
CVS patiënten. De opvattingen van CVS patiënten over hun huisarts werden ook 
onderzocht. De resultaten lieten zien dat slechts de helft van de huisartsen de 
diagnose CVS gebruikte. De belangrijkste reden om de diagnose CVS niet te stellen 
bleek onbekendheid met de criteria voor CVS te zijn. De huisartsen rapporteerden 
dat 68% van de CVS patiënten zelf de diagnose had gesteld. Meer dan de helft van 
de huisartsen gaf aan zich moeilijker te kunnen inleven in de klachten van CVS 
patiënten dan in die van andere patiënten. Deze huisartsen hadden meer problemen 
in de communicatie met CVS patiënten en beoordeelden de samenwerking en het 
contact als slecht. Over de oorzaken van CVS werd door huisartsen en door 
patiënten anders gedacht. Huisartsen schreven de klachten vooral toe aan 
psychosociale factoren, terwijl patiënten vooral lichamelijke oorzaken noemden. Bij 
de communicatie met CVS patiënten zou het de huisarts daarom kunnen helpen om 
onderscheid te maken tussen oorzakelijke en instandhoudende factoren van CVS.
In Hoofdstuk 10 wordt de overdraagbaarheid van CGT voor patiënten met CVS 
onder de loep genomen. De resultaten van het effectonderzoek in Hoofdstuk 4 
hebben laten zien dat het mogelijk is om CGT voor CVS vanuit onderzoeksinstituten 
over te dragen naar therapeuten zonder eerdere ervaring met deze behandeling. 
Voor de implementatie van CGT in de geestelijke gezondheidszorg is de 
overdraagbaarheid van de behandeling van groot belang. De psychotherapeuten in 
het effectonderzoek waren uitgebreid getraind en gesuperviseerd. De vraag was 
echter of zij de behandeling ook volgens protocol hadden aangeboden. Door analyse 
van audio-opnamen van de therapiesessies werd nagegaan in hoeverre de 
therapeuten de verschillende aspecten van de behandeling ook volgens protocol 
hadden uitgevoerd. In 89% van de sessies bleek dat in voldoende mate te zijn 
gebeurd. Wat therapeuten vonden van de uitvoerbaarheid van deze protocollaire 
vorm van CGT voor CVS werd onderzocht door aan het einde van het 
effectonderzoek aan de 13 psychotherapeuten die de behandelingen uitvoerden, een 
vragenlijst voor te leggen. Uit de resultaten bleek dat de psychotherapeuten vonden 
dat CVS patiënten moeilijker te behandelen zijn dan patiënten met psychische 
klachten en patiënten met andere lichamelijke klachten. Het moeilijkste vond men het 
integreren van individuele problemen in de behandeling, het gebrek aan vertrouwen 
in de behandeling van de patiënt en het omgaan met onvoldoende motivatie. Met 
name voor deze aspecten lijkt, naast het ter beschikking stellen van het protocol, 
extra training noodzakelijk. Het protocol zal zo geschreven moeten zijn dat de 
therapeut de behandeling kan individualiseren en handreikingen krijgt met betrekking 
tot het motiveren van de patiënten.
Implementatie van CGT voor patiënten met CVS hangt niet alleen af van de 
overdraagbaarheid van de behandeling naar andere therapeuten, maar ook van de
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economische evaluatie van de behandeling. In Hoofdstuk 11 wordt het eerste 
prospectieve gerandomiseerde onderzoek naar de kosteneffectiviteit van CGT voor 
patiënten met CVS gepresenteerd. Informatie over kosteneffectiviteit is speciaal van 
belang, omdat CGT de enige behandeling voor CVS patiënten is, waarvan de 
effectiviteit werd aangetoond. De kosteneffectiviteitsanalyse maakte deel uit van het 
gerandomiseerde gecontroleerde onderzoek, dat in Hoofdstuk 4 werd gepresenteerd. 
Zowel een gezondheidszorgperspectief (kosten per herstelde patiënt) als een 
maatschappelijk perspectief (kosten per quality adjusted life year) werden gebruikt. 
CGT resulteerde in een beter effect en een lager gebruik van medische faciliteiten 
dan beide controle condities. Gezien de beperkte follow-up is de verwachting dat de 
kosteneffectiviteit verbetert bij een langere tijdshorizon. Echter, bootstrap simulaties 
lieten zien dat de statische onzekerheid van de bevindingen aanzienlijk is. Met name 
het gebruik van het maatschappelijk perspectief, waarbij ook de productiviteitskosten 
in het onderzoek meegenomen worden, heeft veel invloed op de kosteneffectiviteit 
schattingen. Hoewel niet statistisch significant, was het verschil in 
productiviteitskosten tussen de onderzoeksgroepen aanzienlijk. De resultaten 
moeten daarom met voorzichtigheid geïnterpreteerd worden. De werksituatie van 
CVS patiënten moet verder onderzocht worden. Het maatschappelijk perspectief is 
zeker van belang, gezien het feit dat van de 270 patiënten in het onderzoek 76% 
werkte voordat de klachten ontstonden, terwijl ten tijde van het onderzoek nog maar 
33% een baan had. Voorlopig moeten de conclusies van dit onderzoek echter op het 
gezondheidszorgperspectief gebaseerd worden. Het verschil tussen CGT en de 
huidige situatie is klein. Vanwege dit feit en de korte tijdshorizon, lijken de kosten per 
QALY hoog. Als de bevindingen echter geëxtrapoleerd worden naar een tijdshorizon 
van vier jaar, worden de kosten per QALY acceptabeler en is er zelfs sprake van 
dominantie van CGT als de productiviteitskosten mede beschouwd worden.
Tot slot worden in Hoofdstuk 12 de resultaten van de onderzoeken in dit proefschrift 
in een groter geheel bezien. We gaan in op vragen en kritische reacties die ons 
onderzoek heeft opgeroepen, bespreken praktische implicaties alsmede onze ideeën 
over implementatie van CGT voor CVS en geven de richting aan voor toekomstig 
onderzoek. De belangrijkste conclusie is dat met een goede indicatiestelling CGT tot 
herstel kan leiden bij een belangrijk deel van de patiënten met CVS. Toekomstig 
onderzoek naar effectiviteit en kosteneffectiviteit van CGT op lange termijn is 
gewenst om implementatie een goede kans van slagen te bieden. Onderzoek naar 
de werkzame elementen van CGT kan bijdragen aan een verbetering van de 
effectiviteit en de kosteneffectiviteit.
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